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3Abstract
The importance of IL-17 is underscored both by its resistance to control by
regulatory T cells (Treg) and the propensity of Treg to produce this highly
inflammatory cytokine. I addressed whether Th17 cells are inhibited by Treg from
anti-TNF treated rheumatoid arthritis (RA) and psoriatic arthritis patients (PsA) and
defined the underlying mechanisms.
Th17 responses were inhibited by Treg isolated from RA patients responding to the
anti-TNF antibody adalimumab, but not by Treg from healthy individuals or patients
with active RA. Furthermore, in patients with RA, response to adalimumab therapy
was associated with a reduction in RORC+ Th17 cells and an increase in FOXP3+
Treg lacking Helios and CD62L expression. These Treg suppressed Th17 cells
through inhibition of monocyte-derived IL-6, but independently of IL-10 and TGF-ß,
which mediated suppression of Th1 responses. Surprisingly, therapy with the anti-IL-
6 receptor, tocilizumab, did not result in a reduction in RORC+ cells in RA patients.
Rather, tocilizumab reduced T cell IL-21 production, which was associated with a
diminished memory B cell population.
The acquisition of IL-17 suppressor function by Treg was not observed in RA
patients responding to etanercept, a modified TNF  receptor, or in PsA patients
treated with either adalimumab or etanercept. Moreover, response to therapy was not
associated with an increase in Treg number in these patients. In RA patients treated
with etanercept the inability of Treg to suppress Th17 responses was associated with
high levels of IL-17 production and high levels of RORC+ Th17 cells ex vivo. In
4contrast, there was a reduction in IL-17 production and RORC+ Th17 cells ex vivo in
PsA patients treated with both adalimumab and etanercept. Furthermore, depletion of
Treg from PBMC showed that Treg from healthy controls, patients with active PsA
and PsA patients responding to adalimumab can modulate the production of IL-22, a
key cytokine in inflammatory skin disorders. However, PsA patients responding to
etanercept have an impaired ability to regulate production of this cytokine.
In conclusion, the induction of IL-17 suppressing Treg by anti-TNF is both therapy
and disease specific. These data provides a rationale for the therapeutic benefit of
switching between different anti-TNF agents. Furthermore, the induction of highly
potent Treg may offer an explanation as to why patients treated with adalimumab
have an increased risk of developing Mycobacterium tuberculosis (TB).
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Chapter 1 
Introduction
1.1 Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease which affects
approximately 1% of the population, with 3 females affected for each male [1]. It is a
systemic disorder affecting peripheral joints such as hands, wrists, feet and knees in a
symmetrical fashion. Disease is associated with severe deformity and in the early
1990s was estimated to cost £1.256 billion per year in England, with 52% of this sum
as a result of work-related production loss through disability [2].
In addition to severe disability, it has been known since the 1950s that RA is
associated with increased mortality [3] both from the disease itself but also from
associated co-morbidities. A number of factors have been found to correlate with
premature mortality in RA; these include the presence of rheumatoid factor and
rheumatoid nodules at first visit and long-term disease severity [4-6]. Moreover, RA
patients have increased mortality from infections, respiratory disease, non-Hodgkin’s
lymphoma and cardiovascular disease (CVD) than the general population [6, 7].
Indeed the mortality rate from CVD in patients with RA is 50-100% higher than the
general population and has been shown to be predicted by baseline C-reactive protein
(CRP) levels [8] and persistently high disease activity [9].
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Classification of RA is based on 4 main criteria: the numbers of swollen joints, the
presence of autoantibodies, the presence of acute phase proteins and the duration of
symptoms. Patients receive a score for each of these criteria and are classified as RA
if their score is > 6/10 [10].
Disease activity is measured by the disease activity score (DAS)-28. DAS-28 score is
calculated based on the tenderness and swelling in 28 joints, erythrocyte
sedimentation rate (ESR) and a global health assessment. Joint damage is measured
by assessing joint space narrowing and bone erosions on radiographs.
1.1.1 The immunopathogenesis of rheumatoid arthritis
In a healthy individual tolerance to self-tissue is maintained through the removal of
potentially pathogenic cells during development in the thymus, a process named
central tolerance. If pathogenic cells should escape deletion and leave the thymus
there are mechanisms in place to control these cells in the periphery, known as
peripheral tolerance. In order for an autoimmune disease such as RA to develop,
tolerance to self-tissue must be breached. There are a number of factors that
contribute to the breach of tolerance in RA and these factors may differ between
individuals. There is substantial evidence for a genetic association with RA, with
twin studies showing approximately 65% heritability [11]. Genetic similarities in
RA-susceptible individuals are commonly mutations in a single base pair of genes,
referred to as single nucleotide polymorphisms (SNPs). Many of the SNPs associated
with the development of RA are important for key immune responses. However, RA
is not 100% heritable, which means there must be non-genetic factors, which
Chapter 1
26
contribute to the development of disease. These non-genetic elements include
exposure to toxic substances such as cigarette smoke, infection, trauma and
hormonal factors. A breach of peripheral tolerance leads to the inappropriate
presentation of joint specific antigens to T cells in the synovium and the subsequent
chronic inflammation that fails to be suppressed by natural mechanisms.
The pathogenesis of RA can be divided into 5 stages (Table 1.1, pg 27). Each of
these stages is associated with distinct immunopathology. In the text that follows the
contributing factors to the immunopathogenesis of RA are discussed to give a picture
of how tolerance is breached in RA and how this leads to chronic inflammation and
joint destruction. Moreover, the latter part of this text discusses how RA
pathogenesis and joint destruction can be targeted for the amelioration of disease.
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Table 1.1. Immunopathogenesis of rheumatoid arthritis.
Adapted from [14]
Stage Immunology Clinical Symptoms
1.
Breach of
tolerance
Central tolerance
Peripheral tolerance
Genetic susceptibility
Environmental factors (necrosis and
citrullination of proteins associated
with smoking).
Infection (molecular mimicry)
Trauma (joint damage targets already
primed immune system to the joint).
Hormones (oestrogen drives IL-1)
Presentation of self-antigen to T cells
Autoantibody production.
Few clinical symptoms, though
antibodies against citrullinated
proteins are known to be present
up to 10 years before onset of
disease [12, 13].
2. Lymphocyte proliferation and
differentiation of Th17 and Th1 cells
Angiogenesis of the synovial
membrane.
Granulocyte recruitment to the joint.
Characterised by pain and
swelling of the small joints of the
hands and feet. Mild joint
stiffness.
3.
Inflammation
Further recruitment and accumulation
of neutrophils – leading to further
production of chemokines such as
CCL2 and CXCL8.
Recruitment of monocytes and
conversion to macrophages – antigen
presentation and production of TNFα
and IL-1 to activate cells of the
synovium and enhance cellular
recruitment.
Accumulation of functional regulatory
T cells, but no impairment of
inflammation.
Synovial cell hyperplasia.
The knees, ankles, hips, and the
cervical spine and lower jaw
become tender and swollen; this
is accompanied by large
inflammatory nodular masses
within these joints. Warm swollen
joints, pain, and limited motion.
4.
Joint
Damage
Formation of a pannus containing
inflammatory cells producing cartilage-
degrading enzymes.
Activated osteoclasts, chondrocytes and
synovial fibroblast-like cells contribute
to destruction of cartilage.
Synovial membrane takes on anchorage
independent phenotype with altered
oncogene expression and reduced cell
death.
As above with increased swelling,
radiographic evidence of
osteopaenia.
5. Pannus invasion, destruction of
cartilage and subchondral bone.
Chondrocyte proliferation.
Loss of function and deformity,
narrowing of joint spaces and
increased extraarticular
complications.
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1.1.1.1 Central Tolerance:
Mature T cells are characterised by their surface expression of a heterodimeric T cell
receptor (TCR) made up of an alpha chain and a beta chain, which recognises
peptide- major histocompatability complex (MHC). The TCR is associated with a
second cell surface receptor cluster of differentiation (CD) 3, important for
stabilising the receptor complex at the cell surface and for downstream signalling
[15]. In addition either CD4 or CD8 are expressed and these receptors recognise
MHC class II or MHC class I, respectively. It is now known that T cells and B cells
develop from the same progenitor stem cell in the bone marrow, but T cells traffic to
the thymus to complete the maturation process. In order to generate T cells with a
wide range of specificities, random rearrangement of T cell receptors (TCR) takes
place during development. In the thymus, cells progress through a series of
checkpoints to test the specificity of these randomly generated TCR. This results in
the production of mature cells with high specificity for foreign antigens and low
specificity for tissue proteins (self-antigen).
The first checkpoint is named positive selection. During this stage, developing T
cells that fail to recognise autologous MHC molecules die by neglect. At the second
checkpoint, an intracellular protein named AIRE drives the ectopic presentation of
peripheral tissue proteins on MHC in the thymic epithelium [16]. If the TCR has a
high affinity for the antigen expressed, a strong signal will be transduced and the cell
will undergo clonal deletion in a process named negative selection [17].
Alternatively, if the TCR has a low affinity for the antigen presented it will survive
and proceed to enter the circulation.
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The importance of TCR signalling for the selection of the peripheral T cell pool is
highlighted in elegant experiments where CD3ζ-deficient mice in which TCR
signalling is ablated were crossed to mice in which all T cells possess a TCR for a
male antigen, HY. In the absence of a TCR signal, male mice failed to negatively
select auto-reactive HY specific T cells resulting in an autoimmune pathology. In
female mice however, the absence of both antigen expression in the tissues and a
TCR signal resulted in the complete ablation of T cells in the periphery [18],
suggesting that developing thymocytes require a TCR signal. Furthermore it has been
shown that SKG mice that spontaneously develop autoimmune arthritis do so due to
a mutation in ZAP-70, an important molecule in the proximal stages of TCR
signalling. Autoimmunity in these mice was shown to be driven by a reduction in
TCR signalling leading to the positive selection of auto-reactive T cells [19]. Thus a
T cell signal is vital to survival of developing thymocytes, but a strong signal
through the TCR leads to T cell deletion in order to prevent potentially self-reactive
cells causing harm in the periphery.
1.1.1.2 Peripheral Tolerance
T cells are selected on a gradient of reactivity and so some cells that enter the
circulation will be more strongly self-reactive than others. Moreover, not all
autologous proteins can be expressed in the thymus. Thus, there must be mechanisms
in place to suppress immune response to self-antigens in the peripheral tissues. These
include anatomical sequestration, the induction of anergy and the activity of
regulatory T cells (Treg) [20].
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Anatomical sequestration:
The circulation of naive T cells, mediated by the chemokine receptor CCR7 and its
ligands, ensure that cells that have not experienced antigen never enter the non-
lymphoid peripheral tissues. This reduces the possibility of self-antigen being
presented to T cells.
Anergy:
In contrast to their naive counterparts, T cells that have encountered antigen can
migrate into the tissues. However, the transfer of T cells with a TCR specific for the
protein ovalbumin (OVA) to mice with expression of OVA on peripheral tissues
does not result in autoimmunity. Only upon secondary damage to the tissue could a
robust OVA-mediated pathology be triggered [21]. Thus, the presence of
autoreactive T cells in the tissue is not sufficient to drive autoimmunity.
T cell activation in the periphery requires interaction with antigen presenting cells
(APC) expressing an antigenic peptide for which the T cell is specific. Additionally,
T cells require a co-stimulatory signal to become activated. The best-characterised
co-stimulatory interaction is that of CD28 on T cells and B7 family members (in
particular B7-1/CD80 and B7-2/CD86) expressed on APC. CD28 lowers the
threshold required for activation of T cells via the TCR [22]. Mice which are
deficient in CD28 have impaired T cell response to antigen with a reduced activation
of helper T cells and reduced antibody class switching [23]. Thus, binding of B7
family members to CD28 in combination with a TCR signal leads to an increase in
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the transcription and production of interleukin (IL)-2 to promote T cell proliferation
[24].
If a T cell recognises an antigen but does not receive this second co-stimulatory
signal it becomes functionally unresponsive, or anergised [25] (Figure 1.1). In the
absence of inflammation APC do not up-regulate co-stimulatory molecules. Cells
which recognise antigen in this environment may undergo proliferation but will fail
to become pathogenic [20]. T cell anergy can also be induced by interaction of T
cells with tolerogenic dendritic cells (DC) which have undergone incomplete
maturation due to the uptake of apoptotic cells [20]. Furthermore, recent data suggest
that the induction of anergy may not be a passive process, as members of the CD28
family including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed
death 1(PD-1) have been shown to negatively regulate T cell co-stimulation [26].
Thus, in order to break tolerance, self-reactive T cells must escape negative selection
in the thymus. These cells must then encounter antigen in the context of
inflammation.
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Figure 1.1. The development of anergy
As depicted on the left hand panel, immunogenic triggers include the presence of
necrotic cells, abundant pathogens signalling to TLRs in the context of inflammatory
cytokines and few apoptotic cells. These conditions drive the expression of co-
stimulatory markers on DC. If antigen is presented under these conditions it
promotes activation of T cells and the initiation of inflammation. In the absence of
TLR stimulus and/or in the presence of many apoptotic cells co-stimulatory markers
are not upregulated on DC (right hand panel). If T cells recognise antigen presented
by DC in this context they do not receive sufficient signal to become activated but
are instead anergised. Adapted from[20]
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1.1.2 Regulatory T cells
In addition to promoting inflammation, T cell subsets have been shown to suppress
inflammation and maintain tolerance in the periphery. Treg can suppress cytokine
production and proliferation from responder T cells [27-29] as well as suppressing
monocytes, macrophages [30], B-cells and dendritic cells [31, 32].
Thymically derived cells capable of suppressing inflammation were first described in
experiments by Nishizuka and Sakakura.  Mice thymectomised between 2 and 4 days
old developed autoimmune disease which was prevented by transferring cells from
the thymus or spleen of a non-thymectomised adult mouse [33]. These regulatory T
cells were ultimately identified as CD4+ T cells which express the IL-2α receptor,
CD25. Transfer of CD25 depleted CD4+ T cells into nude mice resulted in the
development of systemic autoimmune pathology. This was prevented if the CD25+
cells were transferred shortly after the CD25- cells [34].
In humans, CD25+ cells were also found to have suppressive properties [35].
However in contrast to mice, it was demonstrated that only the population of CD4 T
cells with the highest expression of CD25 were suppressive in humans [27]. In
addition to the expression of high levels of CD25, human Treg have been shown to
express low levels of the IL-7 receptor α, CD127. The combination of these two
markers is able to discriminate between human regulatory and activated T cells [36].
Furthermore, in contrast to responder T cells, Treg are characterised by low levels of
IL-2 and interferon gamma (IFNγ) production [37] and low levels of proliferation
when stimulated in vitro even in the presence of co-stimulatory signals [28]. In
addition to CD25 and CD127, Treg constitutively express CTLA-4 [38], GITR
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(glucocorticoid-induced tumour-necrosis factor (TNF)-receptor-related) protein [39]
and GARP (glycoprotein A repetitions predominant), an orphan TLR and  marker of
activated Treg [40]. Membrane bound GARP binds latent TGF-β produced by T
cells upon activation and is essential for the surface expression of this cytokine on
Treg [40, 41]. As many of the Treg markers discovered to date can at least
transiently be expressed by effector T cells, there remains no definitive surface
marker of Treg in humans.
1.1.2.1 FOXP3 as a definitive marker of regulatory T cells
It was the investigation of a unique Treg marker that led to the discovery of Foxp3,
part of the forkhead family of transcription factors [42, 43]. Human males with
immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)
and the mouse model of this disease, scurfy, have a mutation in FOXP3. This
mutation results in a lack of functioning Treg and the development of autoimmune
disease early in life [44]. The importance of Foxp3 for the differentiation,
maintenance and suppressive function of Treg was confirmed by retroviral gene
transfer of Foxp3 to naïve T cells. Foxp3 transfected cells adopted a regulatory
phenotype similar to that of naturally occurring Treg [42].
Foxp3 prevents the conversion of Treg into responder T cells via either the
amplification or stabilisation of Treg genes [45], or the suppression of target genes
associated with T cell activation [46]. Foxp3 has been shown to interact with a
number of other transcription factors including nuclear factor of activated T-cells
(NFAT) and runt-related transcription factor 1 (Runx-1). It is thought that Foxp3
binding to NFAT prevents the formation of NFAT-AP1 complexes that are important
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for the activation of genes that drive inflammation. Instead Foxp3-NFAT complexes
drive Treg-specific genes. Mutation of the NFAT interaction sites in the Foxp3
protein resulted in an inability to induce a Treg gene expression signature and
suppressor function [47]. A similar loss of function was seen when Foxp3-Runx-1
interactions were disrupted [48].
FOXP3 gene expression also mediates heritability of Treg phenotype and the
generation of induced Treg. Three conserved sequences in the FOXP3 gene,
conserved non-coding DNA sequences (CNS) 1, 2 and 3 have been shown to be
important for these functions. Knockout of CNS3 results in reduced Foxp3
expression and increased proliferation in Foxp3 precursors, suggesting a role in the
thymic development of Treg. CNS2 knockouts showed that this region of the FOXP3
gene is dispensable for Foxp3 expression in thymic Treg but is important in
heritability of Foxp3 expression. If Foxp3+ cells from CNS2 knockout animals are
made to proliferate, they demonstrate a marked impairment in the maintenance
Foxp3. CNS1 is considered entirely dispensable for thymic development but is
thought to be important for peripheral induction of Treg. CNS1 knockout results in a
failure to accumulate Foxp3+ cells over time, however young mice suffer no
pathology, implying that thymically derived Treg are sufficient to prevent
autoimmunity [49].
Recently, it has been found that like other Treg markers, FOXP3 can be upregulated
by responder T cells after activation but this does not confer a suppressive phenotype
[50]. This has cast some doubt on Foxp3 as a definitive marker of Treg. However,
recent advances in epigenetic analysis of Treg has found that conventional T cells
Chapter 1
36
that upregulate Foxp3 display only partial demethylation of CpG residues in the
proximal promoter of FOXP3, thus identifying methylation status of the Foxp3
promoter as a way of discriminating activated responder T cells from Treg [51].
1.1.3 Regulatory T cell development
Treg can be divided into those which develop from immature T cells in the thymus,
termed natural Treg (nTreg) or those which are induced from T cells in the periphery
in response to various tolerising stimuli (iTreg). Additionally, Treg can be induced in
vitro and are also referred to as iTreg, though methods of their induction vary (Figure
1.2).
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Figure 1.2. Differences in natural and induced Treg
Natural Treg (nTreg) develop in the thymus and require a TCR signal, a co-
stimulatory signal, gamma chain cytokines and NFκB signalling. On their surface
these cells express CD25, GARP, GITR, CTLA-4 and TNFR2. At the genetic level
neuropilin-1 (nrp-1), Helios, granzyme A (Gzma) and vascular cell adhesion protein
(Vcam) have been shown to be expressed in murine nTreg. In vivo induced Treg
(iTreg) develop in the lymph node and expand at the site of inflammation. The
factors that can drive this induction are listed in the box. Whilst these cells share the
same surface markers as nTreg, they express lower levels Nrp-1, Helios, Gzma and
Vcam but have increased expression of Ctla-4 and Il10. Compared to in vivo induced
iTreg, in vitro iTreg have reduced gene expression of Helios and Ctla-4 but increased
expression of Il2ra.
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1.1.3.1 Natural regulatory T cells
Naturally occurring Treg (nTreg) arise from a pool of moderately self-reactive cells
that escape negative selection in the thymus [52, 53]. Indeed, experiments where
TCR from Treg were transfected on to responder T cells resulted in a robust
expansion of cells and an autoimmune pathology when injected into lymphopaenic
recipient mice [54]. Moreover, the crossing of mice expressing an OVA TCR to
animals with an AIRE-driven expression of OVA in the thymic epithelium resulted
in a substantial increase in nTreg [55]. This suggests that recognising antigen in the
thymus is essential for developing a Treg phenotype. Indeed, mice which lack the
ability to signal downstream of the TCR fail to generate thymic Treg [19].
Furthermore, there is a decrease in Treg in CD28 deficient mice and mice which are
deficient in CD80 or CD86 [56] suggesting that Treg development also requires a co-
stimulatory signal.
Additionally, evidence suggests that TCR and CD28 signals induce Treg
responsiveness to cytokine signals. Indeed, development of Treg requires the activity
of IL-2 and in lesser part IL-7 and IL-15 signalling through common gamma chain
cytokine receptors. Mice that are deficient in IL-2 or IL-2 receptor a have a reduction
in Foxp3+ thymocytes. Furthermore, mice with a combined deficiency in IL-2, IL-7
and IL-15 or gamma chain cytokine receptors demonstrate a complete ablation of
Foxp3+ thymocytes and peripheral Foxp3+ T cells [57, 58]. A suggested candidate
for mediating gamma chain cytokine receptor signals to Treg is the signalling protein
Signal Transducer and Activator of Transcription (STAT) 5. STAT5 can bind
directly to the Foxp3 promoter and CNS2 [57]. Moreover, knockout of STAT5
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results in a reduction in Foxp3+ thymocytes [59] whereas constitutive expression of
STAT5 results in expansion of Treg cells and a rescue of the CD28 knockout mouse
pathology [60].
Downstream of the TCR signal, the nuclear factor kappa-light-chain-enhancer of
activated B cells (NFκB) pathway has been shown to be important for generation of
nTreg. Whilst, deletion of the p50 subunit of NFκB resulted in an increase of Foxp3
[61], a loss of function mutation of IKK or deletion of Bcl-10, both activators of
NFκB, leads to a reduction in Foxp3+ thymocytes [62]. This suggests that activation
of different NFκB family members may have differential effects on Treg fate.
Recently it has been shown that enhancing NFκB expression using a constitutively
activated IKK transgene led to an increased number of Foxp3+ cells in the thymus. It
was found that in Treg from these mice, CNS3 intronic enhancer region of Foxp3
was demethylated. This suggests that NFκB signalling can promote the
demethylation associated with stable Foxp3 expression in mature Treg [63]. It is
thought that the NFκB family member that contributes to the development of Treg is
c-Rel. c-Rel can mediate the formation of a Foxp3 specific enhanceosome,
containing c-Rel, NFκB family member p65, NFAT, smad and cAMP response
element-binding (CREB) [64]. Moreover, c-Rel-deficient mice have a reduced
number of Treg [65].
Thus in order for a Treg to develop in the thymus, an immature T cell must recognise
antigen and receive a co-stimulatory signal, but this signal must not be so great that
the T cell is deleted. This makes the putative Treg responsive to cytokines, resulting
in the activation STAT5 which directly interacts with Foxp3 to drive the Treg
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phenotype. Additionally, TCR signals can activate the NFκB family member c-Rel
and the consequent formation of a Foxp3 enhanceosome can contribute to the
development of Treg.
1.1.3.2 Induced regulatory T cells
In addition to naturally occurring Treg, under specific conditions expression of
Foxp3 and the acquisition of a suppressive phenotype can be induced in peripheral T
cells. These cells are termed induced Treg (iTreg) and are typically generated by
either a suboptimal signal through the TCR or a strong TCR signal in the presence of
large amounts of transforming growth factor beta (TGF-β) [66]. A population of
iTreg known as Tr1 cells are an exception in that they do not express Foxp3, but
rather like responder T cells, up-regulate Foxp3 after activation. It has been shown
that IL-10 in the presence of repeated TCR stimulation can induce Tr1 cells ex vivo.
Tr1 cells suppress primarily through the production of anti-inflammatory cytokines
IL-10 and TGF-β. As a result, once these cells are activated they can suppress in a
non-antigen specific manner [67].
Using an animal model that generates tolerance to ingested antigens (oral tolerance),
it has been possible to investigate the induction site of iTreg. Oral tolerance is absent
in mice without mesenteric lymph nodes [68], suggesting that lymph nodes are vital
for iTreg generation. However, the expansion of these iTreg is absent when Treg are
unable to traffic to the gut [69]. Thus, Treg need to encounter antigen in the lymph
node, but also experience the site of inflammation in order to proliferate and mount
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an effective response. Although inflammatory environments differ, one could
suggest that this is a general model for the induction of Treg in the periphery.
1.1.3.3 Differences between nTreg and iTreg
It seems clear that thymic Treg are sufficient to prevent autoimmunity because
animals that fail to induce Treg in the periphery do not develop autoimmune
pathology [49]. Thus, what is the role of iTreg? Do they work in concert with natural
Treg? Or do they have a division of labour? One of the biggest hurdles in answering
this question, and indeed in understanding iTreg is that Treg induced in the periphery
are indistinguishable from nTreg. However, microarray analysis of murine natural
and peripherally induced Treg showed that there are differences at the genetic level
between these Treg subsets. Both Helios and Nrp-1 were shown to be expressed at a
higher level in nTreg than iTreg [70]. Furthermore, nTreg had a greater expression of
Gzma, the granzyme A gene, compared to iTreg whilst iTreg were shown to have an
increased expression of the Il10 gene and the Ctla4 gene. Moreover, a genetic
comparison of in vivo and in vitro iTreg revealed that the in vitro induced cells
expressed much less Ctla-4, the negative regulator of CD28 signalling, than in vivo
induced Treg but much more Il2ra (CD25). Despite this, these two populations of
iTreg displayed very similar suppressive ability in vivo [71].
Thornton et al. described Helios, an Ikaros transcription factor family member, as a
marker for thymic Treg. They showed that all CD4+Foxp3+ murine thymocytes were
Helios+ whereas in the peripheral Treg pool the number of Helios+ Treg was 70% in
both humans and mice. Furthermore, it was shown that in vitro induced Treg and
Treg induced in vivo by oral antigen were Helios negative. It seems that under these
Chapter 1
42
conditions Helios could identify thymic Treg [72]. However, there has been some
controversy. Like Foxp3 it appears that Helios may be expressed transiently during
activation [73], and that this is dependent upon differential stimulation conditions. It
was found that induction of Treg from the T cells of RAG-deficient mice, which
have no natural Treg, were 50-60% Helios positive if cultured with APC presenting
subimmunogenic concentrations of antigen. The authors saw similar results to
Thornton et al. if they stimulated cells in vitro with anti-CD3 and anti-CD28 [74]. An
additional study has shown that the induction of Treg by intra-venous injection of
peptide generated cells that express Helios and the continued expression of Helios
was associated with continued antigen dependent stimulation [75]. However, while
these data may preclude Helios as a definitive marker of thymic Treg, there are still
observed differences in Helios gene expression in iTreg [70] so further investigations
into the function of Helios in Treg are required to fully elucidate its role.
Neuropilin 1 (Nrp-1) is a surface marker preferentially expressed by Treg [76].
Moreover, ectopic expression of Foxp3 has the capacity to drive Nrp1 expression
[76, 77]. Sarris et al. showed that in the absence of inflammation the specific
expression of Nrp-1 on Treg increases the contact time with immature DCs. This
makes Treg more sensitive to priming with low levels of antigen than responder T
cells which have little or no expression of Nrp-1 [78]. Conditional knockout of Nrp-1
does not result in an inflammatory phenotype nor a defect in Treg generation [79].
However, targeted deficiency of Nrp-1 on murine Treg resulted in worse
experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple
sclerosis. Transfecting CD4 T cells from these animals with Nrp-1 was sufficient to
suppress proliferation and cytokine production in vitro [80].
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Many mouse models prove the importance of Treg by transferring naïve T cells into
immunodeficient mice, causing disease and then preventing this by the co-transfer of
Treg. Using a murine colitis model Haribhai et al. showed that taking naïve cells
from Foxp3-deficient mice and co-transferring nTreg from a wildtype mouse does
not cure disease. In these experiments disease could only be cured when nTreg were
transferred together with in vitro induced Treg [70]. Moreover, similar experiments
showed that lymphoproliferative disease is only completely absent in Foxp3-
deficient mice adoptively transferred with wildtype T cells upon the conversion of a
proportion of responder T cells to iTreg [71]. This suggests that nTreg and iTreg
have specific distinct roles in suppressing inflammation.
1.1.4 Mechanisms of regulatory T cell suppression
There are a number of proposed mechanisms of Treg suppression (Figure 1.3). These
include both contact-dependent and soluble factor-dependent pathways.
1.1.4.1 IL-2 deprivation
It has been suggested that high expression of the IL-2 receptor α (CD25) on Treg
could outcompete T cells for IL-2, resulting in apoptosis of pathogenic responder
cells. Indeed, pre-treatment of responder T cells with IL-2 reduced levels of
apoptosis when cells were subsequently cultured with Treg [81].
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Figure 1.3. Depiction of different putative mechanisms of regulatory T cell
suppression.
The suppressive mechanisms utilised by regulatory T cells (Treg) to suppress
responder T cells (Tresp) include the production of inhibitory cytokines such as IL-
10, IL-35 and the soluble and membrane bound isoforms of transforming growth
factor beta (TGFβ and mTGFβrespectively), (2) cell killing e.g. granzyme B or IL-2
deprivation through elevated expression of IL-2Rα (CD25) on Treg, (3) enzyme
activity of CD39 and CD73 catalysing the breakdown of adenosine triphosphate
(ATP) to adenosine which can signal to Tresp via their expression of adenosine A2A
receptor (A2AR), (4) inhibition through effects on dendritic cells (DC), including the
triggering of indoleamine 2,3-dioxygenase (IDO) production, (5) contact-dependent
inhibition via cytotoxic T-lymphocyte antigen 4 (CTLA-4) or lymphocyte-activation
gene 3 (LAG-3).
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1.1.4.2 The production of anti-inflammatory cytokines interleukin-10,
transforming growth factor beta and interleukin-35
Cytokines produced by Treg have also been shown to be important for suppression.
Treg express TGF-β-1 on their surface and this can be increased by stimulation with
anti-CD3 in vitro [82]. TGF-β in either the membrane bound form [82] or soluble
TGF-β produced by Treg was shown to be required to inhibit Th1 cell differentiation
and inflammatory bowel disease [83]. Moreover, TGF-β knockout mice have
multifocal inflammatory disease [84]. Similarly, ablation of IL-10 in Foxp3+ cells
showed that IL-10 was important for maintaining tolerance at mucosal surfaces [85].
Furthermore, IL-10 and TGF-β have been shown to mediate the suppressive function
of Treg induced by anti- tumour necrosis factor (TNF) therapy [86].
More recently Treg producing IL-35 have been described. IL-35 is part of the IL-12
family of cytokines, made up of a p35 subunit and EBI3 (Epstein-Barr virus induced
gene 3). In the absence of either subunit, murine Treg which have been adoptively
transferred into lymphopaenic recipients fail to control proliferation and the animals
develop inflammatory bowel disease [87]. Moreover, the addition of recombinant IL-
35 can inhibit both human and murine T cell proliferation. In addition to suppressing
T cells, IL-35 is sufficient to convert responder T cells into hyporesponsive,
suppressive but Foxp3 negative Treg (iTr35). These cells suppress via the production
of IL-35 but not IL-10 or TGF-β. Despite this, IL-10 appears to be required for the
optimal conversion of responder T cells to iTr35 cells. IL-10 mutant mice or
blocking antibodies result in an impairment in conversion but not suppressive
function of iTr35 [88]. Using transwell experiments where murine Treg and
responder T cells were cultured together in the upper chamber and responder T cells
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were cultured in the lower chamber separated by a permeable membrane; it was
shown that optimal IL-35 production was only induced from Treg that had made
direct contact with responder T cells. This suggests that Treg can simultaneously
utilise both contact dependent and soluble factor dependent pathways. Interestingly,
in this assay the neutralisation of IL-10 reduced the suppressive ability of nTreg.
This suggests that IL-35 and IL-10 can function in synergy to suppress responder T
cells after contact dependent interaction [89].
It has been suggested that IL-35-induced Treg can mediate the suppression of IL-17
production, which is largely outside the control of nTreg [90]. Indeed, IL-35 has
been used therapeutically to treat a mouse model of RA, collagen induced arthritis
(CIA), and works through the expansion of Treg and the suppression of IL-17 [91].
There is some debate however about the role of IL-35 in human Treg. Some studies
have shown that human nTreg do not make IL-35 [92] whilst others have shown IL-
35 production by Treg mediates contact independent suppression and conversion of
responder T cells to iTr35 cells [93].
1.1.4.3 CD39
An excess of adenosine triphosphate (ATP) is released by cells as they die and drives
inflammation through the recruitment and maturation of dendritic cells which
express ATP receptors [94]. In turn, the breakdown of ATP into adenosine by the
endonucleotidases CD39 and CD73 can inhibit pro-inflammatory responses [95]. In
mice CD39 and CD73 are co-expressed on Treg and CD39 null mice fail to prevent
allograft rejection in vivo [96]. Moreover, CD39 knockout animals show increased
susceptibility to colitis and this has been linked to a CD39 SNP associated with
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susceptibility to colitis in humans [97]. Similarly, CD73 knockout animals have
increased expression of inflammatory cytokines in a transplantation model. This
deficiency in CD73 is rescued by the addition of an agonist of the adenosine A2A
receptor [98]. Moreover, a study has shown that Treg cannot suppress responder T
cells which lack A2A receptor expression [99]. Thus, the capacity of CD39 and
CD73 to mediate the suppression of inflammatory responses requires adenosine
receptor expression on the target cell.
In humans, however, it is unclear if CD39 and CD73 are co-expressed on Treg. One
study found that CD39 was expressed on Treg, but CD73 was absent [100], whilst
another found that only 0.2% of whole T cells co-expressed CD73 and CD39 [101].
By contrast, others have detected co-expression of CD39 and CD73 on human Treg
[102, 103]. Despite this controversy, CD39 activity has been implicated in the
suppressive function of human Treg.  Gandhi et al. showed that iTreg suppression of
responder T cells was reversed by a CD39 specific blocking antibody [104].
Furthermore, Fletcher et al. described a subset of natural Treg that expressed CD39.
Upon isolation these cells could suppress IL-17, a characteristic not observed in
whole Treg. Suppression was TGF-β-independent and could be imitated by the
addition of adenosine. However, inhibitors of adenosine breakdown or binding did
not reverse the suppressive ability of CD39+ Treg [105]. Thus CD39 expression
identified a population of IL-17 suppressing cells and adenosine demonstrated the
capacity to regulate IL-17 production. However, it is still unclear if the generation of
adenosine by CD39 activity on Treg was required for the suppression of IL-17
responses in this study.
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1.1.4.4 Cytotoxic T-Lymphocyte Antigen 4
CTLA-4, like CD28 can bind CD80 and CD86. It has been shown that in CD28
deficient mice, cells which express CTLA-4 cannot provide a co-stimulatory signal
to the T cell [106]. Moreover, mice that are deficient in CTLA-4 suffer fatal
autoimmune pathology [107, 108] implicating CTLA-4 as a negative regulator of T
cell activation. In contrast to CD28, which is constitutively expressed on T cells,
CTLA-4 is only constitutively expressed on Treg [109, 110]. The interaction of
CTLA-4 with CD80 and CD86 on DCs has been shown to down modulate their
expression [111]. Indeed, autoimmunity in mice with a selective loss of CTLA-4 on
Treg is prevented by the blockade of CD80/86 by CTLA-4Ig [112]. Quite recently it
has been shown that CTLA-4 functions by efficiently binding to B7 family members
and trans-endocytosing the whole molecule. This rips the co-stimulatory molecules
from the surface of APCs so that they fail to effectively stimulate T cells [113].
Whilst this is perhaps the major function of CTLA-4, it has been suggested that this
molecule can contribute to the induction of tolerance through other mechanisms.
There is evidence that signalling through CD80/86 induces indoleamine 2,3-
dioxygenase (IDO) which can degrade tryptophan to by-products which suppress T
cell proliferation [114]. Indeed pharmacological inhibition of IDO abrogates the
protective effects of CTLA-4 Ig [115]. However IDO deficient mice do not resemble
CTLA-4 deficient mice and lack a dysregulated immune phenotype [116]. So
tryptophan breakdown may only comprise a small facet of CTLA-4 biology.
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1.1.4.5 Lymphocyte-activation gene 3 and Granzyme
Another surface marker thought to mediate Treg suppression is lymphocyte-
activation gene 3 (LAG-3), a CD4 homologue that can bind MHC class II. LAG-3-
CD4 interaction can prevent DC maturation and co-stimulatory molecule expression.
Natural Treg express LAG-3 upon activation and this is enhanced in the presence of
responder T cells. Moreover, LAG-3-deficient mice have impaired regulatory
activity. Ectopic expression of LAG-3 on CD4 T cells reduces their proliferation and
confers them with suppressive ability. Despite having greater affinity for MHC than
CD4, LAG-3 does not appear to outcompete CD4 for MHC. In fact the mechanism
of LAG-3 mediated suppression is unknown, though there is a correlation between
LAG-3 expression and IL-10 mRNA in iTreg [117].
Treg have also been show to suppress by granzyme B-mediated cytolysis of effector
cells or APCs [31, 118]. In vivo it was shown that granzyme B was required for
maintenance of skin allograft transplant and the suppression of tumour clearance
[118, 119].
Thus, it is unclear exactly which mechanisms Treg use in vivo. It is possible that they
utilise all of the mechanisms described above and the method of suppression is
dependent upon environmental cues.
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1.1.5 Regulatory T cells in rheumatoid arthritis
As previously discussed, Treg are vital to the prevention of autoimmunity. Thus, it
was hypothesised that Treg from patients with active RA would demonstrate a defect
in number or suppressive function. Some studies have described a decrease in
circulating Treg in patients with RA compared to healthy controls [120-122],
suggesting a numerical defect in Treg may contribute to disease pathogenesis.
However, other groups have shown no difference [123-126] and some have even
shown an increase in Treg in RA patients compared to healthy controls [127, 128].
An increase in FOXP3+ cells has also been reported in the synovial fluid of patients
with RA, and these cells were shown to be potent suppressors in vitro. However, the
activated T cells from this site appear to be resistant to suppression [127], which
explains the inability of Treg to dampen inflammation in the joint.
Upon investigation of the suppressive function of Treg from patients with RA,
Ehrenstein et al. showed that whilst Treg from patients with active RA were
proficient suppressors of proliferation, in contrast to healthy controls, Treg from
these patients were unable to suppress the production of TNF and IFNγ from
responder T cells in vitro. These data have since been confirmed in studies by two
independent groups [129, 130]. Thus, whilst there is some controversy regarding the
numbers of circulating Treg in patients with active RA, there is a consensus that Treg
from these patients are defective. This defect has been associated with reduced
expression of CTLA-4 on Treg from patients with active RA compared to Treg from
healthy controls. Indeed, forced expression of CTLA-4 by PMA treatment was
sufficient to restore suppressive capacity to Treg from patients with active RA [37].
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1.1.6 Factors which contribute to the breach of tolerance in rheumatoid
arthritis
1.1.6.1 Genetic polymorphisms associated with rheumatoid arthritis
Many of the SNPs associated with the development of RA (Table 1.2, pg 52) code
for proteins that, if altered, could change the very nature of the immune response.
Thus providing rare insight into the pathways that lead to the generation of
autoimmunity.
Interestingly, a number of these SNPs can be grouped according to their role in the
immune response. Human leukocyte antigen (HLA)-DR and protein tyrosine
phosphatase, non-receptor type 22 (PTPN22) are important for T cell activation,
TNF receptor-associated factor 1 (TRAF-1), A20 (tumour necrosis factor, alpha-
induced protein 3) and CD40 are members of the TNF receptor signalling family and
IRF5 and STAT4 are important for cytokine responses. Indeed T cell
hyperactivation, TNF activity and widespread cytokine production are key features
of RA pathogenesis. Moreover, antigen presentation (HLA-DR), T cell signalling
(PTPN22) and T cell trafficking (CCL21) are important features of central and
peripheral tolerance. Thus alterations of these pathways caused by RA-associated
SNPs could undermine tolerogenic mechanisms and prolong inflammation.
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Table 1.2 Single Nucleotide Polymorphisms associated with the development of
RA
SNPs can be divided into those that are implicated in antigen presentation and T cell
receptor signalling (yellow), TNF receptor signalling pathways (blue), cellular
differentiation factors (pink), those with weak genetic association but with a role in
RA pathogenesis (purple) and inflammatory amplifiers (green).
SNP Encodes Association of molecule with disease
HLA-DR
MHC class II molecules which
present antigen to CD4 T cells.
All HLA-DR molecules associated with RA
share an amino acid residue on one side of the
antigen-binding site, the shared epitope.
PTPN22
Protein tyrosine phosphatase that
deactivates Lck an important
mediator of T cell signalling.
T cells with the RA-associated SNP display
potent negative regulation of T cell signalling.
Associated with rheumatoid factor positive
RA and an earlier disease onset.
TRAF-1
Negative regulator of TNF
receptor signalling.
Animals deficient in TRAF-1 have increased
proliferation dependent on TNFR2 and
increased cell death dependent on TNFR1.
A20
Negative regulator of NFκB
activation in response to TNF or
TCR signalling.
Conditional myeloid cell knockout of A20
leads to the development of a RA-like disease.
A20 is repressed in RA SNPs.
CD40
Surface molecule required for T
cell dependent antibody response,
induction of co-stimulatory
molecules  on APC and
modulating apoptosis.
CD40 SNP in patients with RA is associated
with a higher rate of joint destruction in
ACPA-positive patients [131].
STAT4
Signalling molecule expressed in
Th1 cells in response to IL-12.
RA associated SNP is located in the third
intron of STAT4.
Individuals homozygous for this SNP are 60%
more likely to develop RA
IRF5
Regulates type I interferons in
response to stimulation via TLR7
and TLR9.
SNP is in the promoter region of the gene and
is associated with ACPA negative patients.
There are increased type I interferons in RA
patients.
PADI4
Encodes  PAD enzymes
responsible for the conversion of
arginine to citrulline under
oxidative stress, differentiation
and apoptosis.
Weak genetic association with RA, despite
ACPA antibodies being a key feature of RA
pathogenesis.
CTLA4
Negatively modulates CD4 co-
stimulation through trans-
endocytosis of CD80/CD86 on
antigen presenting cells.
Weak genetic association with RA in
Caucasians, but RA patients have reduced
CTLA-4 expression on Treg and CTLA-4 Ig
is an effective therapy in RA.
C5
Member of the complement
pathway. C5a is a potent
inflammatory mediator and C5b
is important for the formation of
membrane attack complexes.
C5aR expression on RA synovicytes showed
correlation with the number of swollen joints.
An anti-C5 inhibitor is presently in trials for
the treatment of RA.
CCL21 The ligand of CCR7, important
for the homing of T cells and DC
to secondary lymphoid organs.
Synovial CCL21 induces vascularisation and
is modulated by TNF.
Implicated in the formation of lymphoid
tissue.
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1.1.6.2 The role of infection in the development of rheumatoid arthritis
There has long been considered a link between infection and the development of
autoimmunity. Mice that spontaneously develop EAE do not do so in pathogen free
conditions [132], thus highlighting that genetic susceptibility is not sufficient for the
development of autoimmunity. Microbial infections can initiate or enhance
susceptibility to autoimmunity by stimulating a strong inflammatory response.
Moreover, microbial fragments can directly stimulate fibroblast-like synovial cells
(FLS) via their expression of toll-like receptors (TLRs). Stimulation of FLS with a
TLR2 agonist stimulated the production of chemokines such as CXCL8, CCL5 and
CCL8 for the recruitment of inflammatory cells [133]. In RA, parovirus B19 is
thought to be an infection associated with the development of disease. Parovirus B19
genetic material was detected in the synovial membrane of 75% of RA patients [134]
compared to just 17% in patients with osteoarthritis. Similarly, Epstein barr virus
material is found in 34% of RA patients and just 10% of healthy controls [135].
Microbes can also share epitopes of self-antigens in a phenomenon called molecular
mimicry. These epitopes initiate clonal expansion of T cells in response to the
microbial infection, but inflammation is prolonged because the antigen is also
expressed on the tissues of the infected individual. Porphyromonas gingivalis
(P.gingivalis) is associated with the development of RA. This oral bacterium can
citrullinate the bacterial form of enolase [136]. This may in turn drive a cross-
reaction with human citrullinated enolases. Citrullinated proteins are thought to be
important for the initiation of RA (discussed in section 1.1.71). Indeed, mice with an
RA susceptible MHC (DR4-IE transgenic mice) immunised with P. gingivalis-
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derived enolase developed an autoimmune response upon exposure to mammalian α-
enolase [137]. Thus, infection could initiate an aberrant immune response to self-
tissue.
1.1.6.3 Environmental, hormonal and stochastic factors associated with the
development of rheumatoid arthritis
There are many environmental factors associated with the development of RA
including silica dust and cigarette smoke. These factors are usually associated with
tissue stress and damage. Indeed, expression of TLR3 on FLS allows these cells to
respond directly to RNA from necrotic cells linking tissue trauma to the development
of proliferative, invasive synovial cells in RA [138].
Smoking has been widely described as a risk factor for RA [139] and there is
evidence of increased citrullinated proteins in the bronchoalveolar lavage of smokers
with pulmonary infections [140]. It has been found that cyanide in cigarette smoke
can activate thiocyanate ions in lung tissue, which in turn can be broken down into
homocitrulline. Moreover, increased levels of homocitrulline peptides have been
associated with arthritides in which patients test positive for anti-citrullinated protein
antibodies (ACPA) [141]. Interestingly, smoking is only a risk factor for RA in
individuals who carry HLA-DRB1 shared epitope alleles [142]. Indeed, citrulline
has been shown to fit directly into this conserved region which has a strong
association with the development of RA [143]. Moreover, MHC class II
susceptibility genes for RA have been found to correlate with production of ACPA
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[144]. Thus, this provides a direct pathway for citrullinated proteins to trigger RA in
genetically susceptible individuals.
There is expression of sex hormone receptors on monocytes and in vitro
physiological levels of oestrogen stimulate IL-1 production, but high levels reduce
IL-1 production by RA monocytes [145]. Moreover, IL-6, TNF and IL-1 can drive
the activation of the stress system and the production of glucocorticoids from the
adrenal gland which can in turn modulate the immune response [146].
1.1.7 Proposed rheumatoid arthritis antigens
The final step in the initiation of RA is the presentation of autologous antigen to T
cells. However, the antigen that triggers disease is unknown. Moreover, it is unlikely
to be the same for all patients with RA. It is clear that the immune response
commences some time before the onset of clinical symptoms because a study of
blood donors who later went on to develop RA found that rheumatoid factor
antibodies and ACPA were present up to 3 years before diagnosis [12, 13]. This also
implicates citrullinated proteins or immune complexes as possible triggers of RA and
is discussed more below. In addition, there are a number of endogenous antigens that
are possible candidates for driving RA. Proteins such as type II collagen [147],
proteoglycans [148], aggrecan [149] and heat shock proteins [150] have been shown
to drive responses in lymphocytes from patients with RA more readily than healthy
controls.
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1.1.7.1 Citrullinated proteins
Eighty percent of RA patients present with anti-citrullinated protein antibodies
(ACPA) [151] and serum levels may predict disease activity [152]. Citrullination is a
post-translational conversion of an arginine residue to citrulline. As a result,
citrullinated proteins are unlikely to have been presented to developing T cells in the
thymus, which increases the chances of citrullinated proteins initiating a breach of
tolerance. The conversion of arginine to citrulline is important for gene regulation,
nuclear lamina deorganisation, nucleosomal collapse, vimentin filament collapse,
organising the matrix of keratins, protein demethylation and vimentin regulation
[153]. PAD4 is a peptidylarginine deiminase, part of a family of enzymes responsible
for the conversion of arginine to citrulline. A polymorphism in PADI4, the gene that
codes PAD4, has a weak association with the development of RA. Furthermore, it
has recently been shown that a general PAD inhibitor was able to reduce the severity
of CIA, reducing citrullination, anti-mouse type II collagen antibodies,
histopathology scores and total complement C3 deposition [154].
Citrullinated proteins are detectable in the synovium of RA patients and include
citrullinated fibrin, vimentin, type II collagenase and alpha-enolase [155-158].
Indeed, in the RA synovium, conditions of oxidative stress and cell death are
common [14, 159] and can drive production of intracellular calcium. High levels of
intracellular calcium can trigger the activation of PAD enzymes which catalyse the
citrullination of proteins including vimentin. Loss of membrane integrity associated
with cellular necrosis could expose this protein to uptake by APCs. In individuals
with the RA susceptible HLA allele the citrulline residue may be recognised by the
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shared epitope region and trigger an autoimmune response [153]. In DR4-IE
transgenic mice, only citrullinated fibrinogen could cause arthritis; unmodified
fibrinogen did not drive disease. Moreover, it was shown that intra-articular injection
of antigen to the joint drove disease and this was absent in animals that were injected
elsewhere. Thus, citrullinated proteins specifically drive an arthritis-like disease, but
these proteins must be expressed in the joint [160]. This implies that even if
environmental factors such as smoking generate citrullinated proteins in the lung
tissue, the immune response must be targeted to the joint by an additional factor.
Thus, conditions in the synovium such as stress, apoptosis and cellular differentiation
could activate PADS, increasing citrullination and the chances of presentation of
citrullinated proteins to T cells.
1.1.7.2 Rheumatoid Factor
Rheumatoid factor (RF) autoantibodies are found in approximately 80% of RA
patients [161] and react with the Fc portion of IgG [162]. Rheumatoid factor
production is induced by polyclonal activation of B cells and exposure to antigen-
antibody complexes. IgM rheumatoid factor can bind to the relatively unspecific IgG
induced by polyclonal activation increasing avidity for pathogen [163]. Evidence
suggests that RF is not specific for RA but rather is indicative of an ongoing immune
response. This is based upon the fact that 4-30% of healthy individuals can express
RF [164] and RF is found to be increased in other autoimmune and rheumatic
diseases [163]. Despite this, there is little doubt that RF contributes to RA pathology.
IgM RF is highly multivalent and thus forms large immune complexes that are
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poorly soluble and become trapped in the synovium. Not only does this activate the
complement system but it stimulates phagocytosis and the activation of neutrophils
which produce hydrolytic enzymes contributing to tissue destruction [165]. Epstein
Barr, an infection associated with the development of RA, can induce rheumatoid
factor synthesis from both healthy cells and cells from patients with RA [166]. Thus,
RF may be induced by infection, which in the presence of RA susceptibility genes
and citrullinated peptide-antibody complexes that are present early in disease, may
link infection to the development of RA.
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1.2  Inflammation
1.2.1 T cells:
Once it was established that there were two types of circulating lymphocytes, the
thymus derived T cells and the bone marrow derived B cells, it soon became clear
that these two populations influenced one another. In order for B cells to produce
antibodies against so-called ‘thymus dependent antigens’ they required the presence
of T cells; these cells were named helper T cells. In 1974, Hunter and Kettman
showed that the supernatant from a culture of activated T cells was able to stimulate
B cell proliferation and differentiation [167]. This was one of the earliest
descriptions of the activity of cytokines, now known to be pleiotropic soluble factors
vital for cell-to-cell signalling.
1.2.1.1 The Th1/Th2 paradigm
In 1986 Mosmann et al. first described two distinct subsets of T helper cells Th1 and
Th2, defined by their cytokine profile. Each subset was found to offer help to B cells,
but the nature of the help differed [168].  Thus, it became clear that different Th
subsets are necessary for mounting appropriate responses to different pathogens. Th2
cells are induced by IL-4, but also produce IL-4, IL-5 and IL-13. They are
characterised by the high expression of the transcription factor GATA-3 and are
important for immunity to extracellular pathogens. An aberrant Th2 response is
associated with the development of allergy by assisting B cells in the production of
IgE. Th1 cells are important for cell-mediated immunity; they produce IFNγ and are
induced from naïve T cells by IL-12. T-bet, part of the T-box family of transcription
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factors, is known as the master transcription factor of Th1 cells. It is important for
the production of IFNγ  and the stabilisation of the Th1 phenotype [169].
Furthermore, the ectopic expression of T-bet into polarised Th2 cells results in the
production of IFNγ and suppression of IL-4 and IL-5 [170] (Figure 1.4).
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Figure 1.4. T helper cell subsets
In the presence of IL-4 and IL-13 naive T cells up-regulate GATA-3 and STAT6 and
begin producing IL-13 and IL-4. In the presence of IL-12 naive T cells up-regulate
T-bet and STAT4 and produce INFγ. These two cell fates are mutually exclusive.
Alternatively, if naive T cells are activated in the presence of TGF-β with some
combination of IL-1β, IL-23 and IL-6 cells up regulate RORC (in humans) and
STAT3 and begin producing IL-17 and IL-22. In contrast, TGF-β alone is sufficient
to induce regulatory cells that express FOXP3 and STAT5.
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STAT proteins are vital in T cell lineage commitment and different members of the
STAT family have been shown to be associated with different T helper cell subsets.
STAT6 binds the IL-4Rα gene [171], which allows up-regulation of this receptor,
increased responsiveness to IL-4 and a skewing towards a Th2 phenotype. STAT6
knockout mice demonstrate impaired proliferation in response to IL-4 and a
complete abrogation of IL-4 receptor expression. Furthermore, T cells from these
mice fail to differentiate into Th2 cells in the presence of IL-4 or IL-13 [172, 173].
STAT4 is associated with a Th1 phenotype. It has been shown that STAT4-deficient
mice demonstrate disruption of IL-12-mediated T cell functions including
IFNγ  production and differentiation of Th1 cells. Moreover, T cells from these mice
are skewed towards a Th2 phenotype [174, 175].
1.2.1.2 The role of T cells in the pathogenesis of rheumatoid arthritis
In addition to helping B cells produce antibody, inflammatory cytokines produced by
T cells are directly implicated in the pathogenesis of RA. Studies in mice with CIA
suggested that arthritis in these animals was mediated primarily by Th1 cells. Levels
of IFNγ in the joints of diseased animals were directly correlated with disease
severity. This was matched by an almost complete suppression of Th2 cell cytokines
[176]. Subsequent studies showed that CIA mice treated with IL-12 developed
exacerbated disease and that neutralisation of this cytokine reduced disease severity
[177]. Whilst models in which the p40 subunit of IL-12 was knocked out mirrored
the effects of neutralising IL-12, disease models in which the p35 subunit of IL-12
was knocked out resulted in exacerbation of disease [178]. This contradiction was
explained by the discovery of an interleukin made up of the p40 subunit of IL-12
Chapter 1
63
with a novel p19 subunit, named IL-23 [179]. This suggested that IL-23 could be as
fundamental in autoimmune pathology as IL-12. In fact, subsequent experiments in
which the p19 subunit of IL-23 was ablated showed that it was IL-23 and not IL-12
which mediated autoimmunity in a mouse model of colitis [180]. Like IL-12, IL-23
was found to activate STAT4 but to a lesser extent [179, 181]. Rather, STAT3 was
found to transduce intracellular signals in response to IL-23 [181].
STAT3 is the only STAT where knockout is embryonically lethal indicating an
important role for STAT3 in early development [182]. Immunoprecipitation studies
showed that STAT3 phosphorylation is induced by IL-6 and epidermal growth factor
but not IFNγ  [183]. Interestingly both IL-6 and IL-23 have been shown to be
important for the induction and maintenance of a relatively newly described T helper
cell subset, Th17. Moreover, it was found that retroviral expression of STAT3
enhanced the induction of Th17 cells and STAT3 deficiency reduced expression of
retinoic-acid-receptor-related orphan receptors (ROR)γt [184],  the Th17 cell-
associated transcription factor [185]. Thus STAT3 is considered to be vital for the
differentiation of Th17 cells.
1.2.2 Th17 cells
T cells producing IL-17A were first described in 1995 [186] but it was 10 years later
before these cells were defined as a distinct T helper cell subset. Experiments by
Harrington and colleagues found that the induction of CD4+ T cells that could
produce IL-17 was potently inhibited by IFNγ and IL-4. In addition they showed that
in the absence of Th1 or Th2 cytokines, naïve T cells became Th17 cells and this was
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independent of T-bet, STAT1, STAT4 or STAT6 [187]. RORγt was shown to be
necessary for the Th17 cell phenotype because mice reconstituted with the bone
marrow of RORγt-deficient mice had reduced Th17 cells and transduction of cells
from these animals with RORγt reversed this defect [185].
In mice, Th17 cells can be induced from naïve CD4+ T cells cultured in DC-
conditioned media. This induction is prevented by blocking TGF-β and IL-6. The
importance of these cytokines for Th17 cell differentiation was confirmed by adding
IL-6 and TGF-β to stimulated naïve CD4 cells, resulting in their differentiation into
Th17 cells. The addition of IL-1β further augmented this induction [188, 189]. In
humans, the exact combination of cytokines required to induce Th17 cells in vitro is
still somewhat controversial. It is clear that TGF-β is essential for the induction of
human Th17 cells [190-192]. TGF-β is sufficient to induce RORγt expression but
inhibits its function and this inhibition is only reversed in the presence of
inflammatory cytokines [190]. Thus, it has been shown that in addition to TGF-β, the
differentiation of human Th17 cells can be achieved with inflammatory cytokines
including IL-1β, IL-23, IL-21, IL-6 or combinations thereof [190-193].  This has
been disputed however, as one study has shown that neither IL-6, IL-21 nor TGF-β
was sufficient for the induction of human Th17 cells but rather, T cells required
contact with activated monocytes in the context of TCR ligation [194].
Th17 cells mediate the immune response to fungal infections and in addition to IL-
17A have been shown to produce IL-17F, IL-21, IL-22, IL-26, TNFα and CCL20
[193, 195, 196]. Th17 cells have since been identified as key mediators of
inflammation in autoimmune disease [197]. IL-17 levels have been found to be
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elevated in the periphery of patients with RA [198] and IL-17 has been shown to
contribute to joint degradation in these patients [199]. Moreover, activated
monocytes from the joints of patients with RA have been shown to promote Th17
responses [200]. Indeed the ability of monocytes to contribute to the induction of
Th17 cells during inflammation has been reinforced by a study showing that in RA
levels of TNF producing CD14hiCD16+ monocyte numbers correlate with Th17 cell
numbers [201]. Thus, monocyte-driven Th17 cell development could play an
important role in RA pathogenesis.
1.2.3 Th17 cell stability
Studies have identified cells producing both IL-17 and cytokines associated with
other T helper cell subsets. These Th17 “dual producers” are seen most frequently in
disease settings, such as autoimmunity [202] or allergy [203]. Indeed, the adoptive
transfer of Th17 cells to lymphopaenic mice drives the conversion of Th17 cells to
IFNγ producers and triggers an IFNγ-mediated diabetes [204]. Furthermore, fate
mapping IL-17-producing cells showed that Th17 cells are induced during EAE but
that over time these cells stop producing IL-17 and make other cytokines including
IFNγ. Indeed, it was shown that the primary producers of IFNγ in this model had
previously produced IL-17 and that these ‘ex-Th17’ cells retained Th17 cell genetic
markers [205]. This ability for inflammation to convert Th17 cells may explain why
Treg do not demonstrate the capacity to suppress Th17 cells [206]. Thus conditions
in the synovium may favour the differentiation of Th17 cells, which are outside the
scope of natural Treg. In the absence of negative regulation by conversion to other
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cell types Th17 cells could drive inflammation and joint damage almost entirely
unchecked.
1.2.4 The relationship between regulatory T cells and Th17 cells
In 2006 Bertelli et al. were the first group to suggest that there was a reciprocal
relationship between the development of Treg and Th17 cells [189]. In the presence
of inflammatory cytokines, TGF-β can induce Th17 cells and in the absence of an
inflammatory cytokine milieu the induction of Treg is favoured [188]. More recently
it has been shown that Foxp3 can directly interact with the master regulator of Th17
cells, RORγt, in order to suppress the transcription of IL-17 [207]. IL-17 levels are
higher in the periphery of patients with active RA than healthy controls [208]. Thus
the link between these two functionally distinct cell subsets may have some influence
in the pathogenesis of RA.
The aryl hydrocarbon receptor (AhR), a member of a family of environment-sensing
transcription factors, has been shown to be important for both Th17 and Treg
differentiation [209]. The influence of AhR suggests that both of these cell subsets
may be heavily modulated by an inflammatory environment. Naïve T cells from ahr-
null mice did not form Treg in vitro, whilst Th17 cells were reduced in ahr-null mice
upon the induction of EAE [210, 211]. In a murine colitis model, treatment of mice
with a high affinity AhR ligand, TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin),
ameliorated disease. This correlated with an increase in Treg and a decrease in Th17
cells through demethylation of CpG regions in the FOXP3 promoter and an increased
methylation at the IL-17A promoter [212]. Moreover, TCDD has been found to
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ameliorate disease in NOD mice through the induction of Treg [213]. In human cells,
AhR activation promoted the differentiation of Foxp3 negative Tr1 cells, which
suppressed responder T cells via IL-10 and granzyme B. Furthermore, if the same
starting population of cells was treated with an AhR ligand in the presence of TGF-β,
it induced a subset of Treg which suppressed via the activity of CD39 [104].
In addition to responding to environmental cues via AhR, it appears that a metabolic
sensor, hypoxia inducible factor 1 (HIF-1), can modulate Treg and Th17 cell
balance. Mice with HIF-1α deficient T cells are resistant to the induction of EAE and
this is associated with a reduction in Th17 cells and an increase in Treg [214, 215].
This is of particular interest in RA where an hypoxic synovium is a key feature of
disease [216]. Indeed, these data suggest that the hypoxic environment of the joint
might favour the generation of Th17 cells rather than Treg and thus contribute to
joint damage in RA.
Under acute inflammatory conditions the ability of naïve T cells to sense the
environment and differentially activate AhR or HIF-1α for the development of Treg
or Th17 may allow an incredibly plastic immune response. Indeed, there is now a
consensus that human FOXP3 expressing Treg can simultaneously express RORC,
the human homologue of RORγt, and produce IL-17. Moreover, these cells
maintained their suppressive function but the provision of a TCR signal in
combination with IL-1β, IL-21, IL-23 and IL-2 transformed them into responder T
cells [217-219]. In active RA, Treg are defective [220], perhaps in part because they
have up-regulated expression of RORC and are producing IL-17. Indeed, ‘ex-Treg’
have been described when Foxp3+ cells are transferred into autoimmune susceptible
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mice. These ‘ex-Treg’ lost expression of Foxp3 and up-regulated production of
inflammatory cytokines [221]. Thus, the instability of Treg in inflammatory
conditions may contribute to RA pathology.
1.2.5 Th22 cells
IL-22 production from CD4 memory T cells was first described in 2000 [222-224].
Much more recently, a distinct subset of T cells producing IL-22 but not IL-17, IFNγ
or IL-4 has been identified and named Th22 cells [225-227]. These cells express
CCR6, CCR4, CCR10 and can express low levels of RORγt [227, 228], but it is the
ligand-dependent transcription factor AhR that is fundamentally required for the
production of IL-22 from these cells [229, 230]. Mice deficient in AhR can still
produce IL-17, but lose the capacity to produce IL-22 [231]. Plasmacytoid DCs have
been shown to drive the differentiation of Th22 cells through the production of IL-6
and TNF [228] and this can be amplified by vitamin D [225]. Moreover, some
reports demonstrate a role for IL-23 in the induction of IL-22 production [232, 233]
and in mice IL-23 has been shown to be essential for IL-22 production from CD4 T
cells [234]. Interestingly, despite a key role for TGF-β in the differentiation of Th17
cells, originally thought to be the primary producers of IL-22 [193], TGF-β has been
shown to inhibit IL-22 production [232, 235].
1.2.6 The role of monocytes and macrophages during inflammation
During inflammation monocytes are recruited and differentiate into macrophages at
the site of inflammation [236]. Monocytes detected in the synovium are activated
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and show over-expression of MHC class II, cytokines, granulocyte-macrophage
colony-stimulating factor (GM-CSF) and chemokines [237]. Despite these activities
in the synovium, monocytes are found predominantly in the circulation. It is now
clear that monocytes are not simply a population of precursor cells waiting for their
call to arms. In fact, a number of monocyte populations exist but it is still unclear if
they are functionally different.
The largest human monocyte population has high expression of CD14
(lipopolysaccharide receptor) but lacks expression of CD16  (Fcgamma receptor III).
These cells have been shown to be efficient at phagocytosis, and production of
cytokines including IL-1 and colony stimulating factors (CSF). A smaller subset of
monocytes expresses CD16 in addition to CD14. These cells have been described as
less efficient phagocytes, but much better antigen presenters, with increased levels of
HLA-DR and high production of IFNα.  Furthermore, CD16+ monocytes are the
major producers of TNF in human blood [238] and bear a resemblance to mature
tissue macrophages [239, 240]. Moreover, CD14+CD16+ monocytes have been
shown to be increased in the periphery of patients with RA compared to healthy
controls [241]. A third subset of circulating CD14 low CD16++ monocytes represent
a population of ‘patrolling’ monocytes first described in mice. These cells have been
shown to be poor phagocytes, exhibiting an anti-inflammatory phenotype in a steady
state but specialising in the production of pro-inflammatory cytokines TNF, IL-1β,
and CCL3 in response to viruses and nucleic acids [242]. Thus, monocytes may
contribute to inflammation outside the synovium and upon reaching the joint readily
produce TNF without undergoing differentiation to macrophages.
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Macrophage infiltration to the synovium has been shown to correlate with joint
damage [243]. This is largely due to the capacity of these cells to drive synovitis via
the production of pro-inflammatory mediators. In vitro contact between macrophages
and FLS is sufficient to drive macrophage production of pro-inflammatory IL-6,
GM-CSF and CXCL8 [244]. Similarly, T cells cultured with IL-15 can induce
macrophages to make TNF [237] and by contrast IL-10 inhibits the production of
pro-inflammatory cytokines from synovial mononuclear cells whilst decreasing
expression of HLA-DR [245].
1.2.7 The role of B cells in rheumatoid arthritis
T cells assist B cells in the production of antibody. Indeed, the production of
autoantibodies is a key feature of RA pathogenesis (discussed in section 1.1.7).
Antibodies are produced by plasma B cells, which are somatically mutated B cells
with a memory cell phenotype.  Plasma cells are specifically identified by flow
cytometry via high expression of CD27 and CD38 and low levels of immunoglobulin
(Ig) D [246-248]. However, the production of antibody is not the only function of B
cells. B cells are also efficient antigen presenting [249] and effector cells and have
been shown to be important for the activation of T cells and conversely, the
suppression of inflammation.
There is evidence of ongoing T cell help in the RA joint with ectopic follicular units
functioning to support autoantibody production [250]. In about 23% of patients
CD20+ B cells in the rheumatoid synovial tissue can acquire a very distinct
architecture similar to that of the germinal centre (GC) of secondary lymphoid tissue.
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This structure optimises immune responses through co-localisation of antigen and
antigen responsive cells. High levels of CXCL13 from synovial tissue cells and
lymphotoxin beta (LT-β) from B cells can predict the emergence of germinal centres
in patients suggesting that B cells are at least partly responsible for the formation of
these GC [251]. Adoptive transfer of CD4+ T cell clones into a SCID mouse
transplanted with human synovium drove the production of IFNγ, TNF and IL-1β. T
cell activation upon transfer could be abrogated by the elimination of CD20+ B cells
and the elimination of GC in the joint. This suggests that T cell activation requires B
cell interaction in the GC. Importantly, this capacity of B cells could not be replaced
by other APC and so this indicates that the interaction of B cells with T cells has a
key role in T cell activation [252].
Despite a capacity to drive inflammation, B cell deficient mice develop exacerbated
EAE suggesting a protective role for B cells [253]. B cells from the spleen of CIA
mice stimulated with anti-CD40 were shown to become IL-10 producers. Transfer of
these cells back into CIA mice prevented disease whilst B cells from IL-10 knockout
mice failed to have this effect [254]. Moreover, IL-10 producing cells were shown to
be a distinct B cell subset in mice. Transfer of the transitional-2-marginal zone
precursor B cells, present in the spleen of mice under normal conditions but
increased in the remission phase of arthritis, ameliorated CIA [255]. Recently a
population of regulatory B cells has been described in humans. Identified as
CD19+CD24hiCD38hi, upon stimulation with CD40, these cells suppressed the
differentiation of Th1 cells through production of IL-10. This capacity was reversed
by blockade of CD80 and CD86 suggesting that the effect mediated by these B cells
involves offering co-stimulation to T cells in addition to their production of IL-10
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[256]. An interesting recent development has shown that mice that specifically lack
IL-10-producing B cells have a reduction in Foxp3+ regulatory T cells and a
concomitant increase in inflammatory cytokines suggesting that these two regulatory
subsets may have a developmental relationship [257].
1.2.8 Tumour necrosis factor
TNF forms a membrane bound homotrimer (mTNF) that can be cleaved by TNF-α
converting enzyme to generate a soluble molecule (sTNF). Both soluble and mTNF
can bind and signal to TNF receptors (TNFR). TNFR1 (p55) is ubiquitously
expressed and is thought to favour signals via soluble TNF. The cytoplasmic domain
of TNFR1 contains a death domain important in mediating apoptosis in response to
TNF signals [258]. Animals lacking TNF or TNFR1, demonstrated that TNFR
signalling was vital for the formation of B cell follicles in secondary lymphoid
organs but had little effect on humoral immunity [259]. TNFR2 (p75) expression is
limited to the immune system and is thought to preferentially transduce signals
mediated by mTNF [260] and lymphotoxin family members. Furthermore, TNFR2
mediates lymphocyte proliferation and apoptosis of mature activated lymphocytes in
response to TNF [258]. Both TNF receptors are widely expressed on synovial tissue,
largely out-weighing production of TNF [261].
Most members of the TNFR family activate the transcription factor NFκB (Figure
1.2). In unstimulated cells NFκB is present in the cytoplasm bound to IκB to prevent
it entering the nucleus. This ready state of NFκB allows rapid signalling in response
to cellular activation, a vital characteristic of the immune system. Upon stimulation,
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IκB is phosphorylated by the IKK (IκBα kinase) complex. IKK catalyses the
degradation of IκB allowing NFκB to translocate to the nucleus (Figure 1.5). A wide
range of genes have NFκB-binding domains in their promoter regions and these
include pro-inflammatory cytokines, chemokines, immune receptors and adhesion
molecules, which enhance immune response [262].
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Figure 1.5. NFκB signalling pathway
The binding of soluble TNF to TNF receptor (TNFR) 1 can mediate apoptosis via
associated death domains (DD) signalling to caspases. Signalling of membrane TNF
through TNFR2 activates IκB Kinase (IKK). In turn this leads to the degradation of
IκB, allowing NFκB to translocate to the nucleus where it can directly bind to many
genes, including those that control inflammation. Both of these signals can be
negatively regulated by A20 or TRAF-1. Thus the association of SNPs in these genes
with RA heavily implicates differential responsiveness to TNF with development of
disease.
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TNF is a pluripotent molecule that sits at the pinnacle of inflammation. The
association of SNPs in the TNF receptor signalling pathway (see section 1.1.6.1)
with the development of RA implicates TNF as a trigger of autoimmunity. Moreover,
the high levels of TNF detected in the joints of patients with RA [263] indicates that
it continues to modulate the immune system throughout disease pathogenesis.
In RA, macrophage-derived TNF has been shown to drive angiogenesis contributing
to the aberrant disorganised vascularisation of the synovium [264]. Moreover TNF
can act on endothelial cells to induce the expression of adhesion molecules that
promote the recruitment of circulating immune cells to the joint [265]. Stimulation of
synovium-resident cells such as fibroblast-like synovial (FLS) cells or chondrocytes
with TNF can stimulate the production of matrix degrading enzymes [266],
chemokines and proinflammatory cytokines which can in turn contribute to further
joint damage and cell recruitment [267]. TNF can also drive the maturation of
dendritic cells in the RA synovium stabilising MHC expression and upregulating co-
stimulatory markers to activate T cells [268]. Furthermore, many of the T cells in the
rheumatoid synovium share phenotypic characteristics with T cells activated by
cytokines in vitro, high levels of TNF contributing to this phenotype. In turn these
cells have been shown to stimulate TNF production from monocytes in a contact-
dependent manner [269], initiating a positive feedback system which drives TNF
production in the synovium.
The infiltration of TNF-producing macrophages to the RA synovium is directly
correlated with joint damage [243].  Indeed, TNF can contribute to the dysregulation
in bone metabolism associated with cartilage destruction in RA. The binding of
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RANK (receptor activator of nuclear factor kappa-B) on monocytes to its ligand
RANKL on FLS or T cells drives monocyte differentiation to cartilage degrading
osteoclasts [270]. TNF can bind and signal to osteoclast precursors via their
expression of TNFR1 [271] substantially reducing the amount of RANKL required
for the differentiation of osteoclasts [272]. Moreover, this activity of TNF can
increase the number of osteoclast precursors available for differentiation. In patients
with TNF driven diseases this provides an additional link between high
concentrations of TNF and cartilage degradation [273]. In mice with transgenic over-
expression of TNF, osteoclastogenesis was inhibited by treatment with an osteoclast
inhibitory factor, osteoprotegerin (OPG), though there was no improvement in paw
swelling in these animals [274]. Thus in RA, TNF modulates distinct pathways of
inflammation and cartilage degradation. This highlights the benefits of targeting TNF
for therapeutic purposes.
1.2.9 IL-17
IL-17 is produced primarily by Th17 cells and a small subset of innate lymphocytes
named γδ T cells.  By contrast, IL-17 receptor expression is widespread in the
immune system [275]. One of the primary roles of IL-17 is in the recruitment of
neutrophils to the site of inflammation [276]. In human synoviocytes this is
dependent on NFκB signalling and the production of CXCL8 [277]. In moderate
inflammation, one billion neutrophils per day enter the RA joint, but due to lack of
egress, stay there mediating wide scale non-specific destruction of the synovial
tissue. Neutrophils are rapidly activated by debris and immune complexes and
degranulate releasing proteases, prostaglandins and reactive oxygen intermediates
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(ROI) which contribute to tissue destruction [278]. Additionally, ROI and granular
enzymes from neutrophils can contribute to the breakdown of hyaluronic acid, which
impairs viscosity and lubricative potential of the synovial fluid [279].
In addition to contributing to joint damage through the recruitment of neutrophils,
IL-17 is also a potent stimulator of osteoclastogenesis [280]. Adenoviral driven over-
expression of IL-17 in CIA promoted osteoclastogenesis, bone destruction and
expression of RANK/RANKL in the synovial infiltrate and at sites of erosion. This
increased expression of IL-17 was associated with an increased ratio of RANKL to
OPG, compared to non-transfected animals with a similar clinical score.
Furthermore, systemic OPG treatment of the IL-17 transfected mice was able to
prevent joint destruction through restoration of this balance [281].
Studies in mice have provided substantial insight into the role of IL-17 in
autoimmune inflammation. Overexpression of IL-17A in the joints of mice with CIA
increased the recruitment of neutrophils to the joint and exacerbated disease [282].
Furthermore CIA was shown to be ameliorated by treating animals with anti-IL-17
[283]. In SKG mice that spontaneously develop an autoimmune arthritis, pathology
is driven by a cytokine milieu that favours the production of Th17 cells. Moreover,
there is no evidence of arthritis in IL-6 or IL-17 SKG deficient mice but development
of disease is exacerbated in IFNγ knockout animals due to an increase in Th17 cells
[284]. These data suggest that self-reactive T cells which escape the thymus in RA-
susceptible individuals may be pre-disposed to becoming Th17 cells that can, in turn,
promote an inflammatory environment that favours their stability and differentiation.
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Similar to many inflammatory cytokines, IL-17 can drive the production of cytokines
and chemokines from other immune cells. Indeed, IL-17 produced by T cells in the
joint can stimulate macrophages to produce IL-1 and TNF [285] and synergise with
TNF or IL-1 to enhance the production of CXCL8 or G-CSF to levels above that
induced by IL-17 alone [286]. Like TNF, IL-17 can contribute to the reduction in
apoptosis observed in RA through the induction of synoviolin [287], a negative
regulator of the pro-apoptotic molecule p53 [288].
1.2.10  IL-22
IL-22 is a member of the IL-10 family of cytokines and in addition to helper T
cells,IL-22 is produced by a subset of CD8 memory T cells, γδ T cells, NK cells and
innate lymphoid cells [225, 289]. IL-22 signalling is mediated via a heterodimeric
receptor made up of the IL-22R and the IL-10Rβ [223, 224]. Expression of this
receptor complex is predominantly associated with epithelial cells [290]. The
absence of IL-22R expression on cells of the immune system means that unlike most
cytokines, IL-22 does not signal to immune cells [290]. Downstream of its receptor,
IL-22 activates STAT3 [224, 290-294]. Indeed, IL-22 has been shown to activate
STAT3 more strongly than IL-6, the prototype STAT3 activating cytokine [295]. IL-
22 mediates keratinocyte anti-microbial defence, migratory capacity and terminal
differentiation [296, 297] in part through the induction of IL-20 which amplifies
these responses [298]. The effects of IL-22 are further amplified by TNF [299].
In disease, IL-22 has been shown to be important for epithelial remodelling and
driving keratinocyte proliferation and epithelial hyperplasia due to the expression of
IL-22R on keratinocytes [297, 299]. The role of IL-22 at epithelial barriers is
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highlighted by mice with over-expression of IL-22 which develop a skin disease
closely resembling psoriasis [299]. Indeed, IL-22 has been shown to be associated
with increased disease severity in patients with psoriasis [290, 296, 300].  In vitro it
has been shown that IL-22 promotes osteoclastogenesis, suggesting a pro-
inflammatory role for IL-22 in arthritis. Indeed, IL-22 deficient mice are less
susceptible to CIA and demonstrate decreased pannus formation than control mice
[301]. In patients with RA, IL-22 levels are increased in the synovium and the blood
[208, 302-304]. Mirroring the murine models, IL-22 has been shown to promote
osteoclastogenesis through the induction of RANKL on human synovial fibroblasts
[305]. Moreover, serum IL-22 levels have been shown to correlate with radiographic
progression in RA [306].
In contrast, IL-22 has been shown to be protective in hepatitis [307, 308], IBD [291,
309], graft versus host disease in heart allografts [310], autoimmune myocarditis
[311], allergic airway inflammation [312] and uveitis [313]. Furthermore, the
presence of IL-22 producing cells has been associated with tumour progression and a
worse clinical prognosis [233, 314]. The role of IL-22 as a mediator of tissue repair
rather than destruction has been shown in the delayed healing of mucosa in IL-22
deficient mice [293], the involvement of IL-22 in regeneration of liver tissue [294]
and the IL-22 driven repair of keratinocytes after wounding [226]. Furthermore IL-
22 may mediate the prevention of systemic inflammation driven by
lipopolysaccharide (LPS) through the induction of hepatic LPS binding protein
[315].
Chapter 1
80
The pro versus anti-inflammatory capacity of IL-22 has previously been investigated
using an airway inflammation model. The authors showed that IL-22 deficient mice
and mice treated with an IL-22 neutralising antibody had ameliorated disease.
However, if the same disease was induced in IL-17 deficient mice, the neutralisation
of IL-22 exacerbated disease. Furthermore, whilst in vitro administration of IL-22
protected airway epithelial cells from apoptosis, co-administration of IL-17 worsened
airway inflammation. Thus the authors proposed an interesting model whereby the
presence of IL-17 was the deciding factor in the pro- versus anti-inflammatory
properties of IL-22 [316].
1.2.11 IL-6
IL-6 is a pleiotropic cytokine first identified as a B cell differentiation factor [317]
required for the differentiation of plasma cells [318] and promoting B cell antibody
production [319]. It is now known that IL-6 can also drive the production of acute
phase proteins [320], bone metabolism [321], angiogenesis [322], nerve growth [323,
324], the production of glucocorticoids [146] and the differentiation of Th17 cells
[188-191]. Moreover, IL-6 is particularly important in tipping the balance of
monocyte differentiation towards macrophages rather than DCs [325, 326].
IL-6 is produced by many immune cells as well as fibroblasts, keratinocytes and
endothelial cells [327]. It is part of a family of cytokines that utilise two signalling
receptors, an IL-6 receptor (IL-6R) and a signal transducing molecule gp130. Upon
binding of IL-6 to its membrane bound receptor, gp130 homodimerises and binds the
IL-6/IL-6R complex, forming a functional receptor. IL-6R expression is limited to
Chapter 1
81
monocytes, neutrophils, macrophages, hepatocytes and some lymphocytes, which is
somewhat at odds with the broad spectrum of IL-6 activity. However, in addition to
being a membrane bound molecule, IL-6R can be cleaved from the surface of cells or
generated by alternatively splicing mRNA to form a soluble molecule. Due to the
distinctive signalling mechanism of IL-6, soluble IL-6R can bind IL-6 and signal to
any cell bearing expression of gp130, termed trans-signalling. Furthermore, gp130 is
expressed on most body tissues, which explains the pleiotropic function of IL-6. As
with many cytokines, expression of IL-6 can be modulated by a soluble receptor: in
this case soluble gp130 can prevent the binding of the IL-6/IL-6R complex to gp130
on the cell membrane [328].
IL-6 deletion protects mice from developing CIA and also a second murine arthritis
model, antigen-induced arthritis (AIA) [329, 330]. Notably, mice deficient in IL-6
supplemented with recombinant IL-6 did not have a restoration of wildtype AIA
severity. Only when an IL-6/IL-6R construct was transferred did disease activity
return to levels of a wildtype mouse. Moreover, blocking sIL-6R signalling in
wildtype mice using a soluble gp130 molecule ameliorated disease [331]. Thus, the
induction of arthritis appears to specifically require IL-6 trans-signalling. Indeed, IL-
6 activities specifically mediated via trans-signalling have been shown to be
important for leukocyte recruitment and activation in RA [332].
There are high levels of IL-6 in the synovial fluid of patients with RA [333]. This is
associated with increased sIL-6R levels compared to patients with OA [331, 334]
and is correlated with the presence of osteoclast precursor cells [334]. FLS produce
IL-6 when stimulated with IL-1, TNF or IL-17 and IL-6/sIL-6R is sufficient to
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induce proliferation and RANKL expression on FLS [335, 336]. Furthermore, IL-6
can rescue T cells from apoptosis via the activation of STAT3 [337-339].
1.2.12 The effects of inflammation on regulatory T cells
In an inflammatory environment, such as that observed with RA, the full function of
Treg may be inhibited by inflammatory cytokines. Indeed, IL-6 can make responder
T cells resistant to Treg suppression [340] and TNF has been shown to impair the
expression of FOXP3 [130]. Recently however, the relationship between
inflammation and Treg has been readdressed with data suggesting that inflammatory
signals may be important for the induction of Treg. Indeed, TNF was shown to drive
the expansion and activation of Treg via TNFRII [341], which is widely expressed
on Treg [130]. Moreover, mice in which overexpression of human TNF drives an
arthritic pathology, develop a more severe form of arthritis in the absence of global
TNFR2 expression [342] or TNFR2 expression on haematopoetic cells [343]. There
is a well-documented increase in FOXP3+ cells in the synovial fluid of patients with
active RA and these cells are potent suppressors in in vitro suppression assays.
Though the activated T cells from this site appear to be resistant to suppression
[127]. Thus, perhaps cells can be induced by inflammation, but the presence of
inflammation makes responder T cells resistant to suppression. As soon as
inflammation begins to attenuate, iTreg can begin to function to suppress disease.
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1.2.13 Synovitis
Upon immune response to self-antigen in the joint, positive feedback leads to the
accumulation of cells in the joint, and the promotion of factors which drive bone and
cartilage erosion, ligament damage and bone marrow inflammation [267]. In addition
to these features of disease, inflammatory cytokines have been proposed to
contribute to the fatigue and malaise associated with RA [344]. Whilst morning
stiffness and warm joints are explained by increased extracelluar fluid around the
inflamed area and dilation of the synovial blood vessels deep in the tissue.
Inflammation of the synovium is associated with increased vascularisation, cellular
recruitment and production of cytokines. A pannus of proliferating tissue grows over
the cartilage of the joint and becomes heavily infiltrated with inflammatory,
degradative enzyme producing cells. The pannus infiltrate includes large numbers of
macrophages that produce enzymes which can degrade cartilage matrix [345].
Furthermore, many cells resident in the synovium contribute to tissue damage in RA,
including chondrocytes, osteoclasts and fibroblast–like synovicytes (Figure 1.6).
A surprisingly small amount of damage to articular cartilage is required before joints
are weakened to the point where daily activities or exercise on weight bearing joints
leads to disintegration [14]. Bone erosion occurs in about 75% of RA patients within
2 years of diagnosis [346].
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Figure 1.6. Inflammation in the rheumatoid joint
In the secondary lymphoid organ antigen is presented to T cells. This drives the
maturation of B cells to plasma cells. Upon migration to the joint, these produce
autoantibodies including rheumatoid factor (RF) and anti-citrullinated protein antibodies
(ACPA) contributing to the formation of immune complexes. Antibodies can also
activate infiltrating macrophages (mf) and neutrophils via their Fc receptor (FcR) and
can initiate phagocytosis by dendritic cells (DC). Toll-like receptors (TLR), expressed
on mf and fibroblast-like synovial cells (FLS) can recognise bacterial peptides. In
response to stimulation, cells of the synovium can produce pro-inflammatory cytokines
that can in turn stimulate the production of cytokines, chemokines and matrix
metalloproteinases contributing to joint damage. Functional regulatory T cells are also
found in the joint but responder T cells from this site are resistant to suppression
(adapted from [267]).
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1.2.13.1 Angiogenesis
Hypoxia is a potent stimulator of angiogenesis and the inflamed joint is extremely
hypoxic compared to healthy controls [216]. The synovial lining has dense
microvasculature to provide nutrients to the avascular cartilage, but in RA there is a
redistribution of blood vessels and an increased vasculature deep in the synovium.
This new vasculature is less densely arranged, generating pockets of hypoxia [216,
347]. Adenoviral gene transfer of vascular endothelial growth factor (VEGF)
receptor to block angiogenic signals, reduced the severity of CIA and associated joint
damage [348], suggesting that vascularisation of the synovium is key to RA
pathogenesis. The increased vascularisation observed in RA is concomitant with
insufficient lymphangiogenesis, resulting in an accumulation of immune cells as the
joint.
1.2.13.2 Homing of cells to the joint
Inflammatory cytokines such as TNF and IL-1 can act on endothelial cells to induce
the expression of adhesion molecules (including integrins and selectins) that promote
the recruitment of cells to the joint. In the synovium, fibroblast-like synovicytes,
monocytes and macrophages are the major producers of chemokines, which act to
attract inflammatory cells to the joint [14, 267, 349] (Table 1.3, pg. 86).
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Table 1.3 Chemokines involved in rheumatoid arthritis pathogenesis.
1.2.13.3 Matrix enzymes
Cartilage degradation during RA is driven by over production of matrix
metalloproteinases (MMP)s, proteolytic enzymes that have the capacity to degrade
proteins of the extracellular matrix. MMPs are divided into subgroups including:
collagenases, gelatinases, stromelysins and membrane-type MMPs. MMPs are
secreted as proenzymes and activated by serine proteases such as plasmin or elastase,
or by other MMPs including MMP-3 and MT1-MMP. In rheumatoid synovial tissue,
increased amounts of MMPs are expressed, but certain MMPs have been identified at
the site of cartilage degradation in patients with RA [350]. The function of these is
outlined in the table below (Table 1.4, pg 87). Indeed, inhibition of MMP-1
production in SCID mice injected with RA synovial tissue resulted in reduced
Chemokine Receptor(s) Recruits
CXCL8 (IL-8) CXCR1
CXCR2
Myeloid cells
CXCL5 CXCR1
CXCR2
Myeloid cells
CCL2 (monocyte
chemoattractant protein-1)
CCR2
CCR11
Monocytes, DC, basophils
and polymorphonuclear
cells
CCL5 CCR1
CCR3
CCR5
Memory T cells,
granulocytes, Th1 cells,
macrophages, monocytes,
DC
CCL3 (macrophage
inflammatory protein-1)
CCR1
CCR5
Memory T cells, Th1 cells,
monocytes, macrophages,
DC
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invasiveness of FLS [351]. Moreover, over-expression of MMP antagonists, tissue
inhibitors of metalloproteinases (TIMPs), resulted in the inhibition of FLS-mediated
invasiveness and cartilage destruction in the same synovial transplant model [352]
Table 1.4 Matrix metalloproteinases associated with RA
MMP Type of enzyme Other functions
MMP-1 Collagenase I Cell migration
MMP-3 Stromelysin Cell migration
MMP-9 Gelatinase Chondrocyte apoptosis
and recruitment of
osteoclasts
MMP-13 Collagenase III Osteoclast activation
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1.3 Therapy for rheumatoid arthritis
Initial treatment for RA consists of disease modifying anti-rheumatic drugs
(DMARDS) such as methotrexate, sulfalsalazine, hydroxychloroquine, prednisolone
or leflunomide. The most commonly used DMARD is methotrexate (MTX), an anti-
metabolite drug that was initially thought to work by inhibiting cellular proliferation.
It is now known that methotrexate increases the apoptosis of T cells, increases
endogenous adenosine release, alters the expression of adhesion molecules,
influences production of IL-1 and IL-2 and directs bone formation [353]. Aggressive
treatment with a combination of DMARDs soon after diagnosis has been shown to
be highly beneficial for the control of inflammation and bone erosion in RA [354-
356].
1.3.1 Biologic Therapy
Recently there has been a shift towards a more targeted approach - in particular,
biologic therapies that target pathways known to be important in the pathogenesis of
autoimmune disease (Figure 1.7). Principally due to cost considerations a
combination of conventional DMARDs is used first but if these are inadequate, anti-
TNF therapy is indicated. In addition, for patients who do not respond to anti-TNF
therapy or who cannot take this medication for other reasons (e.g. previous
malignancy) the anti-B cell depleting agent, rituximab, the anti-IL-6 receptor,
tocilizumab and the CTLA-4 Ig, abatacept are also available [357].
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Figure 1.7.  Biologic therapies:
Biologic therapies in RA have targeted pro-inflammatory cytokines with the anti-IL-
1 receptor, anakinra, the anti-IL-6 receptor, tocilizumab and the anti-TNF therapies.
A number of anti-TNF therapies are available to treat RA. These include the soluble
TNFR2 molecule etanercept, the chimeric mouse/human anti-TNFα monoclonal
antibody, infliximab and the entirely humanised anti-TNFα antibody, adalimumab.
Biologic therapies have also been used to block cell-cell interactions. The CTLA-4
immunoglobulin prevents the co-stimulatory activity of CD80 and CD86 on antigen
presenting cells (APC). Depleting B cells using an anti-CD20 antibody, rituximab,
has also been shown to be an effective therapy for RA.
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1.3.2 Anti-Tumour Necrosis Factor therapies
Initial investigations in mice showed that the blockade of TNF in autoimmune
models such as CIA ameliorated disease [358]. Later that it was shown that anti-TNF
was an effective therapy for RA [359]. There are currently a number of anti-TNF
therapies available. These include: etanercept, comprisingthe extracellular portions
of TNFR2 fused to the Fc portion of IgG1; infliximab, a mouse/human chimeric
monoclonal anti-TNF IgG1 antibody and adalimumab, a human monoclonal IgG1
antibody. Etanercept efficiently binds trimers of TNF, but unlike the monoclonal
antibodies, also binds the closely related LTβ. In addition, patients can be prescribed
a second humanised monoclonal antibody, golimumab and certolizumab pegol, a
PEGylated Fab' fragment of a humanised anti-TNF monoclonal antibody. Patients at
University College Hospital (UCH) are predominantly described infliximab,
adalimumab and etanercept so golimumab and certolizumab pegol are not discussed
further.
Infliximab is administered by intravenous infusion every 4 to 6 weeks and has a
terminal half-life of 8-10 days. Due to its chimerism, infliximab is more
immunogenic than the humanised molecules and must administered alongside an
additional immunosuppressant such as methotrexate. Etanercept is administered
subcutaneously via a pre-filled ‘pen’ device taken at home once or twice a week and
has a half-life of approximately 4 days. Adalimumab is also administered sub-
cutaneously every 2 weeks but has a much longer half-life of 10-20 days [265, 360].
Infliximab is now less often prescribed as patients prefer subcutaneous injections to
infusions. Whilst all three therapies reduce TNF and are effective in the treatment of
RA, clinical differences between the therapies have been noted. Monoclonal
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antibody therapy, but not etanercept therapy, is effective in granulomatous diseases
such as Crohn’s disease [361, 362] and sarcoidosis [363, 364]. On the other hand,
RA patients treated with either adalimumab or infliximab have a 7-17 fold higher
risk of developing a Mycobacterium tuberculosis (TB) infection compared to RA
patients treated with etanercept [365].
Initial studies investigating the differences observed between the monoclonal anti-
TNF antibody (infliximab) and the soluble TNFR2 (etanercept) found that etanercept
could only transiently bind trimers of TNF. Furthermore the TNF molecules released
by dissociation with etanercept were shown to be biologically active. In contrast,
infliximab could bind both monomers and trimers of TNF, forming stable complexes
with each molecule. Both infliximab and etanercept have been shown to bind to
membrane TNF and were both able to prevent the ability of mTNF to activate human
endothelial cells. However, infliximab binding to mTNF was more effective in
blocking the activation of endothelial cells than etanercept. Furthermore, infliximab
binding of mTNF was more stable than etanercept with more infliximab molecules
binding to mTNF with a higher avidity. This led the authors to conclude that
infliximab mediates a more complete and sustained neutralisation of TNF than
etanercept [366].
1.3.3 Anti-TNF therapy for the treatment of rheumatoid arthritis
All anti-TNF therapies are recommended for the treatment of RA patients who have
failed methotrexate and at least one other DMARD and have been classified as active
with a DAS >5.1 by a rheumatologist on at least two occasions (NICE guidelines
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October 2007). In RA, approximately 40% of patients respond to anti-TNF therapies
with at least 50% improvement in DAS-28 score. Furthermore, the observed changes
after anti-TNF have provided novel insight into the roles of TNF in the pathogenesis
of RA
In a subset of patients, treatment with anti-TNF therapies results in long lasting
responses associated with prevention of articular damage. Indeed, patients treated
with anti-TNF antibody showed a reduction in synovial infiltration of granulocytes,
macrophages, B cells and T cells and this was shown to correspond with a drop in
serum levels of CCL2 and CXCL8 [367]. Treatment with etanercept was shown to
result in a drop in MMP-1 and MMP-3 as well as a reduction in the ratio of MMPs to
TIMP-1 [368]. Furthermore, long-term therapy with adalimumab decreased the
levels of soluble intercellular adhesion molecule (ICAM) and MMPs and
demonstrated a positive effect on radiological outcome [369]. In vitro treatment of
synoviocytes with infliximab was shown to inhibit RANKL expression and increase
expression of OPG in the supernatant [370]. In patients, treatment with infliximab or
etanercept for 8 weeks increased the expression of OPG in synovial tissue, but had
no effect on the RANKL expression. However, therapy was shown to reduce the
ratio of RANKL:OPG, which would contribute to a reduced osteoclastogenesis and
thus reduced cartilage damage [371].
Anti-TNF therapies also appear to alter autoantibody titres in responding patients.
Indeed, it has been suggested by one study that patients responding to anti-TNF have
a decrease in serum titres of rheumatoid factor and ACPA [372]. Though, there is
some controversy. A second study claims that only RF levels are reduced, whilst
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ACPA levels remain the same [373]. A third study shows a reduction in both sets of
antibodies, but only in responders and in this too RF was more strongly affected than
ACPA [374]. Thus, all 3 studies agree that there is a fall in RF antibodies, which is
perhaps unsurprising given the link between inflammation and the presence of RF
antibodies (see section 1.1.7.2). More studies will have to be done to elucidate what,
if any, effect the blockade of TNF has on ACPA production.
The synovial synthesis of TNF was reduced after infliximab therapy and this was
associated with a fall in IL-1α [375], reduced levels of IL-6 and acute proteins such
as amyloid A, haptoglobin and fibrinogen [376 ]. Furthermore, angiogenic factor
VEGF was significantly decreased in the serum of anti-TNF antibody treated patients
with RA [377], highlighting the role of TNF in driving aberrant angiogenesis in the
RA synovium. An integral role for TNF in the resistance of cells to apoptosis in RA
was confirmed by an induction of macrophage apoptosis in vivo and in vitro in RA
synovial biopsies of patients on long term treatment with both etanercept and
infliximab [378].
Thus anti-TNF therapy targets some of the most aggressive aspects of RA resulting
in a clinical response that reduces pain and disability.
1.3.4 Effects of anti-TNF therapy on regulatory T cells
Inflammation is known to negatively modulate Treg function. Given the abundance
of TNF in the synovium of patients with RA it was proposed that the response to
anti-TNF therapy might be mediated, in part, via a reversal of the Treg defect
Chapter 1
94
observed in these patients. Indeed, Treg from RA patients treated with infliximab
were shown to suppress IFNγ and TNF at comparable levels to healthy controls.
Moreover, it was found that these patients had an increase in the number of
peripheral Treg [124]. This heavily implicated TNF in the modulation of Treg
number and function. Surprisingly, suppression by Treg from patients treated with
infliximab was not mediated via a restoration of CTLA-4 expression on Treg, as
levels of CTLA-4 were similar to patients with active RA [37].
This restoration of suppressive function by infliximab therapy in the absence of a
restoration of CTLA-4 expression, led to an investigation of the phenotypic and
functional characteristics of the Treg from these patients. Ex vivo staining revealed
that patients treated with infliximab had increased levels of CD62L- Treg compared
to healthy controls and patients with active RA [86]. Comparison of the suppressive
function of CD62L+ and CD62L- Treg showed unsurprisingly, that both were
defective in patients with RA. However, whilst CD62L+ Treg were the most potent
suppressors in healthy controls, in infliximab treated patients there was a distinct
shift. The suppressive ability of CD62L+ Treg in infliximab treated patients
resembled that of patients with active RA but CD62L- Treg were much more potent
suppressors than the same population in healthy controls or patients with active RA.
Moreover, in contrast to functional Treg in healthy controls, the neutralisation of
TGF-β and IL-10 abrogated the suppressive ability of CD62L- Treg. Furthermore, it
was shown that the in vitro addition of infliximab to purified CD25- cells from
patients with RA, but not healthy controls, induced a population of FOXP3+ cells.
These cells were shown to be CD62L- and examination of their function in vitro
found that they could suppress IFNγ. Thus, it was concluded that infliximab induced
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Treg with the capacity to suppress IFNγ rather than restoring the suppressive ability
of existing Treg [86].
1.3.5 Anti-IL-6 receptor (tocilizumab)
The targeting of IL-6 with an anti-IL-6 receptor was first suggested to be an effective
therapy in mice, where treatment was sufficient to suppress CIA and protect joints
from destruction [379]. Tocilizumab is a humanised anti-human IL-6 receptor
antibody of the IgG1 subclass, shown to compete for both membrane bound and
soluble receptors of IL-6. It is administered by infusion once every 4 weeks and has a
half life of approximately 10 days [380]. Tocilizumab has been shown to be a
successful therapy in the treatment of RA refractory to both traditional DMARDS
[381] and anti-TNF [382]. Tocilizumab in combination with methotrexate therapy is
indicated if patients have moderate to severe active RA and have failed at least one
anti-TNF therapy and rituximab (NICE guidelines August 2010). More recently,
NICE approved tocilizumab as a first line biologic agent  (NICE guidelines February
2012).
Compared to methotrexate therapy, tocilizumab was shown to reduce proliferation,
beta-1 integrin expression and CD20+ cells in the joint. In contrast, levels of TNF,
CD68 and MMP-3 were unchanged in tocilizumab treated patients 6-8 months after
therapy [383]. Highlighting the importance of IL-6 in B cell antibody production,
another study showed that in tocilizumab treated patients there was a fall in the
number of memory B cells, IgA and IgG expressing B cells and a drop in serum
immunoglobulin levels between weeks 12-24 of therapy [384]. Tocilizumab has also
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been shown to inhibit joint damage, suggesting that IL-6 contributes to the
destruction of cartilage in RA [385].
1.3.5.1 Anti-CD20 (rituximab)
Rituximab targets and transiently depletes CD20+ B cells, which include pre-B cells
and mature B cells but does not directly deplete autoantibody producing plasma
cells. However, short-lived plasma cells are depleted and autoantibody titres do fall.
Despite this, patients depleted of B cells demonstrate a clinical response including a
reduction in joint erosion [386]. The improvement in disease despite the presence of
antibodies highlights the importance of other B cell functions in RA such as antigen
presentation, the production of cytokines and the formation of ectopic germinal
centres.
1.3.5.2 CTLA-4 Ig (abatacept)
Abatacept (CTLA-4 Ig) acts as an exogenous CTLA-4 molecule that blocks the
interaction between CD28 and CD80/86. A recent study has shown by histochemical
staining that whilst levels of TNF, IL-6 and VEGF were unchanged in the synovium
of RA patients treated with abatacept, there was a reduction in MMP-3, CD68, CD4,
CD8, CD20, CD80 and CD86 [387], suggesting that abatacept can reduce cellular
recruitment to the synovium. Whether this is a direct effect of abatacept therapy or
an indirect effect through a reduction of the capacity of APC to offer co-stimulation
to T cells remains to be established. Furthermore, it has been shown that binding of
CTLA-4 to monocytes inhibits RANKL expression and TNF-induced
osteoclastogenesis in vitro in the absence of T cells [388]. Thus, treatment with
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abatacept has the potential to prevent further joint erosion. Notably, many cells in the
synovium up-regulate MHC molecules during inflammation [389]. Blockade of co-
stimulatory molecules with CTLA-4 Ig may prevent the ability of these MHC
molecules to successfully activate T cells and perhaps offers an additional
explanation as to why therapy with abatacept is effective.
1.3.5.3 IL-1 receptor antagonist  (anakinra)
Like disease itself, response of patients to immune targeted biologic therapies
provides insight to disease pathogenesis. Whilst the therapies described above have
all shown to be effective therapies for RA, anakinra, an IL-1 receptor antagonist that
neutralises the activity of IL-1 is not a particularly effective therapy in RA. This was
quite an unexpected finding, since IL-1 is widely expressed in the human synovial
membrane in patients with RA [390] and blocking IL-1 in mouse models of RA
resulted in reduced inflammation and substantial reduction in joint damage [391,
392]. Moreover, crossing human TNF transgenic mice to IL-1α and IL-1β knockout
mice, did not prevent synovitis but did prevent erosion of cartilage, identifying IL-1
as a key mediator of bone erosion in inflammatory arthritis [393]. However, whilst
therapy with anakinra in patients with RA had some effect on inflammation and joint
erosion, in neither of these aspects was anakinra a more effective therapy than anti-
TNF [394, 395]. Notably, the same doses of anakinra used to treat patients with RA
provided an effective therapy for systemic-onset juvenile idiopathic arthritis and
adult-onset Still's disease [395]. Thus IL-1 may not be as important in the
pathogenesis of RA as initially suggested by animal models or, the role of IL-1
downstream of TNF may not be sufficiently distinct to offer any benefit on blocking
TNF.
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1.4 Psoriatic arthritis
PsA is characterised by stiffness, pain and swelling in the joints of the hands and feet
and affects approximately 23% of people with psoriasis. PsA is distinguished from
RA because it presents equally in men and women. Furthermore, inflammation of the
peripheral joints is more common and is more likely to affect all joints of a single
digit rather than the same joints on both sides of the body, which is typical of RA
[396]. Much like RA, PsA can lead to chronic joint damage, increased disability and
increased mortality. Disease activity of PsA patients is measured by the Psoriatic
Arthritis Response Criteria (PsARC), which includes an assessment of 78 tender
joints, 76 swollen joints, a global patient assessment and a global physician
assessment. Skin disease is measured independently by the Psoriasis Area and
Severity Index (PASI).
1.4.1.1 Susceptibility to psoriatic arthritis
Much like RA, PsA has been shown to be heritable; the risk of developing disease in
first-degree relatives of individuals with PsA was 17.7%, notably more than the risk
of developing psoriasis in first degree relatives, which was only 7.7% [397]. There
have been few genome-wide association studies (GWAS) of PsA susceptibility genes
and those that have been done often do not have the necessary power to confirm
differences. Moreover, PsA studies are complicated by the co-presentation of
psoriasis, for which the genetic susceptibility genes are more widely known [398].
Although there are described similarities between skin and joint inflammation in
patients with PsA [399], patients with PsA always present with psoriasis, but patients
with psoriasis do not always develop PsA and this disparity may be based on genetic
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differences. Interestingly, like RA, SNPs associated with susceptibility to PsA
include TNFR signalling pathway members such as A20 and members of the NFκB
pathway [398, 400]. This suggests that common factors may be associated with the
development of all rheumatic autoimmune diseases.
Whilst no GWAS studies have investigated PsA patients specifically, within the
psoriasis studies there is a subset of patients with PsA. This provides an insight into
genetic polymorphisms that might result in the development of PsA in patients with
psoriasis. Compared to healthy controls, psoriasis patients with concomitant PsA
show differences in the genes which encode the class I MHC molecule, in particular
HLA-C, the IL-12 family member IL-12B and the TNFR signalling family member
TNFAIP3-interacting protein 1 (TNIP1). Furthermore, studies have found an IL-1α
SNP variant that is associated with the development of PsA [401]. In psoriasis, SNPs
in genes coding for Th2 cytokines have been associated with disease development.
Similarly, a SNP in the IL-4 receptor has been associated with joint destruction in
PsA and a SNP in the IL-13 gene has been shown to be predictive of PsA
development in patients with psoriasis [402, 403]. A more recent study has identified
a susceptibility locus at the NFκB family member, REL [404].
Environmental factors that have been associated with the development of PsA
include rubella vaccination, injury, recurrent oral ulcers, fractured bones and HIV
[405, 406].
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1.4.1.2 Immunopathogenesis of psoriatic arthritis
Fifty percent of patients with PsA show radiographic lesions at 1 year [407] but PsA
has been found to bear more similarity to the spondyloarthropathies such as
ankylosing spondylitis (AS), than RA. This is due to increased vascularity and
neutrophil infiltration of the synovium in comparison to patients with RA, but similar
levels to patients with AS [408]. Moreover, PsA patients can develop inflammation
at the tendon or ligament attachment sites (enthesis) [409], a feature common in
patients with spondyloarthropathies.
Levels of IL-22 are elevated in the synovial fluid of PsA patients and can drive the
proliferation of FLS [410]. Further analysis of the synovium of PsA patients found
elevated levels of TNF, IL-1β, IL-18, IL-6, IL-2, IL-10, and IFNγ [411, 412].
Furthermore, the synovium of patients with PsA has increased VEGF and
angioproteins [413], large numbers of osteoclasts and alterations in the
RANKL:OPG ratio [414]. T cell and plasma B cell numbers are lower in PsA
patients than in patients with RA [412]. Moreover, there is less pronounced synovial
hyperplasia and fewer monocytes and macrophages in patients with PsA than RA
[415]. In contrast to RA, CD8 T cells and not CD4 cells are important for disease
progression and activated T cells have been identified in both the skin and the joint
[416].
A model has been proposed that links skin and joint inflammation in PsA. CCL22 is
the ligand of CCR4, a chemokine receptor vital for homing to skin. In patients with
PsA, CCL22 production has been detected in the synovium; this may allow
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pathogenic skin homing psoriatic T cells to traffic to the joint and drive synovitis
[417].
1.4.2 Therapy for PsA
Treatment of PsA is similar to RA although the therapeutic options are more limited.
Methotrexate and sulfalsalazine are used first; the former is preferred as it has an
additional therapeutic effect on the skin disease. Methotrexate has been shown to
reduce CCL8 expression, E-selectin expression, ICAM-1 and MMP-3 in the
synovium of patients with PsA. Additionally, synovial lining thickness was reduced,
but vascularity was unaffected [418].
1.4.3 Anti-TNF therapy for the treatment of psoriatic arthritis
PsA patients too can be prescribed anti-TNF therapy, if patients have 3 or more
tender joints and 3 or more swollen joints and have failed at least 2 DMARDS. It has
been shown that osteoclast precursor cells are reduced in the periphery of patients
with PsA treated with anti-TNF [419]. Thus, treatment with anti-TNF has the
potential to reduce joint damage in PsA. Indeed, PsA patients treated with
adalimumab were shown to have decreased T cells and MMP-13 expression in the
synovium [420] and etanercept has been shown to decrease the progression of
radiographic damage in patients with PsA and to promote joint repair [421, 422].
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1.5 Hypotheses and Aims
During autoimmune inflammation cytokines such as TNF and IL-17 drive
vascularisation of the synovium, the production of chemokines, the upregulation of
adhesion molecules for further cellular recruitment, the production of matrix
degrading enzymes from cells of the synovium, osteoclastogenesis, maturation of
cells, the inhibition of Treg suppressive function and the promotion of Treg
instability. The blockade of inflammatory cytokines and in particular anti-TNF
therapy has been shown to be effective in the treatment of both RA and PsA. In this
thesis I sought to investigate the mechanisms through which anti-TNF therapy
mediates the amelioration of disease in patients with RA and PsA.
Patients with PsA and RA demonstrate similar clinical response to monoclonal anti-
TNF antibodies or soluble TNF receptor therapy. Nevertheless, patients can fail one
anti-TNF yet go on to respond to another. Moreover, in granulomatous diseases such
as Chron’s disease monoclonal anti-TNF antibody, but not the soluble receptor is an
effective therapy. Previous studies by our group have shown that infliximab therapy
in patients with RA can induce a population of Treg that suppress IFNγ via the
production of IL-10 and TGFβ. Furthermore, these anti-inflammatory cytokines have
been shown to suppress IL-17, a key inflammatory cytokine in arthritis and skin
disorders.
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Hypotheses:
Based on the findings described, the aim of this thesis was to test the following
hypotheses:
• Anti-TNF monoclonal antibodies and anti-TNF soluble receptor therapy have
different mechanisms of action – only anti-TNF monoclonal antibodies
induce Treg.
• Treg induced by anti-TNF monoclonal antibodies suppress IL-17 production
via the production of IL-10 and TGFβ.
Additionally, data in this thesis suggests that IL-6 regulates Th17 cells and thus a
third hypothesis was formed:
• Based on the ability of IL-6 to control Th17 cells in RA patients treated with
adalimumab, the therapeutic blockade of IL-6 in RA patients would result in
a decrease in Th17 cells.
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Aims:
To test these hypotheses this study will;
1. Determine if the induction of Treg is a common feature of response to all
anti-TNF therapies in RA and PsA.
2. Examine the differences in immune cell subsets in RA and PsA patients
treated with adalimumab and etanercept.
3. Investigate if Treg induced by anti-TNF therapy can suppress Th17
responses.
4. Explore the underlying mechanisms of Th17 cell suppression.
5. Elucidate the effects of tocilizumab therapy on Th17 cells.
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Chapter 2 
Materials and Methods
2.1 Sample Collection
Full consent was obtained from all participants in this study (ref: 02/0240)
(Appendix I). Healthy volunteers were staff and students within the Centre for
Rheumatology at the Windeyer Building, UCL. 50ml of blood was taken from
patients requiring routine blood tests. All subjects were given a numerical code
before storage in order to maintain anonymity. Patients classified as active were
those awaiting anti-TNF therapy and had a DAS28 >5.1. Patients were considered
responders if the DAS score fell by more than 1.2 and the CRP was below 5.
2.1.1 Preparation of Peripheral Blood Mononuclear Cells (PBMC)
Blood was collected in a 50ml universal containing 100U of preservative free
heparin (CD pharmaceuticals) and processed on the same day. Blood was diluted in
an equal volume of complete medium (RPMI 1640) (SIGMA-Aldrich) supplemented
with 100U/ml penicillin and 100µg/ml streptomycin (SIGMA-Aldrich) and 10% heat
inactivated fetal calf serum (FCS) (BIOSERA). The blood was then layered on to
12ml of Ficoll-paque (GE Healthcare) and centrifuged in a Mistral 3000i for
35minutes, 850 x g at room temperature without brake. The PBMC interface was
removed and mixed with complete medium and centrifuged for 10 minutes, 500 x g
at 4°C. The pellet was resuspended in 10ml complete medium and counted as
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described in 2.1.2. Aliquots of cells were removed as required for ex vivo staining,
before the cells were centrifuged and frozen as described in section 2.1.3.
2.1.2 Counting Cells
10µl of cell suspension were mixed with 90µl of 0.4% trypan blue (SIGMA-
Aldrich). The suspension was transferred to a Neubauer counting chamber and cells
were counted using light microscopy. Cells that were bright were counted, and cells
that appeared blue were excluded. Each of the 4 corner squares were counted, 1
corner square contained 16 squares and the cell number within this 4 x 4 chamber
represented 104 cells. Thus, the number of cells was calculated as follows:
2.1.3 Freezing cells
Once PBMC had been isolated from blood, they were resuspended at a concentration
of 2x107 cells/ml in freezing medium (see below). One to two ml aliquots were
transferred into cryovials (NUNC) and stored in a freezing box containing
isopropanol at –70°C for 1-2 days before transfer to liquid nitrogen storage.
Freezing medium: Heat inactivated FCS supplemented with 10 % v/v dimethyl
sulphoxide (SIGMA-Aldrich).
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2.1.4 Thawing Cells
Cells stored in liquid nitrogen were thawed rapidly in a 37°C water bath (Grant),
transferred to a universal tube and complete medium was added in a drop-wise
fashion. The tube was centrifuged at 400 x g for 5 minutes at 4°C, and washed once
more before counting (Section 2.1.2).
2.2 Fluorescent Activated Cell Sorting (FACS)
2.2.1 Buffers and Solutions
FACS buffer: 1 x phosphate buffered saline (PBS), 1% FCS, 0.1% sodium azide
MACS buffer: 1 x PBS (SIGMA-Aldrich), 1% FCS,
2mM Ethylenediaminetetraacetic acid (EDTA)
2.2.2 Cell Surface and Intracellular Staining
Cells were centrifuged at 4°C, 500 x g for 5 minutes and washed in FACS buffer,
before vortexing briefly and adding 20µl of appropriate surface antibodies at the
titrated dilution (Table 2.1, pg 108) for 20 minutes at 4°C. Cells were washed twice
in 100µ l of FACS buffer, before adding fixation/permeabilisation buffer
(eBioscience) for 30 minutes at 4°C. Cells were centrifuged and washed twice in
permeabilisation buffer (eBioscience) before the addition of intracellular antibodies
at the appropriate concentration (Table 2.1, pg 108) for 1 hour at 4°C. When staining
for transcription factors, after washing with permeabilisation buffer, cells were
incubated for 10 minutes with 20µl 0.1µg/ml human immunoglobulin (SIGMA-
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Aldrich) per 106 cells, followed by the addition of intracellular antibodies for 45
minutes. Cells were then washed twice in 100µl permeabilisation buffer before being
resuspended in FACS buffer to be acquired within 48 hours on the BD FACS
Calibur, BD LSR, BD LSRII or the BD Fortessa.
Table 2.1 Antibodies used for flow cytometry with human samples
Antibody Fluorochrome Clone Isotype Dilution Company
CD4 FITC RPA-T4 Mouse IgG1 κ 1:20 BD Pharmingen
PE OKT4 Mouse IgG2b 1:5 eBioscience
PE-Cy7 RPA-T4 Mouse IgG1 κ 1:50 eBioscience
Alexa Fluor 700 RPA-T4 Mouse IgG1 κ 1:40 BD Pharmingen
CD25 PE M-A251 Mouse IgG1 κ 1:10 BD Pharmingen
PE-Cy7 2A3 Mouse IgG1 κ 1:5 BD Pharmingen
APC-Cy7 M-A251 Mouse IgG1 κ 1:5 BD Pharmingen
CD127 PE-Cy5 ebioRDR5 Mouse IgG1 1:40 eBioscience
FOXP3 Alexa Fluor 647 PCH101 Rat IgG2a 1:40 eBioscience
PE 236AIE7 Mouse IgG1 1:40 eBioscience
RORγt PE AFKJS-9 Rat IgG2a 1:200 eBioscience
IFNγ PE-Cy7 B27 Mouse IgG1 κ 1:60 BD Pharmingen
IL-17A Alexa Fluor 647 BL168 Mouse IgG1 1:50 Biolegend
IL-22 APC 142928 Mouse IgG1 1:10 R&D Systems
CD14 PE 61D3 Mouse IgG1 1:50 eBioscience
CD24 PE EBioSN3 Mouse IgG1 1:20 eBioscience
TGF-βRII PE Goat IgG 1:5 R&D
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CD39 PE EBioA1 Mouse IgG1 1:20 eBioscience
STAT3
(pS727)
Alexa Fluor 647 49/p-stat3 Mouse IgG1 1:5 BD Pharmingen
STAT3
(pY705)
Alexa Fluor 647 4/p-STAT3 Mouse IgG2a κ 1:5 BD Pharmingen
CD62L PE-Cy5 DREG-56 Mouse IgG1 κ 1:10 BD Pharmingen
TNFα FITC MAbII Mouse IgG1 k 1:20 eBioscience
Ki67 FITC B56 Mouse IgG1 κ 1::40 BD Pharmingen
CD27 APC H7 M-T271 Mouse IgG1 κ 1:40 BD Pharmingen
PE M-T271 Mouse IgG1 κ 1:40 BD Pharmingen
α ms/hu
Helios
PE 22F6 Armenian
Hamster IgG
1:20 Biolegend
CD19 APC HIB19 Mouse IgG1 κ 1:40 eBioscience
PE-CY7 HIB19 Mouse IgG1 κ 1:40 eBioscience
V450 HIB19 Mouse IgG1 κ 1:20 BD Pharmingen
CD38 PE-Cy7 HIT2 Mouse IgG1 κ 1:40 eBioscience
IL-10 Alexa-Fluor
647
JES3 Rat IgG1 κ 1:20 eBioscience
TGF-β PE 9016 Mouse IgG1 1:20 R&D
CD73 FITC AD2 Mouse IgG1 κ 1:10 eBioscience
IgD FITC IA6-2 Mouse IgG2a κ 1:5 BD Pharmingen
IL-21 Alexa Fluor 647 EBio3A3-
N2
Mouse IgG1 κ 1:20 eBioscience
Unless otherwise specified, all antibodies were generated against human proteins.
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2.2.3 Staining for apoptotic cell markers
Cells were stained with Annexin V PE and 7AAD (7-Aminoactinomycin D) using
the PE Annexin V Apoptosis Detection Kit I (BD). Cells were washed in FACS
buffer and surface stained as described in section 2.2.2. Samples were then washed in
1 x Annexin V binding buffer before the addition of Annexin V PE (1:40 dilution)
and 7AAD (1:40 dilution) for 15 minutes at room temperature. Samples were
resuspended in 150µl of Annexin buffer and the data were acquired on the BD
Calibur within 1 hour.
2.2.4 Staining cells for FOXP3 and pSTAT3
Five hundred thousand PBMC were plated in a 96 well u-bottomed plate at a final
volume of 200µl. Cells were left unstimulated or stimulated with 100ng/ml
recombinant human IL-6 (Peprotech) or 1µg/ml soluble anti-CD3 and 1µg/ml anti-
CD28 antibodies (eBioscience). After incubation the plate was centrifuged briefly
(30 seconds, 800 x g, 4°C) before the addition of BD Phosflow fix buffer 1 (BD)
which had been warmed to 37°C. Cells were incubated in fix buffer for 10-15
minutes at room temperature in the dark before washing in FACS buffer. Cells were
then stained with CD4 PE-Cy7 at a concentration optimised for these buffers (1:20)
for 20 minutes, washed in 100µl of FACS buffer and resuspended in 1 x Phosflow
Perm/Wash buffer I (BD) for a further 15 minutes. Antibodies against STAT proteins
were added in a 1:5 dilution and FOXP3 PE antibodies were added at a concentration
optimised for the Phosflow buffers (1:15) for 30-45 minutes at 4°C. Cells were
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washed once in buffer I and resuspended in FACS buffer for acquisition on the BD
FACS Calibur.
When responder T cells and Treg isolated by FACS (using markers described in
section 2.3.2) were stained for pSTAT3, cells were rested for 1 hour (37°C, 5% CO2)
and then fixed with BD Phosflow fix buffer 1 (BD) as above. As these were isolated
populations and the purity was checked separately, there was no need to stain cells
for surface markers or FOXP3. So, cells were incubated with Phosflow Perm buffer
III for 15 minutes at 4°C before the addition of STAT3 antibodies for 30-45 minutes
at the same temperature. Cells were washed in buffer III and resuspended in FACS
buffer for acquisition on the BD FACS Calibur within 48 hours.
The fold induction of pSTAT3 was calculated as follows:
MFI = mean fluorescence intensity
2.2.5 Preparation of compensation beads
When the BD LSRII was used for large flow cytometry staining panels, a human
Comp Beads Set (BD) (Mouse IgG κ) was used to prepare compensation controls for
the machine. One hundred µl of FACS buffer was added to a FACS tube (BD).
Bottles containing positive and negative sets of beads were vortexed for 15 seconds
before the addition of 1 drop from each bottle to the FACS buffer. One FACS tube
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was an unstained control and to the others 2µl of the desired antibody were added
before incubating at room temperature for 15-30 minutes. One ml of FACS buffer
was added to each tube,  they were centrifuged at 800 x g for 30 seconds and
resuspended in 150µl FACS buffer.
2.2.6 Flow cytometry data analysis
After data acquisition on CellQuest (BD), CellQuest Pro (BD) or FACSDiva (BD)
software, data were analysed using FlowJo version 8.8.4 or version 9.3.3 (Tree Star
Inc.). Live cells were gated based on forward and side scatter properties (Figure 2.1
A).
2.2.7 Preparing cells for sorting
Cells were thawed in complete medium before being washed twice  (10 minutes, 450
x g, 4°C) in 50ml of MACS buffer. The pellet was stained using antibodies against
CD4, CD25 and CD127 (1µl/106 cells), as this cell population is known to contain
the majority of the FOXP3+ Treg fraction  (Figure 2.1B). Antibodies were incubated
for 20 minutes at room temperature in the dark before washing and resuspending in
approximately 1ml of MACS buffer. Cell suspensions were then passed through
35µM cell strainer cap FACS tubes (BD) and kept on ice. Cells were sorted using the
BD FACS Aria and collected in polypropylene FACS tubes (BD) containing media
comprising 50% RPMI 1640 and 50% FCS.
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Figure 2.1. Gating strategies used for flow cytometry
A. Lymphocytes were distinguished from larger cells by forward and side scatter
properties. From this the CD4+ population was identified by high expression of this
marker. B. CD25 and CD127 expression was examined on the CD4+ population.
Subsequently the percentage of FOXP3+ cells in the CD4+CD25+CD127- population
was compared to the CD4+CD25-CD127+ population.
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2.3 Functional regulatory T cell assays
2.3.1 Treg Depletion
Cells were prepared for FACS sorting (described in section 2.2.7) and each sample
was divided into two tubes. For each sample one tube was passed through the FACS
Aria and depleted of Treg, the second tube was passed through the machine but no
cells were depleted. Samples were pooled and washed in complete medium (450 x g,
10 minutes, 4°C) before being counted as described in 2.1.2. Cells were rested at
37°C for 1 hour before being centrifuged at 450 x g, 21°C for 10 minutes. The pellet
of each sample was resuspended in complete medium and 3x105 cells were added to
each well in a 96 well u-bottomed plate with a final volume of 200µl. The well was
supplemented with 1µg/ml anti-CD3 (HIT3a eBioscience) and 1µg/ml anti-CD28
(CD28.2 eBioscience) and incubated at 37°C in 5% CO2 for 3 days. Remaining cells
were stained to determine the purity of the sort, which was typically over 92%.
Additionally cells were stained for FOXP3 to determine the purity of the Treg
fraction (Figure 2.2A). On day 3, 150µl of supernatant were removed for ELISA and
supplemented with 150µl of stimulation mix, consisting of PMA (4 µg/ml) (1:100,
ionomycin (1 µg/ml) and Golgi StopTM (BD) (2µl/ml), and returned to the incubator
for 4 hours. The cells were then stained for IL-17 Alexa Fluor 647 and IL-22 APC
using the antibody dilutions outlined in table 2.1 (pg 108) and the staining protocol
described in section 2.2.2.  The data were acquired on the BD LSR.
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Figure 2.2. Purity of FACS sorted cell populations.
A. Cells were prepared for sort by staining with CD4, CD25 and CD127 and
subsequently stained with FOXP3.  The left panel shows a distinctive population of
CD4+CD25+CD127- cells, which has been depleted in the right panel.
2.3.2 Tresponder-Treg co-culture
FACS sorting (Section 2.2.7) was used to isolate two cell populations:
CD4+CD25+CD127- (Treg) cells and CD4+CD25-CD127+ (responder T) cells.
Samples were centrifuged (10 minutes 450 x g, 21°C) before being resuspended in
complete media for counting (Section 2.1.2).  After resting for 1 hour in a 37°C
incubator, cells were centrifuged (10 minutes 450 x g, 21°C) and resuspended in
complete media at a concentration of 1x105 cells/100µl. Four conditions were set up
for each experiment:
1. Unstimulated Tresp
2. Stimulated Tresp
3. Stimulated Treg
4. 3:1 ratio of Tresp to Treg (stimulated).
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Cells were stimulated with 1µg/ml soluble anti-CD3 and 1µg/ml anti-CD28
antibodies in the appropriate wells. Remaining cells were stained to determine the
purity of the sort, typically above 92% (Figure 2.3).
After 3 days, 150µl of supernatant were transferred to a 96 well flat-bottomed plate
and stored at –20°C for ELISA. Cells were supplemented with 150µl of stimulation
mix, made as above. The plate was returned to the incubator for an additional 4
hours. The cells were then stained for IL-17 Alexa Fluor 647 and IFNγ PE-Cy7 using
the antibody dilutions in table 2.1 (pg. 108) and the staining protocol described in
section 2.2.2. Data were acquired on the BD LSR.
Figure 2.3. The purity of Treg after FACS sorting in healthy controls, patients
with active RA and patients treated with adalimumab or etanercept.
Responder T cells and Treg were isolated by FACS sorting from PBMC.
Representative FACS plots show FOXP3 staining of A. whole PBMC, B. isolated
responder T cells and C. regulatory T cells from healthy controls, patients with
active RA, patients treated with adalimumab and patients treated with etanercept.
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2.3.3 Tresponder-Treg-monocyte co-culture
FACS sorting (Section 2.2.7) was used to isolate Treg and Tresp as described in
2.3.2 and monocytes were isolated based on expression of CD14. Monocytes were
stained with PKH-26 cell membrane dye using the protocol outlined in section 2.3.9.
Samples were centrifuged before being counted (Section 2.1.2). Tresp were
resuspended in complete media at 2x106 cells/ml and Treg and monocytes were each
resuspended at 6.6x105 cells/ml. Cells were set up in a final volume of 200µl in a
ratio of 3 Tresp:1 monocyte or 3 Tresp:1 monocyte:1 Treg. All conditions were
stimulated with 1µg/ml soluble anti-CD3 and 1µg/ml anti-CD28 antibodies for 5
days at 37°C and 5% CO2.
After 5 days 150µl of supernatant were transferred to a 96 well flat-bottomed plate
and stored at –20°C for ELISA. Cells were supplemented with 150µl of stimulation
mix, made as above. The plate was returned to the incubator for an additional 4
hours. The cells were then stained for IL-17 Alexa Fluor 647 and IFNγ PE-Cy7 using
the antibody dilutions in table 2.1 (pg. 108) and the staining protocol described in
section 2.2.2. Data were acquired on the BD LSR II.
As required, additional conditions were used to investigate mechanism of
suppression of Treg from adalimumab treated patients. These are described below;
2.3.4 Cytokine and cytokine receptor blockade
Cells were sorted as described in section 2.3.3 and were plated at the same
concentration in the following conditions:
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Tresp + monocytes
Tresp + monocytes + isotype control
Tresp + monocytes + αIL-6/αIL-1
Tresp + monocytes + Treg
Tresp + monocytes + Treg + isotype control
Tresp + monocytes + Treg + αTGF-β/αIL-10/αIL-10Rα/αp35
Neutralising antibodies were used at the concentrations shown in table 2.2 (pg. 118).
In some conditions 20ng/ml recombinant human IL-6 (Peprotech) was added back to
cultures of Tresp, monocytes and Treg from adalimumab treated patients.
Table 2.2 Neutralising antibodies used in Treg suppression assays
Antibody Clone Isotype Concentration Company
anti-TGF-β 27235 Mouse
IgG1
10µg/ml R&D
anti-IL-10 Goat IgG 10µg/ml R&D
anti-IL-10Rα Goat IgG 10µg/ml R&D
anti-IL-6 Goat IgG 0.1 µg/ml R&D
anti-IL-1β Goat IgG 0.1 µg/ml R&D
anti-p35 27537 Mouse
IgG1
10µg/ml R&D
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2.3.5 Blocking CD39 activity
The working concentration of the anti-CD39 antibody (Table 2.3, pg 119) was
determined to be 2µg/ml in experiments detailed in section 2.3.6.
Table 2.3 Anti-CD39 neutralising antibody clone and working concentration
Antibody Clone Isotype Concentration Company
anti-CD39 A1 Mouse IgG1κ 2µg/ml Biolegend
Thus, upon isolation, each population of cells was divided in two. One half of each
isolated cell subset was untreated and the other half was treated with anti-CD39
antibody. Both were placed in a 37°C water bath for 30 minutes before resuspending
cells at the concentration described in section 2.3.3. Cells were then plated a 96 well
u-bottomed plate in the following conditions and stimulated as described above
(section 2.3.3):
Tresp + monocytes
Tresp + monocytes + Treg
Tresp + monocytes + anti-CD39 treated Treg
anti-CD39 treated Tresp + monocytes
Tresp + anti-CD39 treated monocytes
Cells were stimulated and cultured for 5 days as described in section 2.3.3, then re-
stimulated and stained as described in section 2.2.2.
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2.3.6 ATP consumption Assay
Whole PBMC were thawed, counted and separated into 2 populations. Two µg/ml
anti-CD39 was added to one population and the equivalent volume of complete
medium was added to the other. Cells were incubated at 37°C for 30 minutes,
washed and counted again. Each population was plated at 2.5 x 105 cells/well with at
least 2 replicates.
The ATP consumption assay was performed by Halima Moncrieffe, of the
Immunopathogenesis Group at UCL Institute of Child Health, using a protocol
described in a previous study [101]. The method from that paper is included below:
" “A ! !t !o !t !a !l ! !o !f ! !2 !. !5 ! !x !1 !0!4 ! !c !e !l !l !s !/ !w !e !l !l ! !w !e !r !e ! !i !n !c !u !b !a !t !e !d ! !a !t ! !r !o !o !m ! !t !e !m !p !e !r !a !t !u !r !e ! !f !o !r ! !1 !0 !
!m !i !nutes ! !i !n ! !t !h !e ! !p !r !e !s !e !n !c !e !  !o !f ! ! 2 !5 ! µM ! !A !T !P ! !( !S !i !g !m !a !- !A !l !d !r !i !c !h !) !. ! !C !e !l !l !T !i !t !e !r !- !G !l !o ! !r !e !a !g !e !n !t ! !f !r !o !m !
!t !h !e ! !L !u !m !i !n !e !s !c !e !n !t ! !C !e !l !l ! !V !i !a !b !i !l !i !t !y ! !A !s !s !a !y ! ! ( !P !r !o !m !e !g !a !, ! !M !a !d !i !s !o !n !, ! !W !I !) ! !w !a !s ! !a !d !d !e !d ! !a !s ! !p !e !r !
!m !a !n !u !f !a !c !t !u !r !e !r !' !s ! !i !n !s !t !r !u !c !t !i !o !n !s !. ! !C !e !l !l !T !i !t !e !r !- !G !l !o ! !c !o !n !t !a !i !n !s ! !a ! !s !o !u !r !c !e ! !o !f ! !l !u !c !i !f !e !r !a !s !e !, ! !w !h !i !c !h !, ! !i !n !
!t !h !e ! !p !r !e !s !e !n !c !e ! !o !f ! !A !T !P !, ! !r !e !l !e !a !s !e !s ! !l !u !m !i !n !e !s !c !e !n !c !e ! !t !h !a !t ! !w !a !s ! !r !a !p !i !d !l !y ! !m !e !a !s !u !r !e !d ! !u !s !i !n !g ! !a !n !
!O !p !t !i !m !a ! !l !u !m !i !n !o !m !e !t !e !r ! !( !B !M !G ! !L !a !b !t !e !c !h !, ! !A !y !l !e !s !b !u !r !y !, ! !U !. !K !. !) !. ! !A !T !P !a !s !e ! !a !c !t !i !v !i !t !y ! !w !a !s !
!m!e!a!s!u!r !e!d! !b!y! !a! !r!e!d!u!c!t!i !o!n! !i!n! !l !u!m!i!n!e!s!c!e!n!c!e! !( !l!i!g!h!t! !u!n!i !t!s!) ! !d!u!r!i!n!g! !t !h!e! !a!s!s!a!y!.!”
Dr Moncrieffe collected the data and generated the graph shown in figure 4.7B.
2.3.7 STAT3 inhibitor
PBMC were sorted as described in section 2.3.3. Tresp, monocytes and Treg were
plated in separate wells of a 96 well u-bottomed plate at the concentrations described
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in section 2.3.3. Isolated cell subsets were placed in a 37°C, 5% CO2 incubator
overnight in complete medium or in STAT3 inhibitor VII (Calbiochem) at 5µg/ml in
0.02% DMSO. The following morning cells were combined in the following
conditions:
Tresp + monocytes
Tresp treated with inhibitor + monocytes
Tresp + monocytes + Treg treated with inhibitor
Tresp + monocytes + Treg
Cells were stimulated and cultured for 5 days as described in section 2.3.3, then re-
stimulated and stained as described in section 2.2.2.
2.3.8 Transwell Experiments
A 96 well HTS Transwell permeable support with a 0.4µm pore size polycarbonate
membrane was purchased from Corning Inc. Three hours before plating FACS sorted
cells, the transwell plate was equilibrated by the addition of 175µl of complete
medium to the bottom chamber. The upper chambers were carefully overlaid and a
further 50µl medium to each of these compartments and the plate was placed in a
37°C, 5% CO2 incubator. Tresp were resuspended at 4x10
6 cells/ml and Treg and
monocytes were resuspended at 1.32x106 cells/ml so that cells could be added in a
volume of 25µl in the following conditions:
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Tresp + monocytes (lower chamber)
Tresp + monocytes + Treg (lower chamber)
Tresp + monocytes (lower chamber) + Treg (upper chamber)
One µg/ml of anti-CD3/28 was added in a volume of 10µl to the lower chamber. The
final volume in each well was 235µl. Cells were cultured for 5 days.
On day 5, the medium was removed from the upper and lower chamber of the
transwell, transferred to a 96-well u-bottom plate and centrifuged for 5 minutes at
350 x g 21°C. The supernatant was removed, transferred a flat-bottomed 96 well
plate and stored at –20°C. Fifty µl of cell dissociation buffer (Gibco) was added to
both the upper and lower chambers of the transwell plate and mixed by pipette then
transferred to the 96 well u-bottom plate containing the cells and centrifuged as
above. Cells were supplemented with 200µl of stimulation mix for 4 hours in a 37°C,
5% CO2 incubator and stained as described in section 2.2.2.
2.3.9 PKH-26 Staining of monocytes
PKH-26 dye (SIGMA-Aldrich) was diluted 1:1000 in diluent C (SIGMA-Aldrich).
One ml of the diluted dye was added per 107 cells for 3 minutes in the dark. An equal
volume of room temperature FCS was added for a further 3 minutes to stop the
reaction. Cells were washed twice in complete medium before counting and
resuspending in the correct volume.
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2.3.10 Calculating Suppression
CP  = cytokine production.
Suppressive ability of Treg in depletion experiments was calculated as follows:
Suppression in the co-culture experiments was calculated as follows:
or
2.4 Mouse immunisation and flow cytometry staining
C57BL/6 mice (Charles River) were maintained in specific pathogen-free facilities
under home office guidelines. Mice were immunised with methylated Bovine Serum
Albumin (mBSA - SIGMA-Aldrich) dissolved in water to a concentration of 40
mg/ml. One hundred µg of mBSA were mixed 1:1 with Complete Freund’s adjuvant
and 100µl was injected at the base of the tail. Fourteen days later, mice were boosted
with 100µg mBSA mixed 1:1 in incomplete Freund’s adjuvant in the base of the tail.
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Three days later mice were sacrificed under Schedule 1. All animal handling
components were undertaken by Dr. Clare Notley. The inguinal draining lymph
nodes were removed and a single cell suspension prepared by passing the lymph
node through a 0.7µm cell strainer. Cells were washed in complete medium
(prepared as previously described, and additionally supplemented with 50µM 2-
Mercaptoethanol- SIGMA-Aldrich) and plated at 5x105 cells/well in a 96 well u-
bottom plate. Cells were stimulated with 1ng/ml PMA, 1µg/ml ionomycin and
1µl/ml Golgi Stop for 4 hours at 37°C. After this time the cells were stained for CD4
FITC (RM4-5, 1:200, dilution BD Pharmingen), IL-17A Alexa Fluor 647
(eBio17B7, 1:50, eBioscience) and RORγt (see table 2.1, pg 108). The protocol used
was the same as described in section 2.2.2. Data were acquired on the BD FACS
Calibur.
2.5 Enzyme-linked Immunosorbent Assay  (ELISA)
2.5.1 Buffers and reagents
1xTBS: 20ml 1 x Tris Buffer (pH 7.2), 8.7g NaCl
Blocking buffer: 1 x PBS (SIGMA-Aldrich), 1%  BSA
Dilution Buffer: 1 x TBS, 1%  BSA, 0.05%  Tween 20
Wash Buffer: 1 x PBS, 0.05% Tween 20
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2.5.2 IL-17 ELISA
Ninety-six well NUNC maxisorb (NUNC) plates were coated overnight at room
temperature with 50µ l of 4µg/ml anti-human IL-17 antibody (R&D Systems) in
dilution buffer. The plates were washed 5 times with wash buffer before incubation
with 250µl of blocking buffer for 1.5 hours at room temperature. Samples stored
from previous experiments were thawed and diluted as required and standard curve
prepared from recombinant human IL-17 antibody (R&D Systems) with a top
concentration of 2000pg/ml. The plate was washed a further 5 times, before standard
curve and the samples were added to the plate and incubated for 2 hours at room
temperature. After washing 5 times, 50µl of 0.5µg/ml anti-IL-17 detection antibody
in dilution buffer (R&D systems) were added to the plate for 2 hours at room
temperature. The plate was washed 5 times and 50µl streptavidin-horseradish
peroxidase (R&D Systems) diluted 1/200 were added to the plate for 30 minutes at
room temperature, before a further wash step. One hundred µ l of
tetramethylbenzidine (TMB) (SIGMA-Aldrich) were added to each well and allowed
to develop for 5-10 minutes, the reaction was stopped by the addition of 50µl of 2M
sulphuric acid. The OD values were acquired at 450nm on the MRX TC revelation
(DYNEX technologies) within 1 hour.
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2.5.3 IL-10 ELISA
The IL-10 ELISA was undertaken using the protocol described above. The reagents
specific to this experiment were:
Capture antibody: anti-IL-10  Clone: Mouse IgG1 (R&D)
Detection antibody: anti-IL-10 Clone: Goat IgG (R&D)
Standard: recombinant human IL-10 (R&D)
2.5.4 IL-23 ELISA
IL-23 ELISA was performed with an ELISA Ready-SET-Go Set (eBioscience) and a
96 well NUNC maxisorb plate. Most of the required reagents were included, but
wash buffer and stop solution (2M sulphuric acid) were prepared as above. Plates
were incubated overnight with 100µl of capture antibody (anti-p19) in coating buffer
(supplied). Plates were washed 5 times and blocked for 1 hour at room temperature
with assay diluent (supplied). The plate was washed a further 5 times before plating
serial dilutions of the standard with a top concentration of 2000 pg/ml followed by
the samples at room temperature for 2 hours. The plate was washed 5 times before
the addition of the capture antibody (anti-p40) for 1 hour at room temperature. The
plate was washed as previously and 100µl of Avidin-HRP diluted in assay diluent as
per the protocol were added to each well for 30 minutes at room temperature. The
plate was washed 7 times with 1-2 minutes soaking of the wells in wash buffer
between each wash. One hundred µl/well of substrate solution (provided) were added
to each well for 15 minutes before the addition of 50µl stop solution to each well.
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The OD values were acquired at 450nm on MRX TC revelation (DYNEX
technologies).
2.6 Cytometric Bead Array  (BD)
CBA was undertaken with a series of flex sets (BD); each cytokine of interest was
associated with a different capture bead (IL-17 B5, IL-1 B4 and IL-6 A7) and
reagents were prepared using a human soluble protein master buffer kit (BD).
Samples were thawed and incubated with capture beads for the required cytokines in
a 96-well plate for 1 hour at room temperature. PE detection reagent was added to
each sample and incubated at room temperature in the dark for a further 2 hours. The
plate was then centrifuged at 200 x g for 5minutes and beads were resuspended in
wash buffer and centrifuged again. Each well was resuspended in 300 µl and
acquired on the same day on the BD FACS Array. Samples were analysed using the
BD FACS CAP program.
2.7 Statistical Analysis
Data were analysed using Graphpad Prism. Comparison between healthy controls
and patient groups was measured using an unpaired t test. When patients were
studied ‘pre’ and ‘post’ therapy, a paired t test was used. The probability value is
shown on graphs as appropriate.
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Chapter 3 
Immunologic changes in rheumatoid arthritis patients treated with
anti-TNF
Objectives:
1. Utilise flow cytometry to determine levels of regulatory T cells in healthy
controls, patients with active RA and RA patients responding to either
adalimumab or etanercept.
2. Examine Treg phenotype in healthy controls and RA patient groups using
flow cytometry.
3. Determine if there are differences in key tolerogenic features in patients with
active RA and RA patients treated with adalimumab or etanercept – including
the ex vivo levels of apoptosis and production of anti-inflammatory cytokines.
4. Determine if there are differences in key pathogenic features in patients with
active RA and RA patients treated with adalimumab or etanercept – including
the ex vivo levels of RORC+ Th17 cells and production of IL-17 and IFNγ.
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3.1 RA patients responding to adalimumab, but not etanercept, have
increased peripheral Treg
Previous work by this group has shown that regulatory T cells (Treg) from patients
with RA are compromised in their ability to suppress cytokine production from
responder T cells, in contrast to Treg from healthy controls. In RA patients treated
with infliximab, it was observed that peripheral blood Treg were increased in number
and were capable of suppressing IFNγ in vitro [124]. To confirm that the increase in
Treg observed in infliximab treated patients also occurred following therapy with
adalimumab, a purely human anti-TNF antibody, peripheral blood mononuclear cells
(PBMC) from healthy controls, patients with active RA and RA patients responding
to adalimumab were stained with flow cytometry antibodies for CD4, CD25 and
FOXP3 (Figure 3.1A). As previously published [86, 124], the percentage of
CD4+CD25+FOXP3+Treg in patients with active RA was similar to healthy controls.
In contrast, patients responding to adalimumab had increased peripheral Treg
(p=0.0002). This difference was also observed if Treg were defined as CD4+FOXP3+
(Figure 3.1B). Furthermore, this increased percentage of Treg was absent in patients
with persistently active disease despite treatment with adalimumab (adalimumab
NR).
To determine whether this increase in Treg after therapy was explained by the
neutralisation of systemic TNF, we studied a third anti-TNF therapy proven to be
effective in the treatment of RA, the TNF type II receptor IgG1 fusion protein known
as etanercept. The percentage of Treg in RA patients responding to etanercept was
compared to healthy controls, patients with active RA and RA patients responding to
adalimumab.  Unexpectedly, there was no difference between the numbers of Treg
(either CD4+CD25+FOXP3+ or CD4+FOXP3+) in patients with active disease and
Chapter 3
130
those responding to etanercept. In addition, the percentage of Treg was significantly
lower in etanercept treated patients than in those treated with adalimumab
(p=0.0007)(Figure3.1A,B).
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Figure 3.1. Rheumatoid arthritis patients treated with adalimumab, but not
etanercept, have increased regulatory T cells.
Ex vivo PBMC from healthy controls, patients with active RA and patients
responding to adalimumab or etanercept were surface stained for CD4, CD25 and the
intracellular transcription factor FOXP3. A. Percentage of CD4+ cells that are
CD25+FOXP3+. Points show individual donors and bars show mean percentage
CD4+FOXP3+ cells. Representative FACS plots are gated on CD4. B. Percentage
CD4+FOXP3+ in PBMC from healthy controls, patients with active RA , patients
responding to adalimumab or etanercept and patients  not responding to adalimumab
(adalimumab NR). Points show individual donors and bars show mean percentage
CD4+FOXP3+ cells. Representative FACS plots are shown.
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These differences did not appear to be dependent upon the production of
autoantibodies, as the same overall trend was observed whether the patients were
positive or negative for RF (Figure 3.2 A) or ACPA (Figure 3.2B).
Figure 3.2. Increased Treg after treatment with adalimumab is independent of
autoantibody positivity.
Ex vivo percentage of CD4+FOXP3+ cells was determined in healthy controls (n=6),
A. patients positive for rheumatoid factor (active n=20, adalimumab n=10,
Etanercept n= 6) or B. patients negative for rheumatoid factor (active n=13,
adalimumab n=5, etanercept n=4), C. patients positive for ACPA (active n=14,
adalimumab n=7, etanercept n=4) or D. patients negative for ACPA (active n=12,
adalimumab n=4, etanercept n=1). Bars represent the mean±SE.
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3.2 Treg from patients treated with adalimumab, but not etanercept bear the
hallmarks of induced Treg.
To address whether the increased Treg observed in adalimumab treated patients
represent a population of peripherally induced cells, Treg were stained for CD62L
and Helios. The former has been previously described by this group as a marker of
anti-TNF induced Treg [86], whilst Helios expression is thought to be confined to
thymically derived Treg [72]. As expected, there was a significantly higher
proportion of CD62L negative Treg in patients treated with adalimumab compared to
both patients with active RA and those treated with etanercept (Figure 3.3 A). There
were also more Treg from adalimumab treated patients that lacked expression of
Helios compared to patients with active RA. In patients who did not respond to
adalimumab, the percentage of Helios negative Treg were similar to patients with
active RA (Figure 3.3 B). Notably, there were more Treg negative for both Helios
and CD62L (Figure 3.3 C) in adalimumab treated patients compared to patients with
active RA or patients responding to etanercept.
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Figure 3.3. Treg from patients treated with adalimumab bear the hallmarks of
induced Treg.
Ex vivo PBMC from healthy controls (n=5), patients with active RA (n=10) and
patients responding to adalimumab (n=8) or etanercept (n=8) were stained with
CD4, FOXP3, CD62L and Helios A. Percentage CD62L negative cells in the
CD4+FOXP3+ population. B. Percentage Helios negative cells in the CD4+FOXP3+
population. Data from patients not responding to adalimumab are also shown
(adalimumab NR) (n=4) C. Percentage Helios negative CD62L negative cells in the
CD4+FOXP3+ population. Example FACS plots are gated on CD4+FOXP3+ cells and
show co-staining of CD62L and Helios. For all graphs, bars represent the mean±SE.
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3.3 Proliferation of FOXP3+ T cells
In order to show that the increase in Treg in adalimumab treated patients was not a
result of in vivo proliferation, cells were stained ex vivo for Ki67, an intracellular
marker identifying cells that have recently proliferated. Treg show relatively high
levels of Ki67, in line with data showing that Treg can proliferate substantially in
vivo  [423], however there were no differences in Treg proliferation observed
between healthy controls and the patient groups studied (Figure 3.4 A).
3.4  Proliferation and cell death in rheumatoid arthritis
Proliferation and cell death often form an integral part of RA disease pathology due
to the fundamental role cytokines such as TNF play in these processes [424].
Therefore, I examined proliferation and apoptosis in healthy controls and patients
before and after anti-TNF therapy. There was no significant increase in CD4 T cell
proliferation in patients treated with adalimumab compared to patients with active
RA, healthy controls or patients responding to etanercept (Figure 3.4B).
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Figure 3.4. CD4 cell proliferation in rheumatoid arthritis.
Ex vivo PBMC from healthy controls (n=7), patients with active RA (n=16) and
patients responding to adalimumab (n=11) or etanercept  (n=5) were stained with
CD4, FOXP3 and Ki67. A. Percentage Ki67+ cells in the CD4+FOXP3+ population.
An example FACS plot is shown. B. Percentage Ki67+ CD4 cells, example FACS
plot shown. For all graphs, bars represent the mean±SE.
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To determine the percentage of dead/apoptotic cells present in patients, samples were
stained for flow cytometry with Annexin V and 7AAD: the former is an anti-
phospholipid binding protein which recognises phospholipids on the cell membrane
during apoptosis whilst the latter is a vital dye, permeable only to cells which are
dead or damaged.  When whole PBMC were analysed there were no differences in
early apoptotic cells (Annexin V+ 7AAD-) between healthy controls and the RA
patients studied (Figure 3.5 A). There was a small reduction in dead and dying cells
(Annexin V+7AAD+) in patients with active RA (p=0.26) compared to healthy
controls, though this did not reach significance. Patients treated with adalimumab
had similar levels of cell death as healthy controls, whilst patients treated with
etanercept resembled more closely the level of cell death in patients with active RA
(Figure 3.5 B).
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Figure 3.5. Apoptosis and cell death in rheumatoid arthritis.
Ex vivo PBMC were stained with Annexin V and 7AAD. A ‘live’ gate was not used
for analysis A. Percentage Annexin V+ cells (healthy n=10, active n=16, adalimumab
n=6, etanercept n= 3). B. Percentage Annexin V+7AAD+ cells (healthy n=10, active
n=17, adalimumab n=7, etanercept n= 5). Representative FACS plots are shown.
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It has previously been shown that monocyte cell death is reduced in patients with
active RA compared to healthy controls and that this is reversed by in vitro treatment
with infliximab [425]. Indeed, our data showed a significant reduction in monocyte
cell death in patients with active RA compared to healthy controls (p=0.0006).
Moreover, there was a trend for levels of cell death to be restored to normal levels in
patients treated with adalimumab (p=0.12), but not in patients treated with etanercept
(Figure 3.6). These data may reach significance if the ‘n’ number is increased.
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Figure 3.6. Monocyte death in rheumatoid arthritis.
Percentage Annexin+7AAD+ cells in the CD14+ population. (healthy n=9, active
n=14, adalimumab n=6, etanercept n= 4). A ‘live’ gate was not used for analysis.
For all graphs, bars represent the mean±SE. Representative FACS plots are shown.
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3.5 TGF-β expression on CD4 T cells
Previously, this group has shown that CD4+CD25- derived TGF-β is important for
the induction of FOXP3+ cells in the presence of infliximab [86]. Thus we examined
the expression of TGF-β on FOXP3+ and FOXP3- CD4 T cells. There was no
significant increase in the TGF-β expression on the surface of either FOXP3+ or
FOXP3- T cells from adalimumab treated patients compared to patients with active
RA or patients treated with etanercept (Figure 3.7 A and B). However, some
etanercept treated patients had high levels of TGFβ expression, so increasing the ‘n’
numbers of this study may reveal a significant increase in etanercept treated patients.
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Figure 3.7. Expression of TGF-β on CD4 T cells.
PBMC from patients with active RA and patients treated with adalimumab or
etanercept  (n=4) were thawed and surface stained for CD4 and TGF-β, then stained
for intracellular FOXP3. A. Percentage of surface TGF-β in the FOXP3+ population.
B. Percentage of surface TGF-β in the FOXP3- population. Example FACS plots are
gated on CD4. For all graphs, bars represent the mean±SE.
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3.6 IL-10 production from CD4 T cells
In addition to TGF-β, IL-10 has been shown to be important for the induction of
Treg [426, 427], so we examined IL-10 production by T cells, B cells and monocytes
from peripheral blood. When we examined CD4 T cells, there were no significant
differences in IL-10 production between patient groups (Figure 3.8 A). The source of
IL-10 from CD4 T cells for patients with active RA and those treated with
adalimumab appeared to be FOXP3- cells. Very little IL-10 was detectable from the
FOXP3+ cells by FACS (Figure 3.8 B).
Chapter 3
144
Figure 3.8. IL-10 production from CD4 T cells.
PBMC from patients with active RA and patients treated with adalimumab or
etanercept were thawed and stained for CD4 before stimulation with PMA for 4
hours and subsequent staining with IL-10 (n=6). A. Percentage IL-10+ T cells. Bars
represent the mean±SE. Example FACS plots shown for an active patient and an
adalimumab patient. B. Example FACS plots gated on CD4, show IL-10 staining
from FOXP3+ and FOXP3- populations in a patient with active RA and a patient
treated with adalimumab.
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3.7 IL-10 production from B cells
In contrast to the data from CD4 T cells, there was a trend for IL-10 production from
CD19+ B cells to increase after adalimumab therapy (p=0.07) but not etanercept
therapy (p=0.22) (Figure 3.9 A). CD19+ cells were analysed based on their
expression of CD38 and CD24. Using previous publications as a guideline [428], 3
distinct populations of B cells were identified; CD24hi CD38- cells were classified as
memory B cells, CD24intCD38int were classified as mature B cells and CD24hi
CD38hi were classified as immature B cells. This gating strategy was then applied to
the CD19+IL-10+ cells to determine which subsets were contributing to total B cell
IL-10 (Figure 3.9 B). It appeared that the greatest proportion of IL-10 came from the
mature subset, with less coming from the immature subset and very little from the
memory cell population (Figure 3.9 C). Whilst patients with active RA and patients
treated with adalimumab had similar levels of IL-10 producing cells from the mature
B cell subset, etanercept treated patients possessed significantly more IL-10+ mature
B cells compared to patients treated with adalimumab (Figure 3.9 C). Indeed, despite
low ‘n’ numbers for the active RA cohort there was still a an increase in IL-10+
mature B cells in etanercept patients compared to patients with active RA which may
reach significance if more patients were studied (Figure 3.9 C). There were no
significant differences between any of the patient groups in percentage of IL-10
producing cells in the immature subset (Figure 3.8 D).
As IL-10 production from immature B cells has been shown to be important to Treg
maintenance and stability [257], IL-10 production was analysed from a different
perspective. Rather than examining how B cell subsets contributed to total B cell IL-
10, the percentage of immature cells that make IL-10 was determined. Whilst it
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appeared that immature B cells from adalimumab treated patients made more IL-10
than their counterparts in active patients or those treated with etanercept, these
differences were not significant (Figure 3.9E).
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Figure 3.9. IL-10 production from B cells.
PBMC from patients with active RA and patients treated with adalimumab or
etanercept were thawed and stimulated with PMA for 4 hours before staining for B
cell markers and IL-10 (n=6). A. Percentage IL-10+ CD19+ cells. Bars represent the
mean±SE. Example FACS plots shown for an active RA patient and an adalimumab
treated RA patient. B. Cells were stained for CD19, CD24 and CD38. The left FACS
plot is gated on CD19+ cells and the right is gated on IL-10+ cells. In both cases, cells
were divided into 3 populations: CD24hi CD38- (memory), CD24intCD38int (mature)
and CD24hi CD38hi (immature).  C. Percentage of total B cell IL-10 produced by
mature B cells. Bars represent the mean±SE. D. Percentage of total B cell IL-10
produced by immature B cells. Bars represent the mean±SE E. FACS plot shows an
example of IL-10 production from immature B cells. The graph shows pooled data of
percentage IL-10 production from immature B cells. Bars represent the mean±SE.
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3.8 IL-10 production from CD14+ monocytes
Finally, we analysed the IL-10 production from CD14+ monocytes. Little IL-10 was
detected from this subset but it seemed as though there was more IL-10 production
from monocytes in the etanercept treated patient group than patients with active RA
or patients treated with adalimumab (Figure 3.10) however, this did not reach
significance. Increasing the power of this study may reveal significance or further
analysis may reveal that etanercept treated RA patients fall into distinct groupings
which may explain the variability observed.
Figure 3.10. IL-10 production from monocytes.
PBMC from patients with active RA and patients treated with adalimumab or
etanercept were thawed and stimulated with PMA for 4 hours before staining with
CD14 and IL-10 (n=6). Graph shows pooled data of percentage IL-10+ monocytes.
Bars represent the mean±SE. Example FACS plots shown.
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3.9 Retinoic-acid-receptor-related orphan receptors identify Th17 cells
Previous studies have shown that Th17 cells are increased in the periphery of
patients with active RA [208]. In addition, it is now widely accepted that Th17 cells
and Treg exist on a developmental axis [429]. In this report, I have shown that
patients treated with adalimumab have increased peripheral Treg (Figure 3.1).
Therefore, it was investigated whether these changes in Treg led to reciprocal
changes in Th17 cells in the periphery. It has recently become possible to detect
ROR proteins, the master transcription factors of Th17 cells, by FACS using a rat
antibody specific for the human and mouse ROR homologues. Initial optimisation
was undertaken using cells of harvested lymph nodes from mice immunised with
methylated BSA (see methods section 2.4). These cells were co-stained for RORγt
and IL-17 after 4 hours of stimulation and analysed by FACS. More than 90% of the
IL-17 produced was from cells that expressed RORγt, identifying them as Th17 cells
(Figure 3.11 A). When this was translated into samples from human peripheral
blood, it was clear that IL-17 producing T cells were within the human RORC+
population (Figure 3.11 B). This confirmed the utility of this antibody in identifying
IL-17 producing cells or their precursors.
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Figure 3.11. RORγt as a marker of Th17 cells.
A. Cells from the lymph node of an mBSA-immunised mouse were stimulated for 4
hours with PMA, ionomycin and Golgi stop. Cells were then stained for CD4, fixed
and incubated with an Fc block before the addition of antibodies for RORγt and IL-
17. The isotype control was used to determine gating strategy. B. Histogram showing
expression of human RORC. PBMC from a healthy control were stimulated for 4
hours with PMA, ionomycin and Golgi stop. Cells were then stained for CD4, fixed
and incubated with an Fc block, before the addition of antibodies against RORC and
IL-17. The solid grey histogram is the isotype control for RORC and the outline is
gated on the IL-17+ cells
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3.10 Th17 cells are reduced in patients treated with adalimumab, but not
etanercept.
Using the approach described in 3.8, we explored whether the increase in FOXP3
expression in adalimumab treated patients influenced the expression RORC, the
human ROR homologue. The expression of RORC, was significantly elevated in
active RA patients compared to healthy controls (P =0.0007) whereas RORC+ T
cells were reduced 2-fold in patients treated with adalimumab (P=0.002) but not
etanercept. Moreover, levels of RORC+ cells were significantly lower in patients
responding to adalimumab than those patients who were not responding to therapy
(P=0.02) (Figure 3.12 A). An increased ratio of FOXP3+ cells to RORC+ cells in
adalimumab treated patients compared to any other group confirmed the shift
towards an immunoregulatory T cell phenotype (Figure 3.12 B). These differences
were less pronounced when IL-17 production was determined ex vivo (Figure 3.12
C). Finally, IFNγ production by CD4 T cells was examined because expression of
this cytokine is not known to have an intrinsic relationship with Treg. Thus, as
expected there were no significant differences in IFNγ production between healthy
controls, patients with active RA and patients treated with adalimumab or etanercept
(Figure 3.12 D).
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Figure 3.12. Th17 cells are reduced in RA patients treated with adalimumab,
but not etanercept.
A. PBMC from healthy controls, patients with active RA, patients responding to
adalimumab or etanercept were stained ex vivo for CD4, RORC and FOXP3. Data
from patients not responding to adalimumab are also included (n=4). Bars indicate
mean percentage CD4+RORC+ cells ±SE (n=10). Representative FACS plots reveal
co-staining of RORC and FOXP3 in CD4+ T cells. B. Ratio of RORC+ to FOXP3+
CD4 T cells in the different patient groups and healthy controls. Bars represent mean
±SE C. Ex vivo PBMC were stimulated for 4 hours with PMA before staining with
IL-17 (n=6). Graphs show percentage CD4+ IL-17+ cells. Bars represent mean ±SE
D. Ex vivo PBMC were stimulated as in ‘C’ and stained for IFNγ. Healthy n=7,
active n=17, adalimumab n=19, etanercept n=7.Graphs show percentage IFNγ+
cells. Bars represent mean ±SE
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Summary:
In confirmation of previously published data, this chapter has shown that there is no
difference in the percentage of circulating Treg in healthy controls and patients with
active RA. Like patients treated with infliximab, patients responding to adalimumab
demonstrated an increase in Treg but this was absent in RA patients responding to
etanercept. Response to adalimumab therapy was vital for this increase in Treg
because levels of Treg in patients that failed to respond to therapy were similar to
patients with active RA and those treated with etanercept. Examination of Treg
phenotype showed no evidence of increased proliferation of Treg from adalimumab
treated patients compared to patients with active RA. Indeed, a greater percentage of
Treg from adalimumab treated patients bore markers of induced Treg than etanercept
treated patients or patients with active RA, suggesting an extra-thymic source.
Compared to healthy controls, overall levels of apoptosis were lower in patients with
active RA. The data show differences between apoptosis in adalimumab and
etanercept treated patients but these do not reach significance. Examination of anti-
inflammatory cytokines revealed few significant differences between patients with
active RA and those responding to adalimumab. Though some etanercept treated
patients had high levels of TGFβ and IL-10 production compared to other patient
groups. Examination of changes in inflammatory T helper cell subsets showed that
RORC+ Th17 cells were elevated in patients with active RA compared to healthy
controls and reduced by adalimumab but not etanercept therapy. These differences
were not as stark when IL-17 production by T cells ex vivo was determined. There
were no differences in T cell IFNγ production in any of the patient groups studied.
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Chapter 4 
Regulatory T cell function in rheumatoid arthritis patients treated
with anti-TNF
Objectives:
1. Using well-established suppression assays, confirm a defect in the capacity of
Treg from patients with active RA to suppress IFNγ and determine if Treg
from adalimumab treated RA patients demonstrate a restored capacity to
suppress this cytokine.
2. Demonstrate, using the same approach, that the absence of induced Treg in
etanercept treated RA patients is associated with no restoration of suppressive
function.
3. Use a method where whole PBMC are depleted of Treg to show that Treg
from adalimumab treated patients, but not etanercept treated patients regulate
Th17 cells.
4. Confirm the capacity of Treg to control Th17 cells with co-culture
experiments.
5. Elucidate the mechanism of Treg suppression of IL-17 using anti-IL-10 and
anti-TGFβ blocking antibodies in suppression assays.
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4.1 Treg from RA patients treated with adalimumab, but not etanercept, can
suppress IFNγ production via the production of IL-10 and TGF-β
Our previous publications have shown that Treg from patients with active RA
(RATreg) are defective in their suppression of Th1 responses [124]. This defect was
reversed by infliximab therapy via the induction of Treg. Thus, it was hypothesised
that Treg from patients treated with adalimumab (AdTreg) would be able to suppress
IFNγ, but due to the absence of Treg induction in etanercept treated patients, Treg
from these patients (EtTreg) would remain defective. As previously published, Treg
from healthy controls (HTreg) were able to suppress IFNγ, and this ability was
reduced in RATreg. AdTreg showed equivalent suppressor ability to their healthy
counterparts and as predicted, EtTreg remained defective. In accordance with data
previously published by this group [86], neutralization of IL-10 and TGF-β reversed
the ability of AdTreg to suppress IFNγ (Figure 4.1 A). Furthermore, examination of
IL-10 in the supernatants of these cultures showed that IL-10 increased upon the
addition of AdTreg to autologous responder T cells suggesting that AdTreg but not
RATreg or EtTreg produce IL-10 (Figure 4.1 B).
As TGF-β plays such an intrinsic role in the suppression of IFNγ by AdTreg, we
investigated if CD4 T cells from patients treated with adalimumab have increased
expression of the receptor for TGF-β. A number of adalimumab treated patients
demonstrated high levels of TGF-βRII expression on both the FOXP3+ (Figure 4.1
C) and FOXP3- (Figure 4.1 D) CD4 cells. This did not reach significance but these
data may reveal a difference with sufficient power.
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Figure 4.1. Treg from patients treated with adalimumab, but not etanercept can
suppress IFNγ via the production of IL-10 and TGF-β.
A. CD4+CD25+CD127- cells (Treg) and CD4+CD25-CD127+ cells (Tresp) were
isolated from PBMC and cultured in a ratio of 3 Tresp to 1 Treg and stimulated with
soluble anti-CD3 and anti-CD28 for 4 days before re-stimulating cells with PMA,
ionomycin and Golgi Stop for 4 hours. Bars represent mean suppression of
IFNγ (n=5). Representative FACS plots show IFNγ production from responder T
cells in cultures with or without Treg.  B. Supernatants from the co-culture described
in A. were assayed for IL-10 (n=3) C-D. PBMC from healthy controls (n=4),
patients with active RA (n=24) and patients responding to adalimumab (n=13) were
stained for CD4, TGF-β receptor II and FOXP3. C. Percentage of surface TGF-βRII
in the FOXP3- population. D. Percentage of surface TGF-βRII in the FOXP3+
population. Example FACS plots are gated on CD4. For all graphs bars represent the
mean±SE.
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4.2 Treg from patients treated with adalimumab, but not patients treated with
etanercept suppress IL-17 from whole PBMC
IL-17 has been implicated in the progression of a number of autoimmune diseases
and has been detected in the joints of patients with RA [430].  In contrast to their
ability to suppress responder T cell proliferation or IFNγ production, this lab and
others have shown that both HTreg and RATreg are unable to suppress IL-17
production in vitro [37, 194]. This report has detailed an increase in AdTreg
concomitant with a reduction in Th17 cells; this led me to investigate if Treg induced
by adalimumab therapy could suppress Th17 cells. In early co-culture experiments,
IL-17 production was negligible from responder T cells cultured alone. It is known
that Toll-like receptor-activated monocytes can drive IL-17 production from T cells
[194]. Thus, an approach was used where Treg were depleted from whole PBMC so
that monocytes were present in the culture to promote Th17 responses. However, I
chose not to stimulate PBMC with TLR agonists in order to more closely reflect the
in vivo environment where monocytes may already have been activated. Cells were
sorted into two populations, one sample of whole PBMC and one sample of PBMC
depleted of CD4+CD25+CD127- Treg (for purity see Figure 2.2). These were cultured
for 3 days with anti-CD3 and anti-CD28, and IL-17 secretion was measured by
FACS and ELISA.
The percentage difference in IL-17 production between whole PBMC and PBMC-
Treg was calculated. Consistent with previously published data [37], neither HTreg
nor RATreg showed evidence of suppressing IL-17 as IL-17 did not significantly
alter when Treg were depleted from these samples. However, IL-17 production
increased when adalimumab patient samples were depleted of Treg, suggesting that
AdTreg can suppress IL-17. In accordance with the data reported here suggesting
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etanercept does not directly affect Treg numbers or function, EtTreg showed no
evidence of suppressing IL-17 (Figure 4.2 A). These results were confirmed by
measuring IL-17 using an ELISA assay, showing that IL-17 was only increased
significantly (p=0.001) when the PBMC of adalimumab treated patients are depleted
of Treg (Figure 4.2 B).
4.3 Treg from patients with active RA are unable to suppress IL-22 and this
capacity is restored by treatment with adalimumab, but not etanercept
IL-22 is a cytokine known to be produced by Th17 cells [431] and similarly to IL-17,
has been identified in the synovium of patients with active RA [432]. However, a
recent paper has suggested that IL-22 can be anti-inflammatory during acute liver
inflammation [308]. I therefore assayed IL-22 in PBMC cultures depleted of Treg. In
contrast to their inability to suppress IL-17 production, HTreg were capable of
suppressing IL-22. RATreg had little capacity to suppress IL-22, whilst AdTreg had
a restored capacity to suppress this cytokine (p=0.0159) and this was absent in
EtTreg (Figure 4.2 C).
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Figure 4.2.  Treg from RA patients treated with adalimumab, but not
etanercept, are capable of suppressing IL-17 and IL-22 in vitro.
A. PBMC were separated into 2 fractions, untouched PBMC and PBMC depleted of
CD4+CD25+CD127- Treg. Cells were cultured for 3 days with soluble anti-CD3 and
anti-CD28, and then stimulated with PMA, ionomycin and Golgi Stop. Cells from
healthy controls (n=5), patients with active RA (n=6) and patients responding to
adalimumab (n=6) or etanercept (n=4) were stained for IL-17. Bars represent the
mean of percentage difference in IL-17 production between PBMC and PBMC
depleted of Treg. B. Supernatants from A. were assayed for IL-17 secreted during
culture using ELISA. Bars represent the mean±SE. C. PBMC or PBMC-Treg from
healthy controls (n=2), patients with active RA (n=6) and patients responding to
adalimumab (n=4) or etanercept (n=4) were stained with flow cytometry antibodies
for IL-22. Bars represent the mean of the percentage difference in IL-22 production
between PBMC and PBMC depleted of Treg. Representative FACS plots show IL-22
production from cultures of whole PBMC with (PBMC) or without (Treg depleted)
Treg.
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4.4 Treg from patients treated with adalimumab can suppress IL-17
production from CD4 T cells
In order to confirm that CD4 Treg were suppressing Th17 cells and not another IL-
17 producing cell in whole PBMC, we co-cultured responder T cells in a 3:1 ratio
with Treg, and to drive Th17 cells we added autologous CD14+ monocytes.
Monocytes were stained with a cell membrane dye (PKH) before culture so that they
could be excluded from analysis. The addition of monocytes to responder T cells was
sufficient to drive IL-17 and enhance IFNγ production from T cells (Figure 4.3 A).
However, the addition of monocytes to this co-culture system did not reduce the
capacity of HTreg or AdTreg to suppress IFNγ, nor alter the defect in RATreg or
EtTreg (Figure 4.3 B).
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Figure 4.3. Monocytes drive Th17 responses but do not alter Treg function.
A. Responder T cells (Tresp) from adalimumab treated patients were cultured with
1µg/ml anti- CD3/28, alone or in the presence of PKH-stained monocytes for 5 days.
FACS plots indicate IL-17 production from the PKH negative population. B. Treg,
Tresp and monocytes were isolated and cultured with anti-CD3/CD28. Bars
represent mean suppression of IFNγ ±SE. Healthy (n=4), Active (n=4), Adalimumab
(n=6), Etanercept (n=4). Representative FACS plots show IFNγ production from
cultures of responder T cells and monocytes with or without Treg.
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Using this approach to investigate the suppression of IL-17, it was confirmed that
only AdTreg could suppress IL-17 from responder T cells. IL-17 production either
stayed the same or increased upon the addition of HTreg, RATreg or EtTreg.
Moreover, Treg isolated from patients not responding to adalimumab did not acquire
the capacity to suppress IL-17 (Figure 4.4 A). Assaying IL-17 in the culture
supernatants revealed that its production fell only when AdTreg were added to their
autologous responder T cells and monocytes (Figure 4.4 B). Of interest, there was
more IL-17 present in the supernatants of responder T cells and monocytes from
adalimumab treated patients, compared to the other patient groups and healthy
controls.  This was consistent with the data presented in Figure 4.2 B, where the
highest IL-17 production was detected in PBMC depleted of Treg from adalimumab
treated patients.
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Figure 4.4. Treg isolated from RA patients treated with adalimumab can
suppress Th17 cells.
A. Treg, responder T cells (Tresp) and monocytes from healthy controls, patients
with active RA and patients responding to adalimumab or etanercept were isolated
and cultured with anti-CD3/CD28 (n=10). Data are also shown for patients not
responding to adalimumab (adalimumab NR) (n=3) Bars represent mean suppression
of IL-17 ±SE. Representative FACS plots show IL-17 production from responder T
cells co-cultured with monocytes with or without Treg. Monocytes were excluded
from analysis by PKH staining B. Supernatants from A. were analysed for IL-17 by
CBA. Bars represent the mean±SE.
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4.5 Suppression of IL-17 is independent of IL-10 and TGF-β
Next we used neutralising antibodies to IL-10 and TGF-β to investigate the role of
these cytokines in the suppression of IL-17. In accordance with previously published
data using infliximab treated patients [86], the blockade of IL-10 alone, TGF-β
alone, or both TGF-β and IL-10 was able to significantly reduce the ability of
AdTreg to suppress IFNγ. In contrast, blockade of IL-10 and TGF-β had no effect on
the ability of Treg from adalimumab treated patients to suppress IL-17, indicating
that these Treg control IFNγ and IL-17 through distinct mechanisms (Figure 4.5 A).
To provide further evidence that that IL-10 signalling was not mediating the AdTreg
suppression of IL-17, an anti-IL-10 receptor antibody alone or in conjunction with
TGF-β and IL-10 neutralising antibodies was added to the cultures. Under none of
these conditions was the ability of AdTreg to suppress IL-17 reversed (Figure 4.5 B).
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Figure 4. 5. Suppression of IL-17 by AdTreg is independent of IL-10 and TGF-β
The suppression assay described in Figure 4.4 was repeated with adalimumab patient
samples A. Neutralising antibodies to IL-10 and TGF-β were added to cultures. Cells
were stained for IL-17 and IFNγ. Bars represent mean suppression of IL-17 or IFNγ
(n=5). B. Neutralising antibodies to IL-10 receptor were added to cultures alone or in
the presence of anti-IL-10 and anti-TGF-β. Bars represent mean suppression of IL-
17±SE (n=3).
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4.6 Patients treated with adalimumab have more Treg expressing CD39 than
healthy controls, patients with active RA or patients treated with
etanercept.
CD39 is an ectonucleotidase involved in the breakdown of ATP into adenosine, a
molecule with known anti-inflammatory properties [433]. In 2009, a paper by
Fletcher et al. described a population of CD39+ Treg with the capacity to suppress
IL-17 [105]. We examined ex vivo expression of CD39 on Treg from RA patients
and found that a significantly greater proportion of AdTreg bear the expression of
CD39 than HTreg, RATreg or EtTreg (Figure 4.6 A). The breakdown of ATP to
AMP and then adenosine requires CD39 to work in tandem with a second enzyme
CD73. In mice, it has been shown that CD39 and CD73 co-localise on FOXP3+ Treg
[96], though there is some debate about co-expression on human Treg [101-103,
434]. The data here indicate that CD39 and CD73 do co-localise in whole PBMC,
however very little CD73 is detected on CD4 cells, despite clear expression of CD39
suggesting that perhaps CD39 and CD73 do not co-localise on human Treg (Figure
4.6. B).
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Figure 4.6. CD39+ Treg are increased in RA patients treated with adalimumab
A. PBMC from healthy controls, patients with active RA and patients treated with
adalimumab or etanercept (n=6-8) were stained with CD4, CD39 and FOXP3. Graph
shows percentage FOXP3+ CD39+ cells. Bars represent the mean±SE. Representative
FACS plots shown. B. FACS plots showing co-staining of CD39 and CD73 from a
healthy individual. The panel on the left is whole PBMC and the panel on the right is
gated on CD4 T cells.
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4.7 CD39 is not required for the suppression of IL-17 by Treg from
adalimumab treated RA patients
A second recent paper showed that blockade of CD39 using an anti-CD39 (αCD39)
antibody impaired the suppressive function of in vivo induced Treg [435]. Using the
same blocking antibody, we were able to demonstrate by FACS that it bound
effectively to CD39 at 2µg/ml (Figure 4.7 A). In conjunction with a collaborator, Dr.
Halima Moncrieffe who had previously published data investigating the function of
CD39 [101], we were able to show that the antibody effectively impaired CD39
activity. In this assay, PBMC were supplemented with luciferase conjugated ATP: as
the ATP was broken down the amount of light emitted was reduced. In healthy
controls, patients with active RA and patients treated with adalimumab, incubation
with the blocking antibody resulted in a reduced breakdown of ATP compared to the
cells incubated with medium alone. RA PBMC incubated with medium used a
substantial amount of ATP in the duration of the assay and so showed the greatest
difference when treated with the blocking antibody, thus confirming the
effectiveness of the αCD39 antibody as a suppressor of high endonucleotidase
activity (Figure 4.7 B).
Finally, we used the αCD39 blocking antibody to determine if CD39 was required
for the suppression of IL-17. We incubated AdTreg with either the antibody or with
medium for 30 minutes before washing thoroughly and adding to responder T cells
and monocytes, as previously described. Under these conditions the ability of Treg to
suppress IL-17 was unaffected (Figure 4.7 C). As CD39 is also expressed on other
cells, monocytes or responder T cells were treated with αCD39. The data suggest
that incubating responder T cells with αCD39 before culturing with untreated
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monocytes drove them to produce more IL-17 than a culture of responder T cells and
monocytes alone. Similarly, blocking CD39 on monocytes before culturing with
untreated responder T cells drove the responder T cell to make up to twice as much
IL-17 as a culture of untreated responder T cells and monocytes (Figure 4.7 D),
perhaps suggesting that CD39 has a Treg-independent role in the regulation of IL-17
production. However, to discount an effect of the anti-CD39 antibody interacting
with monocytes via their Fc receptor expression it would be vital to use an isotype
control in any future experiments.
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Figure 4.7. CD39 does not play a role in the suppression of IL-17 by Treg from
adalimumab treated patients
A. Whole PBMC from healthy controls were treated for 30 minutes with media (left
panel) or 2µg/ml of anti-CD39 (right panel) and then stained for expression of CD4
and CD39. B PBMC from healthy controls, patients with active RA and patients
treated with humira (the commercial name of adalimumab) (n=2) were treated with
medium (white bars) or 2µg/ml of anti-CD39 (black bars) and supplemented with an
ATP-luciferase construct. After 30 minutes the level of ATP in the well was
measured as light emitted. C. Treg from adalimumab treated patients were incubated
with or without the anti-CD39 antibody for 30 minutes before culturing with
autologous responder T cells and monocytes for 5 days. Bars represent mean
suppression of IL-17±SE. (n=5) D. FACS plots of adalimumab treated patients
showing IL-17 production from T cells after 5 days. The left panel shows IL-17
production from a culture of Tresponders and monocytes, the middle panel shows
IL-17 production when Tresponders were treated with anti-CD39 (39Tresp), before
culture with autologous monocytes and the right panel shows IL-17 production from
Tresponders cultured with monocytes that had been pre-treated with anti-CD39
(39monocyte). FACS plots are representative of 4 experiments.
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4.8 Treg pSTAT3 levels in response to TCR stimulation
A paper demonstrating that murine Treg could control Th17 responses in a STAT3
dependent manner [436] led us to investigate whether this signalling molecule was
associated with the suppression of IL-17 by AdTreg. Initially, it was investigated if
activation of Treg with anti-CD3 and anti-CD28 (αCD3/28) resulted in an increased
phosphorylation of STAT3 in adalimumab treated patients compared to patients with
active RA or those responding to etanercept. STAT3 phosphorylation was examined
using flow cytometry in order to reduce the number of cells required for analysis, but
also to remove the need to isolate cell subsets. However, the phosflow antibodies are
designed to work in specific buffers, and in particular the STAT antibodies require a
buffer with a very high percentage of methanol. This means that any additional
surface or intracellular staining that is required must be carefully optimised. We
established the optimal conditions to stain CD4 and FOXP3 (Figure 4.8 A), though
the quality of FOXP3 staining was clearly impaired by the phosflow buffers. We
stimulated PBMC with either a positive control, IL-6, or αCD3/28 then measured
pSTAT3 at 15 minutes and 1 hour. 15 minutes is the recommended time required for
IL-6 stimulation to phosphorylate STAT3, thus as expected, levels of pSTAT3
increased after 15 minutes stimulation with IL-6. Fifteen minutes stimulation with
anti-CD3 and anti-CD28 was not sufficient to activate the STAT3 pathway. After 1
hour of incubation with IL-6 pSTAT3 levels were still elevated compared to
unstimulated. Moreover, 1 hour of anti-CD3 and anti-CD28 stimulation was
sufficient to phosphorylate STAT3 in both responder T cells and Treg (Figure 4.8 B).
We proceeded to examine STAT3 phosphorylation at 1 hour with anti-CD3 and anti-
CD28. Baseline pSTAT3 levels from unstimulated FOXP3+ and FOXP3- cells were
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similar amongst all patient groups but perhaps slightly elevated in healthy controls
(Figure 4.8 C/D). After stimulation, the fold induction of pSTAT3 in FOXP3+ and
FOXP3- cells was calculated. In the FOXP3– population there was a slight increase in
pSTAT3 induction in patients with active RA compared to healthy controls or
patients treated with adalimumab. Due to a large standard error it is difficult to
interpret the data from etanercept treated patients. In FOXP3+ cells there was a trend
showing an increased induction of pSTAT3 in AdTreg compared to RATreg
(p=0.09); there also appeared to be a greater induction of pSTAT3 in AdTreg than in
HTreg or EtTreg (Figure 4.8 C/D).
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Figure 4.8. Ex vivo STAT3 signalling in T cells from patients with active RA
A. Ex vivo PBMC from a healthy control were stained for CD4 (upper panel) and
FOXP3 (lower panel) using BD phosflow buffers. FACS plots are representative of
the quality of staining achieved. B. Histograms showing pSTAT3. PBMC from an
adalimumab treated patient were left unstimulated or treated with αCD3/28 or IL-6
at different time points. The solid grey histograms are unstimulated cells and the
outlines are cells that have been stimulated. C. pSTAT3 in FOXP3- cells. The mean
fluorescence intensity (MFI) of pSTAT3 was determined in unstimulated cells
(upper), this was compared to the MFI of cells stimulated for 1 hour with αCD3/28
and the fold induction of pSTAT3 was calculated (lower). Healthy n=2, active n=7,
adalimumab n=10, etanercept n=5.Bars represent the mean±SE D. pSTAT3 in
FOXP3+ cells. As in ‘C’ The MFI of pSTAT3 was determined in unstimulated cells
(upper) or fold induction of pSTAT3 upon stimulation of αCD3/28 for was
calculated (lower). ‘n’ numbers as in ‘C’. Bars represent the mean±SE.
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In the previous experiments, I had been using the STAT3 phospho-serine antibody
for determining the phosphorylation state of STAT3 because it had been available in
the lab. However, a review of the literature showed that maximal activation of
STAT3 requires both tyrosine and serine phosphorylation [437]. Optimisation of
these phosflow antibodies showed that they are both activated by IL-6 but the
difference from unstimulated was most pronounced with the pTyr705 antibody
(Figure 4.9 A). Thus, future experiments utilised pTyr705 phosphorylation as a read
out of STAT3 phosphorylation.
In order to validate data shown in Figure 4.8 and to overcome the problems with
staining FOXP3 in phosflow buffers, we sorted populations of CD4+CD25+CD127-
Treg and CD4+CD25+/-CD127- responder T cells and performed the same
experiment, using IL-6 stimulation as a positive control. Due to low ‘n’ numbers
there was substantial variation, but IL-6 stimulation induced pSTAT3 relatively
equally in RATreg and AdTreg. There is however, a suggestion that the stimulation
of responder T cells with IL-6 induced less phosphorylation of STAT3 in
adalimumab treated patients than in patients with active RA (Figure 4.9 B). When
stimulated with αCD3/28, responder T cells from patients with active RA had a
greater increase in pSTAT3 than responder T cells from patients treated with
adalimumab. In contrast, when Treg were stimulated with the αCD3/28 there was a
greater induction of pSTAT3 in the AdTreg than RATreg (Figure 4.9 B). Whilst
there was a lot of variation and the ‘n’ numbers were low, these data matched the
data gathered ex vivo, indicating that pSTAT3 may have some role in the function of
AdTreg. Moreover, the similarity between these and the ex vivo data suggests that
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both pSer727 and pTyr705 antibodies are sufficiently sensitive to detect differences
in STAT3 phosphorylation between patient groups.
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Figure 4.9. STAT3 signalling in isolated populations of responder T cells and
Treg
A. Isolated CD4+CD25-CD127+ cells (Tresp) from a patient with active RA were
unstimulated or stimulated with IL-6 for 1 hour and then stained for flow cytometry
with anti-pSer727 (left panel) or anti-pTyr705 antibodies (right panel). The solid
grey histograms are unstimulated cells and the outlines are cells that have been
stimulated with IL-6. B. Tresp and CD4+CD25+CD127- cells (Treg) were isolated
from PBMC. Cells were unstimulated or stimulated with IL-6 or anti-CD3 and anti-
CD28 for 1 hour. Histograms depict 1 patient with active RA (solid red are
unstimulated and the blue outlines are stimulated cells) and 1 RA patient treated with
adalimumab (solid green are unstimulated and the orange outlines are stimulated
cells). Graphs show the cumulative fold induction of pSTAT3 (n=2). Bars represent
the mean fold induction of pSTAT3 ±SE.
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4.9 Treating cells with a pSTAT3 inhibitor
Next, we purchased an inhibitor specific for STAT3, but not STAT5, an important
STAT in Treg differentiation [57]. Using IL-6 to provide a stimulus, we were able to
show that the inhibitor abolished induction of pSTAT3 in both responder T cells and
Treg (Figure 4.10 A). We then set up an assay to determine if the inhibitor could
suppress the function of pSTAT3. Isolated responder T cells were cultured overnight
with the inhibitor (iTresp) before adding them to monocytes. After 5 days, cells were
re-stimulated and IL-17 production by responder T cells was examined. In
comparison to responder T cells and monocytes without inhibitor, it appeared that
when iTresp were added to monocytes for 5 days there were fewer cells at the end of
culture (Figure 4.10 B). Moreover, when we examined the T cells by FACS, iTresp
did not produce IL-17, as might be expected, but they also failed to produce IFNγ.
This suggested that the activity of the inhibitor or the DMSO in which it was
resuspended was killing the cells. As a result, it was decided to titrate the antibody so
as to use the lowest possible inhibitory concentration in future experiments. This
experiment had only an ‘n’ of one, but it seemed as though all concentrations of the
inhibitor tested reduced the level of phosphorylation to that of unstimulated cells or
lower (Figure 4.10 D). That the level of phosphorylation dropped below that of the
unstimulated in some conditions may suggest that there is some background
phosphorylation of STAT3 in unstimulated cells. In future experiments an inhibitor
concentration of 0.039µM should be sufficient to inhibit STAT3 phosphorylation
however, this could be titrated further and the viability of responder T cells and Treg
after culture needs to be tested. Once the inhibitor is optimised, inhibitor treated Treg
can be added to cultures of responder T cells and monocytes to determine the role of
STAT3 in the suppression of IL-17.
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Figure 4.10. Inhibition of pSTAT3
A. Responder T cells (Tresp) and Treg from adalimumab treated patients were
stimulated with IL-6 for 15 minutes in the presence or absence of 5µM of pSTAT3
inhibitor (n=1). B. Live cell gate after 5 days culture of isolated Tresp and CD14+
monocytes. Tresp were untreated (left panel) or treated overnight with the inhibitor
before addition to monocytes for 5 days (right panel). C. IL-17 and IFNγ production
from T cells after 5 days culture. FACS plots show cultures of Tresp and monocytes,
inhibitor treated Tresp (iTresp) and monocytes. D. Graph shows the fold induction of
pSTAT3 in cells treated with STAT3 inhibitor. Whole PBMC from an RA patient
treated with adalimumab were treated with 0.02% DMSO or with indicated
concentrations of inhibitor (diluted in 0.02% DMSO) for 45 minutes. Cells were then
supplemented with media (unstimulated) or stimulated with IL-6 for 15 minutes
before staining with anti-CD4 and anti-pTyr705 antibodies. The fold induction of
pTyr705 in CD4 cells stimulated with IL-6 was determined for each concentration of
inhibitor (n=1).
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4.10 Neutralisation of the p35 subunit of IL-35
It has been suggested that IL-35 production from Treg can control Th17 responses
[91], though very little is known about the role of IL-35 in human Treg. A recent
paper described the use of a neutralising antibody targeted at the p35 chain of IL-35
which specifically inhibited IL-35, but not other members of the IL-12 family,
including IL-12, IL-27 and IL-23 [438]. We used the same antibody to elucidate a
possible role for IL-35 in the ability of AdTreg to suppress IL-17. Low ‘n’ numbers
resulted in large variability so there were no significant differences and the
experiment would need to be repeated generate sufficient power from which to make
conclusions (Figure 4.11).
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Figure 4.11. Blocking IL-35 p35 subunit
Treg, responder T cells and monocytes from adalimumab treated patients were
cultured for 5 days in the presence or absence of anti-p35 antibody (n=3). Bars
represent the mean suppression of IL-17 ±SE.
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4.11  Suppression of IL-17 by adalimumab Treg is mediated through the
suppression of IL-6
We had originally supplemented the co-culture assay with monocytes because
monocyte-derived cytokines such as IL-6, IL-1β  and IL-23 [194, 439, 440] are
known to be important drivers of Th17 cells. Having investigated a direct pathway of
Treg suppression of IL-17, we considered the possibility that AdTreg may be
suppressing Th17 cells in an indirect manner, via the suppression of monocytes.
Thus, the production of IL-23 was measured in cultures containing monocytes and
stimulated responder T cells from adalimumab treated patients with or without Treg.
Very little IL-23 was detected, but it was clear that addition of Treg to responder T
cells and monocytes did not reduce IL-23 production (Figure 4.12 A). IL-6 and IL-
1β are both known to be early inflammatory mediators, however IL-1β production
from all of the patient groups studied was very low (Figure 4.12 B) and neither
AdTreg nor EtTreg showed a capacity to suppress it (p=0.1) (Figure 4.12 C).
Interestingly, levels of IL-6 were the highest in cultures of responder T cells and
monocytes from patients with active RA and those treated with adalimumab and
lower in etanercept treated patients (Figure 4.12 B). Nevertheless, IL-6 production
was reduced upon the addition of autologous Treg to adalimumab T responders and
monocytes. This was not observed in patients with active RA or those treated with
etanercept, but rather, IL-6 increased following addition of these Treg, paralleling
their ability to increase rather than suppress IL-17 production (Figure 4.12 D).
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Figure 4.12. Treg from patients treated with adalimumab suppress IL-6, but not
IL-23 or IL-1β
A. Responder T cells and monocytes from adalimumab treated patients were cultured
with and without Treg. After 5 days supernatants were assayed for IL-23 by ELISA
(n=6). Bars represent mean IL-23 ±SE. B. Supernatants from cultures of responder T
cells and monocytes from healthy controls and the different patient groups were
assayed for IL-1β and IL-6 by CBA (n=5-10). C. Suppression assays were
performed with samples from adalimumab and etanercept treated patients and IL-1β
concentration was determined by CBA. Suppression was calculated as described in
the methods (adalimumab n=8, etanercept n=5). Bars represent the mean
suppression of IL-1β ±SE. D. IL-6 concentration from supernatants of suppression
assays was determined by CBA and suppression of IL-6 was calculated (active n=4,
adalimumab n=8, etanercept n=5). Bars represent the mean suppression of IL-6 ±SE.
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In order to confirm a link between IL-6 and the suppression of IL-17 in these assays,
an IL-6 neutralising antibody was added to cultures of adalimumab monocytes and
responder T cells. This reduced production of IL-17 from responder T cells, imitating
the effects of adding AdTreg to the culture (Figure 4.13 A). As a control, an IL-
1β  neutralising antibody was also used in these assays. Surprisingly, the effect of
blocking IL-1β was identical to blocking IL-6 (Figure 4.13 A). Analysis of the
culture supernatants showed that IL-6 production was abolished by anti−IL-6 but
was also dramatically reduced by anti-IL-1β (Figure 4.13 B). In contrast, whilst
anti−IL-1β blocked IL-1β production and this was not altered by the combined
blockade of IL-1β and IL-6, the blockade of IL-6 alone had no impact on the
production of IL-1β (Figure 4.13 C). This suggests that IL-6 is the key mediator of
IL-17 production by T cells in RA patients treated with adalimumab. Indeed, the
suppression of IL-17 by AdTreg was reversed by the addition of 20ng/ml
recombinant human IL-6 to cultures of responder T cells, monocytes and Treg from
adalimumab treated patients (Figure 4.13 D).
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Figure 4.13. IL-17 suppression by AdTreg is reversed by the addition of IL-6
A. IL-17 production from T cells after culture for 5 days. Responder T cells and
monocytes were cultured with an isotype control antibody (left panel), an anti-IL-6
antibody (middle panel) or an anti-IL-1β antibody (right panel). FACS plots are
representative of 4 independent experiments. B. IL-6 production from responder T
cells and monocytes as determined by CBA after 5 days of culture with an isotype
control antibody (-), an anti-IL-6 neutralising antibody or an anti-IL-1β neutralising
antibody as indicated (n=4) C. IL-1β production from responder T cells and
monocytes as determined by CBA after 5 days of culture with an isotype control
antibody (-), an anti-IL-1β neutralising antibody or an anti-IL-6 neutralising antibody
as indicated (n=4) D. Suppression of IL-17 by AdTreg cultured in the presence (+)
or absence (-) of IL-6 (20ng/ml) (n=4).
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4.12 The suppression of IL-17 and IL-6 by AdTreg does not require cell-cell
contact
Data from other groups has suggested that Treg suppression of monocytes is at least
partly contact dependent [441]. In order to determine if the ability of AdTreg to
suppress monocyte-driven IL-17 was contact dependent, the co-culture experiments
described above were repeated in a transwell plate. AdTreg were cultured in contact
with responder T cells and monocytes in the lower chamber of a transwell plate, or
plated in the upper chamber where they were separated from responder T cells and
monocytes by a permeable membrane. Suppression of IL-17 was unaffected when
contact was prevented between AdTreg and their autologous responder T cells and
monocytes (Figure 4.14 A). This was confirmed by CBA analysis of culture
supernatants (Figure 4.14 B). Furthermore, separation of Treg from responder T cells
and monocytes did not impair IL-6 suppression (Figure 4.14 C). Thus, the capacity
of AdTreg to suppress Th17 responses is mediated by a soluble factor.
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Figure 4.14. Suppression of IL-17 is not contact dependent
A. Treg from patients responding to adalimumab were cultured in a transwell plate
either in contact with autologous monocytes (contact) and responder T cells, or
separated by a permeable membrane (separated). Bars represent suppression of IL-17
±SE as measured by FACS (n=5). Representative FACS plots are shown. B.
Supernatants from A were assayed for IL-17 by CBA. The left-hand graph shows
absolute levels of IL-17 ±SE. The right-hand graph shows the calculated suppression
of IL-17 ±SE. C. Supernatants from A were assayed for IL-6 by CBA. The left-hand
graph shows absolute levels of IL-6 ±SE. The right-hand graph shows the calculated
suppression of IL-6 ±SE. (n.s.) - not significant.
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Summary:
As previously published, this chapter has shown that RATreg are defective in their
ability to suppress IFNγ. Suppression of this cytokine is restored to healthy levels in
patients responding to adalimumab, but not patients responding to etanercept.
Depletion of Treg from whole PBMC showed that neither HTreg nor RATreg
demonstrated the capacity to regulate IL-17 production. In contrast, AdTreg could
regulate IL-17 production from whole PBMC but his was not seen in patients
responding to etanercept. Co-culture experiments showed that the presence of
monocytes could drive IL-17 production from T cells and suppression assays where
Treg were added to cultures of responder T cells and monocytes confirmed that
AdTreg, but not HTreg, RATreg or EtTreg, could suppress IL-17. In contrast to the
suppression of IFNγ, suppression of IL-17 by AdTreg was not mediated via IL-10
and TGFβ.
Further investigations showed that the activity of CD39 on AdTreg was not
responsible for the capacity of these cells to suppress IL-17. Examination of pSTAT3
expression in FOXP3+ cells showed that AdTreg express elevated levels of pSTAT3
upon TCR stimulation and this may implicate STAT3 in the capacity of these cells to
suppress IL-17. Finally, it was shown that AdTreg regulate Th17 cells via the
modulation of monocyte-derived IL-6 in a contact independent manner.
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Chapter 5 
Immunological changes in rheumatoid arthritis patients treated with
tocilizumab
Objectives:
1. Utilise flow cytometry to determine the levels of regulatory T cells and Th17
cells in RA patients before and after tocilizumab therapy.
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5.1 Treg and Th17 cell levels are unchanged in patients treated with
tocilizumab
The data in the previous chapter highlighted the importance of IL-6 in IL-17
mediated inflammation. Thus, I proceeded to study a small cohort of RA patients due
to commence a novel anti-IL-6 receptor therapy, tocilizumab. These patients all had
active RA and had failed conventional DMARD therapy as well as anti-TNF and, in
some cases, rituximab. The data presented in this chapter comes from a cohort of 8
patients. A substantial portion of the data is cross-sectional, though for some aspects
of the study I had access to PBMC from the same patients before and after therapy.
Peripheral blood samples were collected from patients immediately prior to their first
infusion and at 6 weeks post therapy, prior to their second infusion. There was a lot
of variation between patients studied, although - when compared to healthy controls
– there was a trend for the percentage of FOXP3+ cells to be much higher in patients
before therapy with tocilizumab (p=0.09). Furthermore, the patients studied appeared
to divide into 2 groups. Further investigation revealed that those patients with the
highest levels of FOXP3 expression were rheumatoid factor (RF) negative whilst the
patients with lowest expression of FOXP3 were RF positive. This may be indicative
of different therapeutic histories, as RF positive patients are more likely to have
previously been treated with the B cell depleting agent, rituximab. Irrespective of RF
positivity, tocilizumab therapy had no effect on peripheral Treg numbers in the
patients studied (Figure 5.1 A).
When RORC+ Th17 cells were examined, compared to healthy controls percentage
Th17 cells were elevated in RA patients before tocilizumab therapy (p=0.009).
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However, after therapy the levels of RORC+ cells were unchanged. Next, the
population of Treg that also express RORC were examined: to explore whether this
was altered after therapy with tocilizumab. Whilst levels of these double positive
cells were relatively low overall, RA patients before tocilizumab therapy had raised
levels compared to healthy controls (p=0.04). After therapy, levels of these cells
were variable but there was no significant difference from patients before therapy
(p=0.34)(Figure 5.1 C).
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Figure 5.1. Treg and Th17 cells in RA patients treated with tocilizumab.
Ex vivo PBMC from patients before (pre) and after (post) therapy with tocilizumab
were stained for flow cytometry with CD4, FOXP3 and RORC. A. Percentage
CD4+FOXP3+cells.  B. Percentage RORC+ CD4 T cells C. Percentage
FOXP3+RORC+ CD4 T cells. For all graphs points show individual donors and bars
show mean percentage.
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5.2 CD4+ T cells after tocilizumab therapy
In addition to examining the Th17/Treg balance in these patients, other features of T
cells that might be altered by the neutralisation of IL-6 signalling were examined.
The percentage of CD4+ T cells was the same in patients before and after therapy
(Figure 5.2 A). This was mirrored by data showing that T cell proliferation ex vivo
was similar before and after therapy, as determined by Ki67 staining (Figure 5.2 B).
Figure 5.2. CD4 T cell proliferation after tocilizumab therapy.
A. Percentage CD4 T cells from patients before (pre) and after (post) therapy with
tocilizumab. B. Percentage Ki67+ CD4 T cells before (pre) and after (post) therapy.
Points show individual donors and bars show mean percentage.
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Samples from the same patient before and after therapy were used to determine the
effects of tocilizumab on T cell cytokine production. Levels of TNF were variable
between individuals and were differentially affected by tocilizumab, making it
difficult to determine the effect of neutralising IL-6 on TNF production (Figure
5.3A). Surprisingly, in 2 of 3 matched pairs, the neutralisation of IL-6 receptor
appeared to drive the production of IL-17, though this increase was not significant
(p=0.71) (Figure 5.3 B). Similarly, the changes in IL-10 production after therapy
were not consistent, with 2 patients showing very small changes and a third patient
showing a large increase in IL-10 (Figure 5.3 C). Thus, despite being matched pairs
there is too much variability in individual response to therapy to make conclusions
about the effect of IL-6 blockade on cytokine production by T cells.
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Figure 5.3. T cell cytokine production after tocilizumab therapy.
PBMC from matched patients before (pre) and after (post) therapy were thawed and
stained for CD4 before stimulation with PMA for 4 hours. A. Percentage TNF+ T
cells. B. Percentage of IL-17+ T cells. C. Percentage IL-10+ T cells. Representative
FACS plots show a matched patient sample ‘pre’ and ‘post’ therapy. On all graphs
connected dots represent the same patient before and after therapy.
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5.3 Changes in B cells after tocilizumab therapy
As IL-6 is an important B cell growth factor, the B cell population was examined for
changes after tocilizumab therapy. There was a trend for an increased percentage of
CD19 B cells overall (p=0.09) (Figure 5.4 A). This was not explained by an
increased proliferation of B cells as the percentage of Ki67+ B cells was unaffected
after therapy (p=0.36) (Figure 5.4 B). Levels of immature B cells, which have been
described as regulatory, appeared to fall slightly after therapy, though this was not
significant (p=0.36) (Figure 5.4 C). Similarly, there were no differences in
proliferation of immature B cells (Figure 5.4 D). Production of both pro-
inflammatory (TNF) (Figure 5.4 E) and anti-inflammatory (IL-10) (Figure 5.4 F)
cytokines by B cells was variable and there were no consistent changes after therapy.
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Figure 5.4. Changes in B cell populations after tocilizumab therapy.
A. Percentage CD19+ cells from patients before (pre) and after (post) therapy with
tocilizumab. Points show individual donors and bars show mean percentage. B.
Percentage Ki67+ B cells from patients before and after therapy with tocilizumab was
determined. C. Percentage immature B cells (CD19+CD24hiCD38hi) from patients
before and after therapy with tocilizumab. D. Percentage Ki67+ immature B cells
from patients before and after therapy with tocilizumab. E. Percentage TNFα+
CD19+ B cells from 3 matched patients. Connected dots represent the same patient
before and after therapy. F. Percentage IL-10+ CD19+ B cells from 3 matched
patients.
Chapter 5
197
5.4 A reduction in memory B cells and IL-21 production after therapy with
tocilizumab
It has been reported that tocilizumab therapy resulted in a fall in the percentage of
memory B cells [384]. When the levels of CD27+IgD- memory B cells were
investigated in patients treated with tocilizumab, there was a decrease in this
population after therapy in 3 patients (Figure 5.5 A). Furthermore, a drop in the
percentage of antibody producing plasma cells was observed after tocilizumab
therapy (Figure 5.5 A). Interestingly, this drop in the percentage of memory and
plasma B cells was matched by a fall in IL-21 production by T cells in these patients
(Figure 5.5 B). Indeed, IL-21 has been shown to be critical for the development of
memory B cells [442] so these two observations may be linked. However, this
requires further study of sufficient power to determine if these differences represent a
consistent outcome of therapy.
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Figure 5.5. Memory B cell population, plasma cells and IL-21 production by T
cells is reduced after tocilizumab.
A. Whole PBMC were stained ex-vivo for B cell markers. FACS plots show staining
of CD27 and IgD on the CD19+ B cell population in a matched patient sample ‘pre’
and ‘post’ therapy. Plasma cells are identified at IgD-CD27hi and post-switched
memory cells are identified as IgD-CD27+Representative of 3 matched pairs. B.
FACS plots show Percentage IL-21+ CD4 T cells in a matched patient sample ‘pre’
and ‘post’ therapy. Representative of 2 matched pairs.
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5.5  Changes in STAT3 signalling after tocilizumab therapy
Finally the phosphorylation of STAT3 was examined, a key downstream factor in
IL-6 signalling. There were no consistent differences in the baseline level of
pSTAT3 in patients before or after tocilizumab therapy (Figure 5.6 A). In contrast,
upon stimulation with IL-6 all patients showed an increase in pSTAT3. However, in
patients treated with tocilizumab, the level of pSTAT3 induced was much lower than
untreated patients (Figure 5.6B). Due to the variability in the baseline levels of
pSTAT3, this reduction in pSTAT3 upon stimulation was not reflected when fold
induction of pSTAT3 was calculated (Figure 5.6 C).
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Figure 5.6. STAT3 signalling in patients treated with tocilizumab.
Ex vivo PBMC from patients before (pre) and after (post) therapy with tocilizumab
were left unstimulated or stimulated with IL-6 for 15 minutes before staining with
CD4 and pSTAT3 antibodies for flow cytometry A. The mean fluorescence intensity
(MFI) of pSTAT3 was determined in unstimulated cells and cells stimulated with IL-
6, B. Fold induction of pSTAT3 by IL-6 was calculated. Connected dots represent
the same patient before and after therapy.
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Summary:
Compared to patients who had yet to commence tocilizumab treatment, 6 weeks after
therapy there were no differences in the percentage of Th17 cells ex vivo. Additional
investigation saw no differences in Treg levels or production of IL-10 and TNF from
CD4+ T cells or CD19+ B cells. In contrast, a fall in plasma B cells was associated
with a reduction in IL-21 production from T cells after therapy with tocilizumab.
pSTAT3 expression in response to IL-6 stimulation was lower in patients after
therapy with anti-IL-6 receptor, though when the fold induction of pSTAT3 was
calculated the differences before and after therapy failed to reach significance.
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Chapter 6 
Immunological changes in psoriatic arthritis patients treated with
anti-TNF
Objectives:
1. Determine the percentage of Treg in patients with active PsA and compare to
patients with PsA responding to adalimumab or etanercept.
2. Utilise a Treg depletion approach to explore the capacity of Treg from active
PsA patients and anti-TNF treated PsA patients to suppress IL-17 and IL-22.
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6.1 The effects of adalimumab treatment on regulatory T cell numbers is
specific to patients with RA
To investigate if the increase in Treg in the peripheral blood of RA patients treated
with adalimumab is disease specific, the percentage of Treg from patients with active
psoriatic arthritis (PsA) and PsA patients treated with anti-TNF was determined.
There was no difference in the percentage of Treg between healthy controls, patients
with active PsA and patients treated with anti-TNF, suggesting that the increase in
Treg following adalimumab therapy is specific for RA (Figure 6.1A).
6.2 Th17 cells are reduced in PsA patients treated with anti-TNF
In accordance with published data showing that Th17 cells are increased in the
periphery of PsA patients [443], RORC+ CD4 cells were also significantly increased
in patients with active PsA compared to healthy controls (p=0.009). There was a
trend towards a reduction in RORC+ cells in adalimumab treated patients (p=0.08)
but whilst the percentage of RORC+ cells in etanercept treated patients also appeared
to fall this failed to reach significance (p=0.28) (Figure 6.1 B). In contrast, upon
examination of IL-17 production by these cells there was a trend towards a fall in IL-
17+ T cells after treatment with etanercept (p=0.07) but not adalimumab (p=0.2)
(Figure 6.1 C). Increasing the ‘n’ number of these studies should provide sufficient
power to confirm a drop in Th17 cells in PsA patients treated with anti-TNF. The ex
vivo production of IFNγ  was similar in healthy controls, patients with active PsA
and patients treated with adalimumab. In contrast, there was a trend for production of
IFNγ to be reduced in patients treated with etanercept (p=0.08) (Figure 6.1 D).
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Figure 6.1. CD4 T cells in psoriatic arthritis.
A. Percentage CD4+FOXP3+ in PBMC from healthy controls, patients with
active PsA and PsA patients responding to adalimumab or etanercept (n=8). Bars
represent the mean±SE. B. PBMC from healthy controls (n=9), patients with active
PsA (n=12) and PsA patients responding to adalimumab or etanercept (n=5) were
stained ex vivo for CD4 and RORC. Bars indicate mean percentage CD4+RORC+
cells ±SE. C. Ex vivo PBMC from healthy controls (n=6), patients with active PsA
(n=12) and patients treated with adalimumab or etanercept (n=5) were stimulated for
4 hours with PMA before staining with IL-17. Graphs show percentage IL-17+
lymphocytes. Bars represent mean ±SE D. Ex vivo PBMC were stimulated as in ‘C’
and stained for IFNγ. Graphs show percentage IFNγ+ lymphocytes. Healthy (n=6),
active (n=12), adalimumab and etanercept (n=3). Bars represent mean IFNγ
production ±SE.
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6.3 Proliferation and cell death in patients with PsA
We next examined proliferation and cell death in patients with PsA. There were no
differences in proliferation between healthy controls, patients with active PsA and
PsA patients treated with adalimumab or etanercept in either total CD4+ T cells
(Figure 6.2 A) or FOXP3+ T cells (Figure 6.2 B). When cell death was determined
there was no significant difference between healthy controls and patients with active
PsA however, there was a trend for etanercept treated PsA patients to have increased
levels of total cell death after therapy (Figure 6.2 C). Moreover, similar to their RA
counterparts, patients with active PsA have a significant reduction in monocyte cell
death compared to healthy controls (p=0.02)(Figure 6.2 D).
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Figure 6.2. Proliferation and cell death in psoriatic arthritis
(A-B). Ex vivo PBMC from healthy controls (n=7), patients with active PsA (n=12)
and PsA patients responding to adalimumab (n=3) or etanercept  (n=4) were stained
with CD4, FOXP3 and Ki67. A. Percentage Ki67+ CD4 cells. Bars represent the
mean±SE. An example FACS plot is shown. B. Percentage Ki67+ cells in the
CD4+FOXP3+ population. Bars represent the mean±SE. An example FACS plot is
shown. C. Ex vivo PBMC (healthy n=10, active n=5, etanercept n= 5) were stained
with Annexin V and 7AAD. A ‘live’ gate was not used for analysis. Graph shows
percentage Annexin V+7AAD+ cells. Bars represent the mean±SE. Representative
FACS plots are shown. D. Percentage Annexin+7AAD+ cells in the CD14+
population (healthy n=9, active n=5). A ‘live’ gate was not used for analysis. Bars
represent the mean±SE. Representative FACS plots are shown.
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6.4 Treg from PsA patients treated with anti-TNF are unable to suppress IL-
17 production from PBMC
Little is known about the functional characteristics of Treg in PsA, although
regulatory T cells from patients with psoriasis are known to be defective [444]. It is
known that IL-17 and IL-22 are heavily involved in the aetiology of psoriasis [445]
and that 70% of patients with PsA develop arthritis after the onset of skin disease
[446]. Therefore, utilising the depletion approach described in section 4.2, it was
investigated if Treg from PsA patients responding to anti-TNF therapy were capable
of suppressing IL-17. By ELISA there was an overall increase in IL-17 production in
patients with psoriatic arthritis compared to healthy controls, or anti-TNF treated
PsA patients, matching the Th17 data presented in figures 6.1 B and C (Figure 6.3.
B). However, both flow cytometric and ELISA data showed that, like healthy
controls, patients with active PsA and PsA patients treated with both anti-TNF
therapies showed no increase in IL-17 upon the depletion of Treg, suggesting an
inability to suppress this cytokine (Figure 6.3 A-B).
6.5 Suppression of IL-22 by Treg from patients with PsA
In order to determine the ability of Treg from patients with PsA to suppress IL-22,
Treg were depleted from whole PBMC as previously described. Cells from healthy
controls showed an increase in IL-22 production upon the depletion of Treg,
suggesting that healthy Treg can suppress IL-22. Surprisingly, in patients with active
PsA the production of IL-22 increased substantially following the depletion of Treg.
This suggests that PBMC from patients with active PsA have the potential to produce
large quantities of IL-22 but that this is readily suppressed by Treg from these
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patients. In PsA patients treated with adalimumab the data matched that of healthy
controls. In etanercept treated patients, there was no evidence of an increase in IL-22
following the depletion of Treg, suggesting that Treg from etanercept treated patients
are unable to suppress IL-22 (Figure 6.3 C).
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Figure 6.3. Modulation of IL-17 and IL-22 production by Treg in PsA patients
before and after anti-TNF therapy.
PBMC were separated into 2 fractions, one with whole PBMC and the other depleted
of CD4+CD25+CD127- Treg. Cells were cultured for 3 days with soluble anti-CD3
and anti-CD28. After 3 days cells were stimulated with PMA, Ionomycin and Golgi
Stop. A. Cells from healthy controls (n=4); patients with active PsA (n=3) and
patients responding to adalimumab (n=3) or etanercept (n=3) were stained with flow
cytometry antibodies for IL-17. Bars represent the mean percentage change in IL-17
production between PBMC and PBMC depleted of Treg (%IL-17 suppression). B.
Supernatants were assayed for IL-17 using ELISA. Bars represent the mean±SE. ‘n’
numbers as for part A C. Cells were stained with flow cytometry antibodies for IL-
22. Healthy n=2, PsA n=6, adalimumab n=4, etanercept n=4. Bars represent the
mean of percentage difference in IL-22 production between PBMC and PBMC
depleted of Treg. Representative FACS plots are shown.
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Summary:
Compared to healthy controls, there were no differences in the percentage of
circulating Treg in patients with active PsA or PsA patients responding to
adalimumab or etanercept. In contrast, there was a sharp increase in Th17 cells in
patients with active PsA compared to healthy controls and this was reduced in PsA
patients responding to both adalimumab and etanercept therapy. There were no
differences in ex vivo IFNγ production between healthy controls, patients with active
PsA and PsA patients responding to anti-TNF. There were also no differences in the
proliferation of CD4 T cells or Treg. Like RA patients, cell death was lower in
patients with active PsA and this reached significance when monocyte cell death was
determined.
Neither patients with active PsA nor patients responding to adalimumab or
etanercept demonstrated an ability to suppress IL-17 production from whole PBMC.
In contrast, Treg from patients with active PsA showed a clear capacity to restrain
IL-22 production. This suppression of IL-22 was not altered by therapy with
adalimumab but did appear to be impaired by therapy with etanercept.
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Chapter 7 
  Discussion
7.1 The distinctive properties of regulatory T cells from rheumatoid arthritis
patients treated with adalimumab
7.1.1 The suppression of Th17 responses
The major finding from this work is that Th17 cell responses can be suppressed by
Treg from RA patients responding to adalimumab (AdTreg) via the control of
monocyte-derived IL-6 production (Chapter 4). Suppression of IL-17 was not
apparent when Treg from healthy individuals were analysed (Figure 4.4) suggesting,
as previously published, that this cytokine can be resistant to the effects of Treg [37].
The potential of anti-TNF monoclonal antibody (mAb) therapy to regulate this
highly inflammatory pathway is reflected in the shift away from Th17 cells ex vivo in
RA patients treated with adalimumab (Figure 3.12). However, responder T cells from
adalimumab treated RA patients still maintain the capacity to produce high levels of
IL-17. In the absence of Treg, cultures of responder T cells from adalimumab treated
patients produce much more IL-17 than healthy controls or patients treated with
etanercept. This is dramatically reduced by the addition of AdTreg (Figure 4.4),
highlighting the potent modulation of Th17 responses by these cells.
Additionally, the data presented here show that in RA patients, the suppression of the
Th17 associated cytokine IL-22 [195, 232, 447] mirrors the suppression of IFNγ
rather than IL-17 (Figure 4.2). Indeed, the depletion of Treg from whole PBMC of
healthy individuals resulted in an increase in IL-22, suggesting that healthy Treg can
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effectively suppress this cytokine. However, in healthy controls levels of IL-22 were
very low (Figure 4.2). In patients with active RA, the removal of Treg resulted in
levels of IL-22 that were similar or reduced, suggesting that Treg from these patients
are not capable of suppressing IL-22. Like the capacity to suppress IFNγ,
suppression of IL-22 was restored in RA patients treated with adalimumab, but not
patients treated with etanercept. The differential regulation of IL-17 and IL-22 is
surprising considering that these cytokines are both known to be produced by Th17
cells. However, a distinct population of Th22 cells, producing IL-22 but not IL-17
has recently been described [448]. The production of these cytokines by different cell
subsets may explain how healthy Treg can suppress IL-22 but not IL-17 production.
7.1.2 An intrinsic suppression of IL-17 production
When Treg were added to cultures of responder T cells and monocytes from patients
with active RA and RA patients treated with etanercept the production of IL-17
increased (Figures 4.2 and 4.4), suggesting that Treg from these patients make IL-17.
Treg production of IL-17 has been well documented [217-219], as has the propensity
of Treg to convert to Th17 cells [219, 449, 450]. Indeed, work in this laboratory has
shown that under inflammatory conditions Treg display increased production of IL-
17. However, AdTreg made less IL-17 after 5 days than patients with active disease
(RATreg) or those treated with etanercept (EtTreg) [451]. Thus, Treg from
adalimumab treated RA patients are distinctive from Treg in healthy controls and
other RA patients in that they show both an intrinsic and an extrinsic suppression of
IL-17, which results in a clear reduction in overall IL-17 levels.
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7.1.3 Regulatory T cells from rheumatoid arthritis patients treated with
adalimumab share phenotypic similarities with induced regulatory T
cells
Previous data from this group showed that the chimeric anti-TNF mAb, infliximab,
induced a population of functional CD62L negative Treg in patients with RA [86]. In
this study it has been shown that adalimumab treated RA patients also have an
increase in CD62L negative Treg. Furthermore, these Treg express lower levels of
Helios, the marker of thymic Treg, compared to Treg from patients with active RA
(RATreg) (Figure 3.3). Thus, AdTreg bear distinctive hallmarks of induced Treg
(iTreg). It is interesting that the CD62L negative AdTreg and the Helios negative
AdTreg are not entirely overlapping populations, perhaps suggesting that double
negativity for these markers offers the best method for the ex vivo identification of
Treg induced by adalimumab therapy.
There is controversy however, surrounding Helios as a marker of thymic Treg
(discussed in the introduction section 1.1.3.3). Furthermore, a loss of CD62L
expression is not unique to iTreg but is associated with a memory T cell phenotype
[452]. So these markers do not prove that Treg have been induced by therapy.
However, the increase in Treg in RA patients treated with adalimumab is not
explained by proliferation of existing Treg, as levels of Ki67 are similar before and
after therapy (Figure 3.4). Moreover, these cells suppress IL-17 in contrast to
functional Treg from healthy controls (HTreg) and Treg from patients with active
RA (RATreg) (Figure 4.4). Thus, a population of Treg is present in RA patients
treated with adalimumab that is not present in any other patient group. This supports
previously published data demonstrating that anti-TNF mAb therapy in RA induces a
population of functionally and phenotypically distinct Treg [86]. It is tempting to
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speculate that the disease exacerbation that eventually occurs following cessation of
anti-TNF therapy may be delayed due to the presence of AdTreg.  Indeed, one of the
first studies to examine recurrence of disease activity once anti-TNF therapy was
stopped, found that those patients treated with infliximab, did not flare as rapidly as
those that received only methotrexate [453]. Thus, it would be interesting to discover
if patients treated with adalimumab and etanercept flare equally after cessation of
anti-TNF therapy.
7.2 How do regulatory T cells from adalimumab treated rheumatoid arthritis
patients suppress IL-17?
7.2.1 Monocyte suppression
It is interesting that the Treg induced by adalimumab therapy in RA control Th1 and
Th17 pathways through separate mechanisms. Treg are thought to use multiple
pathways to control target cells, but these data demonstrates for the first time that
independent modalities of suppression can be employed to regulate different human
effector T cell lineages. IL-10 and TGFβ were required for the suppression of Th1
responses (Figures 4.1 and 4.3). The requirement for IL-10 was highlighted by the
impairment of IFNγ suppression upon the blockade of IL-10 (Figure 4.5) and the
increased IL-10 production upon the addition of AdTreg to autologous responder T
cells (Figure 4.1). However, by flow cytometry, IL-10 production could not be
detected from Treg (Figure 3.8). Thus, these data do not exclude the possibility that
the IL-10 required for the suppression of IFNγ is made by responder T cells in
response to a signal from AdTreg. In contrast, the neutralisation of IL-10 and TGF-β
had no effect on the ability of AdTreg to suppress IL-17 (Figure 4.5). Rather, an IL-
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10 and TGF-β independent modulation of IL-6 appeared to be pivotal. The pattern of
IL-6 suppression by AdTreg exactly matched that of IL-17 (Figure 4.12) and the
neutralisation of IL-6 in cultures of responder T cells and monocytes from
adalimumab treated RA patients imitated the IL-17 suppressing abilities of AdTreg.
Moreover, addition of IL-6 reversed the ability of AdTreg to suppress Th17 cells
(Figure 4.13). The capacity of AdTreg to directly suppress monocyte IL-6 production
was confirmed by showing that monocytes from patients with active RA made less
IL-6 when cultured with AdTreg than with autologous RATreg or Treg from RA
patients treated with etanercept (EtTreg) .
Previous publications have shown that Treg suppression of monocytes is partly
contact dependent [441].  However, inhibition of IL-6 and IL-17 was not impaired
when Treg contact was prevented in a transwell system (Figure 4.14). Thus,
suppression of these responses must be mediated by a soluble factor secreted by
AdTreg. It is still unclear what this soluble factor might be; IL-35 production by
Treg (Figure 4.11) may offer an explanation, though more experiments are needed to
confirm a role. The blockade of IL-10 was shown to be unimportant for the
suppression of Th17 cells (Figure 4.5), however other Th2 cytokines such as IL-4 or
IL-13 could suppress the production of IL-17 by altering the balance of cytokines in
vivo. Indeed IL-4 can suppress disease in mice with collagen-induced arthritis (CIA)
[454]. Moreover, IL-4 and IL-13 have been detected in human Treg [441, 455, 456].
However, Sarkar et al. show that IL-4 does not directly modulate Th17 cells in CIA
and is more important for the suppression of Th1 cells. Thus perhaps in humans too,
Th2 cytokines predominantly modulate Th1 responses, explaining the inability of IL-
10 to suppress Th17 responses from RA patients treated with adalimumab.
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Recently it has been shown that during septic shock, human Treg can inhibit
monocyte survival through the production of a soluble factor that activates the
Fas/FasL pathway [457]. Not only does this offer an explanation for the AdTreg
capacity to suppress monocyte-derived IL-6 (Figure 4.12), but the ability of AdTreg
to trigger the apoptosis of monocytes offers an explanation as to why adalimumab
but not etanercept treated RA patients show an increase in monocyte cell death
(Figure 3.6). It has recently been published that in healthy individuals, responder T
cells and not Treg are responsible for Fas/FasL driven monocyte apoptosis. The
authors show that this mechanism of monocyte apoptosis is defective in patients with
RA [458]. AdTreg have been shown to be functionally distinct from HTreg, so it
would be interesting to investigate if the capacity of AdTreg to suppress IL-6 and IL-
17 is linked to the killing of monocytes in culture.
7.2.2 Activation of the phospho-STAT3 pathway
It is intriguing that suppression of IL-17 in RA patients treated with adalimumab is
mediated via the suppression of IL-6, more so when AdTreg show increased
activation of STAT3, a component the IL-6 signalling cascade, upon stimulation
compared to their counterparts that do not suppress IL-17 (Figures 4.8 and 4.9).
STAT3 is considered to be a marker of Th17 cell lineage but, in a decisive shift in
the accepted paradigm, STAT3 expression in murine Treg was shown to be essential
for the capacity of these cells to suppress IL-17 [436]. Moreover, it has been shown
that the ablation of STAT3 during the induction of Treg from murine responder T
cells prevented the acquisition of suppressive function [459]. This implicates
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STAT3, a signalling molecule known to drive Th17 cell differentiation, in the
suppression of IL-17 and the function of iTreg.
Interestingly, recent evidence suggests that Treg are generated and function in a
manner defined by their microenvironment. For example, IRF4, a Th2 associated
transcription factor can form complexes with FOXP3 in Treg to mediate suppression
of Th2 driven inflammation. In the absence IRF4 expression in Treg, there is an
unprovoked Th2 driven pathology [460]. Similarly, expression of T-bet in Treg
allows them to express CXCR3 to trigger accumulation at the site of an on-going
Th1 response [461]. Thus, it is tempting to speculate that the presence of large
quantities of IL-6 and IL-17 in RA patients during the adalimumab-driven induction
of Treg defines the phenotypic and functional properties of the cell that is induced.
That is a Treg that suppresses IL-6 and IL-17 responses in a STAT3-dependent
manner.
A recent study by Chaudhry et al. suggests that it is not IL-6 that activates STAT3 in
Treg, but rather, IL-10 via the high expression of IL-10R on Treg [462]. This IL-10-
dependent model of STAT3 mediated suppression is supported by some of the data
presented in this study. For example, Treg from adalimumab treated patients
stimulated with IL-6 do not show the same pattern of pSTAT3 induction as those
stimulated via the TCR (Figure 4.9). Furthermore, AdTreg may make IL-10, which
could act in an autocrine manner upon the cell to activate STAT3. However, in
contrast to the data presented by Chaudhry et al., IL-10 is not required for the
suppression of IL-17 by AdTreg (Figure 4.5). It is possible that the mechanism of
STAT3 activation differs in human and murine Treg. Indeed, a number of factors
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activate the STAT3 pathway and could be important for the capacity of AdTreg to
suppress Th17 responses. One such factor may be IL-35 which, like IL-6, signals to
target cells using the receptor molecule gp130. Although a recent study in mice has
shown that IL-35 activates STAT1 and STAT4 but not STAT3 [463].
The ideal experiment to determine a role for pSTAT3 in the function of AdTreg
would be to use a STAT3 inhibitor to effectively impair suppressive function and
then replicate this data with siRNA knockdown of STAT3 in AdTreg. In the absence
of this functional readout, the initial experiments examining the pSTAT3 expression
in TCR stimulated Treg (Figures 4.8 and 4.9) were designed simply to determine if
there were differences in pSTAT3 expression upon activation of Treg. In these
experiments IL-6 was routinely used as a positive control to drive the
phosphorylation of STAT3. Regardless of whether pSer727 or pTyr705 was used as
a marker of STAT3 phosphorylation, the MFI of IL-6 stimulated cells was higher
than unstimulated cells (Figure 4.9 A) or cells stimulated with anti-CD3 and anti-
CD28 (Figure 4.8 B and Figure 4.9B). Moreover, the shift in MFI seen upon
stimulation with IL-6 was reversed in the presence of a STAT3 inhibitor (Figure 4.10
A) and the fold induction of pSTAT3 was shown to be reduced in a concentration
dependent manner upon treatment with inhibitor (Figure 4.10 D). Whilst these
changes seem consistent, the MFI of both pTyr705 and pSer727 were low and the
fold change in pSTAT3 was small. In order to make this a more robust positive
control the assays could be supplemented with soluble IL-6 receptor in order to
amplify the signal via gp130.
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7.3 The role of interleukin-6 in Th17 cell differentiation: Insight from
tocilizumab treated rheumatoid arthritis patients
The importance of IL-6, but not IL-1, for the modulation of Th17 cells in patients
with RA was unexpected (Figure 4.12). Both cytokines have been shown to be
important for human Th17 cell differentiation [190, 195, 439, 464]. However, the
data in adalimumab treated RA patients shows that even in the presence of IL-1β, the
neutralisation of IL-6 reduces IL-17 production (Figure 4.13 B).
Thus it was predicted that RA patients treated with tocilizumab, the anti-IL-6
receptor antibody, would have a reduction in Th17 cells. Furthermore, due to the
reciprocal relationship between Treg and Th17 cells, it was hypothesised that these
patients would demonstrate an increase in Treg. Surprisingly, whilst the levels of
Treg were similar in healthy controls and RA patients examined before anti-TNF
therapy (Figure 3.1), the percentage of peripheral Treg was much higher in RA
patients before tocilizumab therapy than in healthy controls (Figure 5.1 A). This is
likely to be explained by the fact that patients commencing tocilizumab have been
treated with multiple DMARDS and biologic agents, including up to 3 different anti-
TNF therapies and perhaps also rituximab. Six weeks after the first infusion with
tocilizumab there were few differences in peripheral Treg and Th17 cells (Figure
5.1). However, there was a reduction in the production of the Th17 cell cytokine, IL-
21, by CD4 T cells of patients treated with tocilizumab (Figure 5.5 B). This may
suggest that there is some inhibition of the Th17 cell profile in patients treated with
tocilizumab. Indeed, differences in the balance of Treg and Th17 cells have recently
been observed 12 weeks after therapy [465], which suggests that there may be more
notable changes in these populations at a later time point.
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7.4 Tocilizumab therapy: Targeting B cells?
In contrast to the T cell data, the neutralisation of IL-6 signalling altered the B cell
populations in 3 patients after 6 weeks of therapy. The data presented here show a
reduction in the number of CD27+ IgD- memory B cells (Figure 5.5A), mirroring
data which has previously been published [384]. Furthermore, these patients also
demonstrated a reduction in the percentage of plasma cells (Figure 5.5A).
Interestingly, IL-21 is thought to be important for plasma cell differentiation [466].
Thus, the reduction in IL-21 production from CD4 T cells after tocilizumab therapy
(Figure 5.5 B) could offer an explanation for the reduction in this B cell subset. This
may suggest that tocilizumab therapy could be appropriate for patients with B cell
driven pathology and offers a benefit over rituximab in that it may target the primary
producers of pathogenic autoantibody.
7.5 Immunopathogenic features of psoriatic arthritis
There have been few studies investigating the immunopathogenesis of psoriatic
arthritis (PsA). Here it has been shown for the first time that compared to healthy
controls there is no alteration in peripheral Treg levels in patients with active PsA
(Figure 6.1 A). Moreover, the ability of Treg from patients with active PsA to
suppress IL-22 and IL-17 is similar to Treg from healthy controls (Figure 6.3),
suggesting that there may be no dysfunction in Treg from patients with PsA. This
may explain why the induction of Treg in PsA patients treated with anti-TNF is not a
feature of therapeutic response (Figure 6.1 A).
Unlike RA, the T cell repertoire in the synovium of PsA patients is skewed towards
CD8 rather than CD4 T cells [416]. Indeed, there are a number of features of PsA
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that distinguish disease from active RA and suggest a greater similarity to
spondyloarthropathies such as ankylosing spondylitis (AS). In particular the IL-23
pathway, perhaps through the control of Th17 cells, has been implicated in the
pathogenesis of AS [467] and also psoriasis [400]. The data presented here shows
that IL-17 production from whole PBMC (Figure 6.3 B), levels of RORC+ Th17 cells
(Figure 6.1 B) and levels of IL-17+ cells ex vivo (Figure 6.1 C) were much higher in
patients with active PsA than patients with active RA, thus suggesting a key role for
IL-17 as pro-inflammatory mediator in PsA. Interestingly, a drop in the levels of
Th17 cells was associated with response to both adalimumab and etanercept therapy
(Figure 6.1 C). Elucidating how etanercept can reduce Th17 levels in PsA but not
RA might provide further insight into the mechanism of action of etanercept therapy.
Due to the differences between PsA and RA, in addition to investigating CD4 T cells
in the pathogenesis of PsA, future work should examine CD8+ T cell cytokine
production or cytotoxic activity and whether these responses are adequately
controlled by Treg from patients with active PsA.
7.5.1 The role of IL-22 in the pathogenesis of psoriatic arthritis
In recent years, lymphocyte-derived IL-22 has been shown to be heavily involved in
inflammatory skin disorders including psoriasis [468-470] and PsA [410]. So it was
hypothesised that the amelioration of disease seen in psoriatic arthritis patients
treated with anti-TNF may be due to the altered capacity of Treg from these patients
to suppress of IL-22. In contrast to patients with RA (Figure 4.2), Treg from active
PsA patients were shown to be potent suppressors of IL-22 as levels of IL-22 were
dramatically increased upon the depletion of Treg from cultures of whole PBMC.
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Similarly, Treg from healthy controls and PsA patients responding to adalimumab
could suppress IL-22. Thus, it was surprising that the depletion of Treg from the
PBMC of etanercept treated PsA patients did not affect the production of IL-22
(Figure 6.3 C). This suggests that Treg from PsA patients responding to etanercept
have ‘lost’ the capacity to suppress IL-22 and perhaps indicates that IL-22 is not pro-
inflammatory in these patients.
Under some conditions IL-22 has been shown to have anti-inflammatory and tissue
reparative properties [226, 291, 293, 294, 307-310].  However, IL-22 has been
shown to be pro-inflammatory in skin conditions [290, 296, 300, 471], including PsA
[410] and all evidence suggests that IL-22 is pro-inflammatory in RA [208, 302-
304]. Although, it has been suggested that the presence of IL-17 defines the pro-
versus anti-inflammatory effects of IL-22 [316]. Thus, perhaps the reduction in Th17
cells in PsA patients treated with etanercept favours the anti-inflammatory properties
of IL-22 and promotes the repair of tissue damaged by inflammation. How, or why,
anti-TNF therapy would impair Treg suppression is unclear and why this is seen in
etanercept treated PsA patients but not adalimumab treated PsA patients remains to
be elucidated. It may be that Treg from etanercept treated patients continue to
suppress CD4 T cell production of IL-22 but therapy triggers the production of IL-22
by another cell subset that is not so readily suppressed by Treg. Co-culture
experiments with different cell subsets would offer some clarification of the role of
IL-22 in PsA and the capacity of Treg to suppress its production.
Chapter 7
223
7.6 Anti-TNF therapy induces a different response in rheumatoid arthritis
and psoriatic arthritis
If adalimumab treatment ameliorates disease in RA, perhaps in part through the
induction of Treg, then one would predict that this anti-TNF agent would work in
another disease setting via the same mechanism. However, the data presented in this
study reveals that after treatment with anti-TNF, patients with PsA do not have an
increase in peripheral Treg (Figure 6.1 A) and Treg from PsA patients do not acquire
the ability to suppress IL-17 (Figure 6.3).
7.7 Potential models for the induction of regulatory T cells by anti-TNF
monoclonal antibody therapy in rheumatoid arthritis.
It is unclear why adalimumab did not induce Treg in patients with PsA when it has
been shown to do so in other disease settings. Likewise there is no clear explanation
as to why adalimumab induces Treg in patients with RA whilst etanercept treated RA
patients show no increase in Treg (Figure 3.1) and a continued Treg defect despite
responding to therapy (Figures 4.1, 4.3 and 4.4). In the following sections a number
of models for the adalimumab driven induction of Treg in patients with RA are
discussed and their validity is assessed based on the data presented in this study.
7.7.1 The neutralisation of TNF
Studies examining the effect of TNF on Treg have generally proposed a model
whereby TNF can signal to, and block, the suppressive capacity of Treg. Thus, upon
the neutralisation of TNF and in the absence of this signal, Treg function is restored
[130, 472]. Indeed, this effect of TNF on Treg was shown to be mediated via
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recruitment of PKC-θ to the immune synapse. In Treg treated with TNF, a reduction
in suppressive function was associated with recruitment of PKC-θ to the immune
synapse and in patients with active RA, treatment of Treg with a PKC-θ inhibitor
restored suppressive function [129, 130]. However, if TNF was sufficient to impair
the activity of Treg and its blockade reversed this effect, then both anti-TNF
therapies would be equally effective in restoring Treg function. Rather, the data
presented here suggests that the Treg defect in patients with active RA is not simply
a direct result of the presence of inflammation because, despite an equivalent clinical
response, EtTreg remain defective (Figures 4.1, 4.3 and 4.4). Moreover, the
persisting defect in EtTreg suggests that the defective suppression by RATreg is not
simply explained by the inflammation associated with RA making responder T cells
less susceptible to suppression. This supports previous findings by this group [124]
and others [129, 130] in which cross-over experiments showed that responder T cells
from patients with active RA are not resistant to Treg suppression. Therefore, the
inability of Treg to control inflammation in patients with active RA is due to a defect
in Treg rather than unresponsiveness of responder T cells.
In a recent report, anti-TNF therapy was shown to down-regulate genes associated
with TNF pathways regardless of response to therapy. This led the authors to propose
a model whereby clinical response to therapy is associated with TNF-independent
pathways and that these pathways might be specific to the individual [473]. Indeed,
the observations in this study suggest that anti-TNF monoclonal antibodies and
etanercept exert their therapeutic effects in RA through distinct mechanisms which
are seemingly independent of the blockade of TNF (Figure 3.1) and may underlie the
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fact that patients with RA who fail one form of anti-TNF can respond to another
[474, 475]
7.7.2 Differential binding of adalimumab and etanercept to membrane bound
TNF
Whilst the differences in Treg induction between therapies and disease do not define
a common role for TNF in Treg biology, establishing that the induction of Treg is
specific to RA patients treated with adalimumab might provide some insight into the
requirements for the peripheral generation of Treg. One of the explanations that may
account for the difference in Treg induction between the anti-TNF antibodies and
etanercept in RA is their respective binding efficacies for soluble and transmembrane
TNF (mTNF). Both infliximab and etanercept were shown to bind to mTNF and
were both able to prevent mTNF-mediated activation of human endothelial cells.
However, infliximab binding to mTNF was more effective in blocking the activation
of endothelial cells than etanercept, and infliximab association with mTNF had a
higher avidity and was more stable than etanercept. This led the authors to conclude
that infliximab mediates a more complete and sustained neutralisation of TNF than
etanercept [366].
Thus, perhaps the induction of Treg in RA patients treated with the anti-TNF mAb
(Figure 3.1) is mediated via a sustained neutralisation of TNF, as opposed to a
substantial yet incomplete neutralisation of TNF in RA patients treated with
etanercept. However, in PsA patients these differences in the ability of anti-TNF
therapies to bind and neutralise TNF would be the same and yet there is no induction
of Treg in adalimumab treated PsA patients (Figure 6.1 A). Recently, a number of
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studies have suggested that TNF and signalling through TNFR2, is fundamentally
required for the induction of Treg. Moreover, it has been suggested that anti-TNF
therapies impair this induction [476]. In this TNF-driven model of Treg induction,
the more transient neutralisation of TNF in etanercept treated patients would be more
likely to result in an induction of Treg. Thus, a disparity in the neutralisation of TNF
may not be sufficient to explain the induction of Treg in RA patients treated with
adalimumab.
7.7.2.1 Alterations in apoptosis induce an immunoregulatory phenotype.
Mitoma et al. showed that whilst infliximab and etanercept could bind to mTNF and
drive the up-regulation of E-selectin in a human Jurkat T cell line transfected with
mTNF, only infliximab could induce apoptosis. Infliximab-mediated apoptosis was
reversed by a mutation of mTNF that prevented signal transduction [477]. These data
suggests that anti-TNF antibodies preferentially signal to cells that express mTNF.
This could have a number of implications. Firstly it offers an explanation as to why
monocytes, the primary population of cells expressing mTNF [478],  from RA
patients treated with adalimumab have an increase in monocyte cell death but
etanercept treated patients do not (Figure 3.6). Secondly, it is known that an
abundance of apoptotic cells promotes tolerance and can contribute to the induction
of Treg. Indeed it has been shown that the uptake of apoptotic DCs by live immature
DCs prevents maturation and the production of inflammatory cytokines whilst
stimulating the production of TGF-β and the induction of FOXP3+ Treg [479].
Moreover, murine anti-CD3 therapy, a T cell depleting biologic agent, was shown to
mediate the induction of Treg via phagocyte production of TGF-β upon the uptake of
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apoptotic T cells [480]. Thus, perhaps in RA patients treated with adalimumab there
is an increase in apoptotic monocytes that are taken up by phagocytes and in turn
produce anti-inflammatory cytokines that can drive the induction of Treg.
7.7.2.2 The activation of p38 downstream of membrane-bound TNF
In addition to driving apoptosis, reverse signalling through mTNF has been shown to
activate the MAP kinase pathway [481]. The p38 MAP kinases regulate cytokine
production in response to cytokine stimulation. In vitro treatment of the mucosa of
Crohn’s disease patients with infliximab was shown to transiently induce p38
expression [482]. Moreover, it was shown that etanercept therapy failed to activate
this pathway [483]. Thus differential activation of the p38 pathway could provide an
explanation for the differences observed in RA patients treated with adalimumab.
This may also provide a link between the purported requirement of TNF for the
induction of Treg [476] and the induction of Treg by antibodies which neutralise
TNF. P38 can drive the production of TNF [484]. Perhaps anti-TNF antibodies bind
to mTNF on the surface of monocytes and via p38 initiate a transient burst of TNF
production. This may act locally upon responder T cells to induce a population of
Treg. However, this theory does not explain the capacity of infliximab to induce
Treg from isolated responder T cells in vitro [86]. Interestingly, activated T cells
have been shown to express mTNF [485]. Thus, reverse signalling through mTNF on
activated responder T cells might initiate a burst of TNF production from the T cell
that is used in an autocrine manner to drive the induction of Treg. A lower
expression of mTNF on the monocytes or T cells of patients with PsA may explain
the inability of adalimumab therapy to induce Treg in these patients.
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7.8 What is the mechanism of action of etanercept?
The lack of functional Treg in RA patients treated with etanercept is discordant with
the high levels of TGF-β expressed on both FOXP3+ and FOXP3- CD4 T cells in
some patients (Figure 3.7). Furthermore, the expression of TGF-β and the production
of IL-10 by monocytes (Figure 3.10) and B cells (Figure 3.9) from etanercept treated
RA patients should create ideal conditions for the induction of Treg and yet there is
no evidence of such an induction (Figure 3.1). Thus, perhaps the IL-10 and TGF-β
produced by monocytes and T cells from RA patients treated with etanercept support
the restoration of tolerance in these patients without the induction of Treg. Indeed,
both IL-10 and TGF-β  have been shown to suppress inflammation [486]. This
theory is supported by ELISA data in which the production of IL-17 and IL-6 from
cultures of responder T cells and monocytes from etanercept treated RA patients
remains very low after 5 days (Figures 4.4 B and 4.12 B). It is not clear how
etanercept might mediate this induction of tolerance and why it would not be
imitated by anti-TNF antibodies. Thus, in RA, etanercept as well as adalimumab has
distinct effects on immune regulation and the challenge will be to discover how
etanercept mediates these effects.
7.9 Clinical implications of the differences in anti-TNF therapy
Ostensibly, blockade of both TNF and IL-17 pathways in patients with RA could
confer a therapeutic advantage upon adalimumab therapy, but could also render the
patient more prone to infection given the importance of these cytokines for host
defence. RA patients treated with either adalimumab or infliximab have a 7-17 fold
higher risk of developing a Mycobacterium tuberculosis (TB) infection than RA
patients treated with etanercept, most likely due to re-activation of the latent
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bacterium [365]. TB is a granulomatous infection where macrophages and
inflammatory cells are recruited to the site of infection to form a barrier around the
mycobacterium. It is known that IFNγ production is particularly implicated in
immunity against TB, as animals which lack the ability to make this cytokine are
more susceptible to infection [487, 488].  Although IL-17 may have a limited role in
primary infection, it appears to control granuloma formation and bacterial burden,
both of which would be critical to TB reactivation [489, 490]. Healthy Treg can
prevent an effective immune response to TB [491-493], and therefore it is possible
that AdTreg, through inhibition of Th1 and Th17 responses, would have a profound
effect on TB immunity. In contrast, regulatory T cells from RA patients treated with
etanercept are unable to modulate either Th1 or Th17 cells (Figures 4.1-4.4),
consistent with the finding that this agent has little impact on the incidence of TB
[365]. The challenge will be to refine anti-TNF antibody therapy such that these
induced Treg can permit cessation of treatment for these inflammatory diseases,
thereby inducing tolerance, but also protect patients from developing TB.
Similarly, it is known that anti-TNF mAb therapy, but not etanercept, is effective in
granulomatous diseases such as Crohn’s disease [361, 362] and sarcoidosis [363,
364]. The key difference between adalimumab and etanercept therapy in RA is the
capacity of adalimumab therapy to drive the induction of Treg. Like patients with
RA, it has been published that there is an increase in peripheral Treg in Crohn’s
disease patients treated with adalimumab [494]. Furthermore, a number of recent
publications have found IL-17 secreting T cells and macrophages surround the
central core of granulomas in patients with sarcoidosis [495, 496]. These cells were
shown to persist in relapsed patients, but were absent in patients who recovered
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[495]. This identifies Th17 cells as important in the granuloma phase of disease, as
has also been published in TB [490]. Together, these reports offer a theory as to why
adalimumab, but not etanercept therapy, is a suitable treatment in granulomatous
diseases. Namely, that adalimumab treated patients have an induction of Treg that
can suppress IL-17 producing cells surrounding the granuloma, resolving
inflammation and ameliorating disease. The inability of etanercept therapy to induce
IL-17 suppressing Treg, may explain the failure of this drug to treat granulomatous
diseases.
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7.10 Conclusion
In conclusion, the results presented here show that despite a similar clinical response
to therapy, adalimumab, but not etanercept treated RA patients demonstrate an
induction of Treg with distinct functional properties. The capacity of these Treg to
suppress not only IFNγ but also potently arthritogenic Th17 cells highlights the
potential of adalimumab therapy to drive a restoration of tolerance in patients with
RA. In contrast to the regulation of Th1 responses, suppression of IL-17 is not
dependent upon IL-10 or TGF-β production. Rather, the suppression of Th17 cells by
Treg from adalimumab treated RA patients is mediated via the modulation of
monocyte-derived IL-6. This capacity to control both IL-6 and IL-17 was shown to
be dependent upon the Treg production of an unknown soluble factor and this thesis
has identified activation of STAT3 as possible avenues for future research. Finally, it
has been shown here for the first time, that patients with PsA have no numerical
deficiency in Treg and that these Treg have no defect in their capacity to suppress
IL-22, a cytokine known to drive inflammation in PsA. Furthermore, both
adalimumab and etanercept treatment in patients with PsA can reduce circulating
Th17 cell numbers which may be a contributing factor in clinical response to
therapy.
This study has shown that there is substantial variation in the immunoregulatory
effects of biologic therapies, even those that block the effects of the same cytokine.
This variation is dependent upon the disease which is treated and the
pharmacoimmunologic properties of the therapy used. The identification of these
differences and the investigation into how they might contribute to therapeutic
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response has formed a large part of this study. Indeed, the data presented here have
provided a rationale for the therapeutic benefit of switching between different anti-
TNF agents, offered an explanation as to why patients treated with anti-TNF mAb
therapy have an increased risk of TB and offered insight into in vivo induction of
Treg which could potentially be harnessed for therapy.
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7.11 Study Limitations
The primary finding of this study was that Th17 cell responses can be controlled by
AdTreg via the suppression of monocyte-derived IL-6 production. However, the data
presented here shows that AdTreg can modulate IL-6 and IL-17 production and that
IL-6 can regulate Th17 cells. It does not conclusively prove that AdTreg suppress
Th17 cells via this mechanism and does not exclude a direct effect of AdTreg on
Th17 cells. Thus, it would be interesting to establish an effective assay system
without the presence of monocytes to validate these findings.
Many of the conclusions in this study are based on changes in the proportions of
cells, for example the percentage of Treg (Figure 3.1) or Th17 cells (Figure 3.10).
Whilst this is informative, it may not be entirely representative of the on-going
changes in patients. For example, biologic therapy may drive an absolute increase in
circulating lymphocytes through a redistribution of cells from the joint and thus may
alter the proportions of cell subsets without changing their absolute number. This is
particularly important if you see a fall in the percentage of cells in the periphery, as
observed with plasma B cells after therapy with tocilizumab (Figure 5.4). This
decrease could be representative of an increase in the percentage of other B cell
subsets. Furthermore, if the capacity of adalimumab to drive apoptosis was targeted
to cells which express mTNF (as discussed in 7.7.2.1), the Treg population may be
protected whilst the absolute number of activated T cells may be reduced and this
may be reflected in an increase in peripheral Treg. For this reason, examining
absolute number of cells alongside the proportion of cells would provide greater
insight into the immunologic changes of patients before and after immunotherapy.
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Similarly, large changes in the percentage of a small subset of cells, for example IL-
10 or IL-17 producers, may only be representative of a small change in absolute
number of cells. Without a functional correlate it is difficult to determine what effect
these small changes may have, particularly as the role of many cytokines is context
dependent and thus, difficult to dissect in human subjects. When studying differences
ex vivo in humans without context the only option is to interpret observed differences
and if possible, extend this to further functional studies. As regards IL-17, the low
production of this cytokine from T cells must be considered alongside the
widespread expression of IL-17 rececptor [275] which would enhance its potency.
Indeed, cytokine receptor expression at the site of inflammation, the capacity of cells
to amplify their effects through further recruitment of cells, co-operation with other
cytokines and the localisaton of cytokine producing cells will all have an effect on
the potentcy of particular cytokines.
In experiments where neutralising antibodies were used, isotype controls were not
applied consistently. An isotype demonstrates that any effects observed are specific
to the function of the antibody and not a generic effect of adding an antibody to cells.
This is particularly important in assays using monocytes because the Fc portion of
antibodies can signal through Fcγ receptor on monocytes, which may skew
responses. Future experiments where neutralising antibodies are used as a tool to
investigate the suppressive mechanism of AdTreg should always include an isotype
control condition.
In order to confirm differences between patient groups I predominantely used
multiple unpaired ‘t’ tests. In all of these tests the confidence limit is 95% which
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means that there is a 1 in 20 chance that there will be a false positive result (Type I
error). With each additional group that is compared, the chance of a false positive
result increases, for example, if 4 groups are compared there is a 4/20 chance of a
Type I error. This lowers the confidence limit of the combined tests to 80%. When
using multiple tests, it is possible to take into account the number of comparisons
made in order to reduce the chance of a false postive outcome. One way of doing this
is to apply a Bonferroni correction where the significance level is lowered relative to
the number of comparisons made. So if the desired significance level of all the tests
is 0.05, this number is divided by the number of groups compared. Using the
previous example, this would bring the significance level to 0.0125 or 99.9%
confidence that the differences observed are not as a result of a Type I error.
Lowering the threshold for significance in this way does increase the chances of
excluding real differences between groups (Type II error). The chances of a Type II
error increase with the number of comparisons made because the significance level
can become so low as to make the test irrelevant. However for a small number of
multiple comparisons it provides an adequate way to reduce Type I error.
Throughout this study, patients were classified as responding if their DAS28 score
fell by 1.2 and their CRP was below 5. Inflammatory markers are incorporated into
the DAS score in order to give an overall impression of response. However, if a
patient had a fall in DAS28 greater than 1.2 but still had an elevated CRP they were
not included in the ‘responder’ group. These stringent classifications mean that some
patients responding to therapy may have been excluded from analysis and does
represent a limitation of this study. Nevertheless, these patients would not have been
included in the non-responders group as ‘non-responders’ were classified as those
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that did not have a drop of at least 1.2 in their DAS28 score. Perhaps in future studies
classification criteria should be less stringent and the data presented in a manner that
allows the identification of outliers and distinct groupings of patients. This may, in
turn, offer greater insight into differential responses to therapy.
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7.12 Future Work
7.12.1 Investigating the suppression of IL-17
In order to investigate the mechanism of Treg suppression of IL-17, I propose
examining monocyte cell death in cultures of responder T cells, monocytes and Treg
from RA patients treated with adalimumab. If there is an increase in monocyte cell
death in these assays I would inhibit FasL on Treg or responder T cells in the
presence of monocytes and determine if this alters the ability of AdTreg to suppress
IL-17. Additionally, I would use a Fas agonist to activate the Fas pathway in the
absence of Treg to determine if this mimicked the suppression of IL-17 by AdTreg.
I would also continue to investigate the role of IL-35 in mediating the AdTreg
suppression of IL-17. If blocking IL-35 proves to impair the capacity of Treg to
suppress IL-17 then it would be necessary to determine that the anti-p35 antibody
was in fact blocking IL-35 and not another IL-12 family member. Conditions with
and without an isotype control should prove that any observed effects of the
blockade of IL-35 are independent of Fcγ receptor signalling by the neutralising
antibody. Additionally, it would be interesting to elucidate the role of pSTAT3 in the
function of AdTreg. Like IL-6, IL-35 uses the molecule gp130 as a receptor, thus
there may be a link between the production of IL-35 and the activation of STAT3.
The best approach to investigate a role for STAT3 in Treg function would be to
repeat co-culture suppression assays using a STAT3 inhibitor. This should show if
STAT3 is important and if it is, the regulation of this pathway could be investigated
further.
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7.12.2 How are Treg induced by anti-TNF?
First, I would examine mTNF expression levels on monocytes and responder T cells
from patients with RA and PsA. Differences in expression levels of mTNF might
explain differences in the action of anti-TNF mAbs in RA and PsA. Additionally, I
would examine the capacity of both adalimumab and etanercept to induce apoptosis
in vitro. Depending on the results, it would be interesting to see if apoptotic
monocytes from these assays have the capacity to differentially induce Treg when
they are taken up by phagocytes.
In order to determine whether the anti-TNF molecules differentially bind to mTNF in
vitro, I would biotinylate and fluorescently label adalimumab and etanercept and
perform binding assays that I would measure by flow cytometry or fluorescent
microscopy. Next, I would investigate what, if any, intracellular pathways are
activated by the in vitro addition of adalimumab and etanercept to cells from patients
with RA. In particular, I would examine the p38 pathway and the apoptosis
pathways. I would also determine if adalimumab and etanercept treatment of cells
from patients with RA differentially activates NFκB, to see if TNF signalling is an
important feature of Treg induction.
7.12.3 Investigating Treg function in PsA
I think it is necessary to determine if there is in fact a defect in Treg from patients
with PsA. To do this, I would examine the capacity of Treg from PsA patients to
suppress proliferation and the production of IFNγ and TNFα. I would also repeat
suppression assays to determine if etanercept treated patients do ‘lose’ the capacity to
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suppress IL-22 production. Additionally, it would be interesting to see if Treg from
patients with PsA can regulate CD8 T cell populations.
If suppression assays confirm that Treg from etanercept treated PsA patients are not
capable of suppressing IL-22 and that levels of IL-22 remain high in these patients, I
would investigate the inflammatory properties of IL-22 in this setting. In order to
dissect the role of IL-22 in PsA it would be preferable to take samples from the skin,
joint and blood of patients with PsA. I would first examine IL-22 receptor expression
to determine if there is an altered responsiveness to IL-22 in PsA patients treated
with etanercept. Then, I think it would be interesting to undertake a approach
combining experiments by Sonnenberg et al. [316] and Mitra et al. [410]. I would
culture synovial fibroblasts from patients with active PsA with autologous T cells or
T cells from etanercept treated patients and measure proliferation of the synovial
cells. Then I would differentially block or add-back IL-17 and IL-22 to investigate
the capacity of IL-22 to convert from a pro- to anti-inflammatory cytokine in an IL-
17-dependent manner.
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Appendix I. Patient consent form
Royal Free and University College Medical School
UNIVERSITY COLLEGE LONDON
WINDEYER INSTITUTE OF MEDICAL SCIENCES
DEPARTMENT OF IMMUNOLOGY AND MOLECULAR
PATHOLOGY
Rayne Building, 5 University Street, London WC1E 6JF
Telephone 020 7679 9146
Fax  020 7679 9143
Email: j.mcgovern@ucl.ac.uk
http://www.ucl.ac.uk/medicine/bloomsbury-rheumatology/
Project Title:  The function(s) of regulatory T cells in rheumatoid arthritis
Principal Investigator:   Professor Michael Ehrenstein
Description of Project:  Investigation into function(s) of regulatory T cells in
the above mentioned patients
Ethical Approval No: 02/0240
Confidentiality is strictly maintained at all times. Your name will not be known
to anyone other than the staff immediately involved in collecting the sample.
All data will be anonymous and untraceable to the volunteer except by those
immediately involved in collecting the sample.
Please read and sign the following declaration:
I confirm that I have read and understood the information relating to this
study. I have had the opportunity to ask questions and I understand that I can
withdraw from this study at any time without giving a reason.
Signature of volunteer:…………………….………
Print:……………………….….
Date:………….
Signature of person taking blood:……………….          Print:
Date:………….
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